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1.0 INTRODUCTION
1.1 Abstract
Cigarette smoking is a leading cause of premature death and preventable illness; more
than 480,000 deaths annually in the U.S. are attributable to smoking. Of the more than 34
million U.S. adult smokers, more than half make a quit attempt each year but more than 90%
will relapse within 6 months. Twin studies show that smoking cessation is more than 50%
heritable, thus genetics plays a significant role in cessation. However, the understanding of
genetic susceptibility to cessation failure is still in its nascent stages. Genetic studies of
smoking cessation have typically used short-term follow-up or cross-sectional design, study
design characteristics that cannot account for multiple quit attempts and relapse episodes over
time, a phenomenon common in smokers. Additionally, prior genetic studies have often
excluded light smokers even though light smokers comprise 15% of U.S. adult smokers, and
few studies have examined genetic associations specifically among women. These factors limit
the understanding of genetic susceptibility in smoking cessation because mechanisms of
addiction may vary between light and heavy smokers as well as between men and women.
To overcome these limitations, we used existing high-quality genetic and phenotype data
available in the Nurses’ Health Study (NHS) and NHS 2, two large all-female cohorts with up to
38 years of longitudinal measurement of cigarette smoking for nearly 13,000 former/current
smokers. We conducted a systematic review of the current evidence of genetic associations
with smoking cessation focusing on genetic variation within biological pathways influencing
nicotine addiction to inform two complementary methods of single nucleotide polymorphism
(SNP) selection: 1) a candidate SNP approach, and 2) a candidate gene approach selecting
thorough coverage of SNPs within genes that influence mechanisms of nicotine addiction. We
examined the selected SNPs associations with 1) the likelihood of smoking cessation
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throughout adulthood and 2) the likelihood of relapse during adulthood and the proportion of
follow-up in relapse.
Using this approach, SNPs were observed to be associated with smoking cessation
throughout female adulthood. Several SNP associations provided evidence to suggest that the
associations may differ between light versus moderate to heavy smokers. Furthermore, SNPs
were observed to be associated with the likelihood of sustained abstinence after successful
cessation and, among women who relapsed, with the proportion of follow-up in relapse. The
findings also revealed that some SNP associations with proportion of follow-up in relapse were
stronger in women who quit smoking post-menopause. This research advanced understanding
of the role of genetics of persistent smoking throughout adulthood, specifically in women. The
evidence holds relevance for guiding precision medicine approaches to smoking cessation and
indicate the need for intervention approaches to long-term cessation management and relapse
prevention.
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1.2 Specific Aims
In the U.S., nearly half of all cancer deaths (48.6%) from 2005-2009 and nearly one-third
(32.6%) of all deaths from either cancer, cardiovascular disease or pulmonary disease were
attributable to smoking.1 Cigarette smoking and secondhand tobacco smoke are associated
with at least 480,000 deaths annually, making smoking the primary source of premature death
in the country.1 Smoking caused morbidity and mortality begins to decrease upon cessation,
with the risk of coronary heart disease decreasing to that of a non-smoker and cancer mortality
risk decreasing by 50% after 15 and 10 years of abstinence, respectively.1 Smoking prevalence
has declined in recent decades, but even so the absolute number of smokers remains large; in
2017, 34.3 million U.S. adults were current smokers.2 Most smokers attempt to quit each year,
but less than 3% permanently succeed.3,4 Approximately 50% of those who quit relapse within
the first year and, after five full years of abstinence, relapse rates remain as high as 25%. 5
Many smokers require multiple quit attempts before achieving long-term cessation.5 Improving
understanding of factors that explain variability in smoking cessation and relapse can aid in
refining smoking cessation intervention approaches.
Though a large twin study found risk of smoking cessation failure is more than 50% heritable6,
understanding of genetic susceptibility to cessation failure is still in its nascent stages. More
refined understanding is needed to fully realize the translational potential of this line of inquiry.
Three pathways that contribute to biochemical nicotine response and addiction-related cognitive
behavioral phenotypes are nicotine metabolism, nicotinic acetylcholine receptor and
dopaminergic pathways.7 Thus, these are the key pathways to focus on for genetic association
studies of smoking cessation. Prior genetic studies have predominantly focused on genetic
variants in these pathways but have been limited by short-term follow-up, cross-sectional
design, or being embedded within short-term smoking cessation intervention trials with
insufficient power to account for both gene and intervention effects.
6

Additionally, although as many as half of all U.S. adult smokers are light (≤5 cigarettes per day)
or non-daily smokers8, they have been largely excluded from prior genetic studies. The
mechanism of addiction may differ between light and heavy smokers, with a positive
reinforcement model of addiction likely explaining light smoking9 and a negative reinforcement
model (e.g. withdrawal-avoidance) contributing to heavy smoking.3 Similar differences in
addiction mechanisms may also exist by biological sex as women tend to be more responsive to
sensory stimuli of cigarette smoking and men may be strongly driven by biochemical response
to nicotine.10 In addition, though men and women have similar rates of quit attempts, women
are less likely to quit during a single quit attempt.11 Contributing to disparate quit rates between
men and women are factors impacting cessation that are unique women (e.g. menstruation and
menopause) or that disproportionately affect women (e.g. stress/anxiety, weight gain).12 While
there are differences between men and women, there are few studies of women and several of
those available have focused only on smoking during pregnancy.13,14
Since the rate of smoking relapse is high even after long periods of abstinence, understanding
the role of genetic variability in smoking cessation and relapse throughout adulthood can
improve development of tailored interventions with potential to reduce the public health burden
of smoking. However, the current body of evidence relies on short-term follow-up and single
timepoint comparisons of former and current smoking status and cannot account for multiple
quit attempts and relapse episodes over time, phenomena that are common in smoker
phenotypes. In addition, though potential differences in risk factors and addiction mechanisms
exist between men and women, few studies have examined genetic associations with smoking
specifically among women. The goal of the proposed study was to address this knowledge gap
by characterizing associations between genetic variants and long-term smoking cessation and
relapse phenotypes among women. We focused on genetic variants in biological pathways
hypothesized to influence biochemical nicotine response and/or cognitive-behavioral addiction
7

phenotypes. Genetic variants and candidate genes were identified through a systemic review of
the current evidence. We then used existing high-quality genetic and phenotype data from the
Nurses’ Health Study (NHS) and NHS-2, two large all-female cohorts with high-quality genetic
data and smoking behavior measures for up to 20 timepoints per participant over up to 38 years
of follow-up. The NHS and NHS-2 data also includes both light and heavy smokers which
allowed us to examine genetic susceptibility to cessation and relapse in light smokers, an understudied but growing population of smokers, while also evaluating the heterogeneity of genetic
risk between light and heavy smokers. We addressed our goal of characterizing genetic
susceptibility to smoking cessation failure and degree of relapse throughout adulthood with the
following three aims.
1.2.1 Aim 1
Specific Aim 1: Conduct of a systematic review of the evidence of genetic associations with
smoking cessation focusing on genes in known nicotine addiction pathways. The evidence was
synthesized by findings of associations between smoking cessation and: Aim 1a) variants of
genes within the nicotine metabolism pathway, Aim 1b) variants of genes encoding nicotinic
acetylcholine receptors, and Aim 1c) variants of genes influencing the dopaminergic pathways.
Our findings informed the SNP and gene selection for Aims 2 and 3.
1.2.2. Aim 2
Specific Aim2: Among ever-smokers at baseline, we determined the longitudinal associations of
single nucleotide polymorphisms (SNPs) with the probability of smoking cessation throughout
adulthood in women using two complementary strategies for SNP selection: Aim 2a: a
candidate SNP approach in which 10 SNPs were identified in the evidence review from Aim 1
and Aim 2b: a pathway approach using coverage of SNPs (including novel SNPs) in genes
identified as potentially influencing nicotine addiction. We also determined if genetic
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associations apply to all smokers regardless of smoking intensity or if some associations were
heterogenous between light and moderate/heavy smokers.
1.2.3 Aim 3
Specific Aim 3: Among female former smokers, we determined the association between the 10
SNPs identified in Aim 1 and likelihood of relapse to smoking throughout adulthood; and,
conditional on relapse, the SNP associations with the proportion of follow-up returned to
smoking throughout adulthood. We also determined if genetic associations apply to all smokers
regardless of heaviness of smoking or if associations were heterogeneous by smoking intensity.

9

2.0. BACKGROUND
2.1 Public Health and Clinical Significance
Cigarette smoking is a leading cause of severe illness including cancer, cardiovascular
disease, and chronic pulmonary obstructive disease, making smoking the largest cause of
preventable death in the U.S., responsible for more than 480,000 deaths annually.1 In 2010,
smoking-related healthcare costs in the U.S. reached $170 billion, nearly 9% of total healthcare
spending in the nation.15 More than $100 billion of these costs were paid by federally funded
programs such as Medicare, Tricare or Veterans Affairs benefits. Cigarette smoking not only
leads to greater utilization of healthcare services, it is linked to increased absenteeism from
work, magnifying the societal burden caused by smoking.1 Despite a decline in smoking
prevalence in recent decades, there were still 34.3 million U.S. adult smokers in 2017. Smoking
caused morbidity and mortality begins to decrease upon cessation, with the risk of coronary
heart disease in former smokers returning to that of a non-smoker after 15 years of abstinence
and lung cancer mortality risk decreasing by 50% after 10 years of abstinence.1 Most smokers
attempt to quit each year, but only 7% are able to quit for 6-12 months16 and less than 3%
permanently quit.3,4 The prospect of long-term cessation is dismal as relapse rates remain as
high as 50% in the first year after quitting, dropping only to 36% and 25%, respectively, after 2
and 5 fully abstinent years.5 Long-term cessation and prevention of relapse is crucial for
improving health, thus a clear understanding of factors associated with successful cessation
and prevention of relapse is needed to develop targeted interventions aimed at increasing longterm/permanent cessation rates.
2.1.2 The Role of Genetic Variation in Smoking
Genetic susceptibility is likely to be a key factor in smoking behavior as twin studies
suggest nicotine dependence, withdrawal symptoms, and smoking cessation are between 31%
and 60% heritable.6,17-19 Despite the value of this line of inquiry, so far genetic association
10

studies have largely focused on associations between genetic variants and smoking behaviors
such as cigarettes per day (CPD) or time to first cigarette of the day, which are behaviors
typically used to quantify the degree of biochemical dependence on nicotine.20 The few large
GWAS studies that examined smoking cessation used cross-sectional measures to compare
current and former smoking status21, which fails to capture key characteristics of smoker
phenotypes, such as length of time quit and number/duration of relapse episodes over lifetime
smoking history. Investigation of these lifetime smoker characteristics has also been limited in
non-GWAS cohort studies by single timepoint assessment of smoking cessation outcomes as
well as small sample sizes and short-term follow-up.22-29 Due to the dearth of genetic studies
with large sample sizes and longitudinal data, much of what is presently known regarding
genetic susceptibility to cessation failure comes from genetic studies embedded within smoking
cessation intervention trials.30-47 These trials are limited by small sample sizes, a limitation
further exacerbated by the need to stratify genotype by smoking cessation intervention arm.
Furthermore, cessation trials focus on short-term outcomes, usually measuring abstinence after
8-weeks to 6-months of follow-up. Because the risk for relapse remains high for years after
quitting, the follow-up in these studies is too short to characterize genetic associations with longterm cessation or relapse.
2.1.3 Differences Between Men and Women
Heterogeneity in the mechanisms influencing addiction may be present between men
and women. Women experience reduced odds of cessation compared to men for a single quit
attempt11 and risk factors for relapse can differ between men and women.12 While some
distinctions in risk factors between men and women may be due to motivational factors such as
avoidance of weight gain, evidence suggests women may relapse due to stress, anxiety and
negative effect whereas men may respond to cravings. Women are also more responsive to
sensory stimuli of cigarette smoking and environmental cues associated with smoking48,
11

whereas men may be more strongly driven by biochemical response to the nicotine and
withdrawal avoidance.10,49 Furthermore, hormonal differences pre- and post-menopause as well
as the administration of exogenous sex hormones via hormone replacement therapy (HRT) can
influence cigarette smoking in women. Higher estrogen levels are associated with faster
nicotine metabolism which contributes to earlier onset of craving and withdrawal symptoms50,
and increases in progesterone may increase the severity of withdrawal and craving.51 However,
in post-menopausal women, HRT may help mitigate negative effect associated with smoking
cessation.52
Thus, some heterogeneity in mechanisms of addiction and genetic risk factors likely
exist between men and women. Furthermore, genetic susceptibility in women may differ preand post-menopause and with HRT. Given these potential differences in risk factors and
addiction mechanisms, it is necessary to determine genetic susceptibility to smoking cessation
specifically among women. Yet, most genetic studies of smoking cessation are of both men and
women and do not assess differences by biological sex. The limited studies that have
evaluated differences by sex have typically done so after the fact and were likely underpowered
to detect statistically significant interactions.43,53 Furthermore, the few genetic studies of
specifically of women and smoking typically focus solely on smoking during pregnancy.13,54
2.1.4 Differences Between Light and Heavy Smokers
Limitations in understanding the role of genetics in smoking behavior are further
exacerbated by the exclusion of smokers consuming less than 10 CPD from nearly all prior
genetic studies. Light smoking is typically defined as consuming <5 CPD and daily light
smokers comprise ~15% of U.S. adult smokers.8 Furthermore, up to 35% of U.S. adult cigarette
smokers report light non-daily smoking, thus it is estimated that the total proportion of light
smokers in the U.S may be as high as 50%.8 The exclusion of 15 - 50% of smokers from prior
studies means genetic findings are not generalizable to between 5 and 17 million U.S. adult
12

smokers. The need for research focused on light smokers is important because different
biological pathways may be involved in persistent light versus heavy smoking.55 Light smokers
exhibit addictive behavior that is positively reinforced by the “boost” in mood or concentration
experienced from smoking,9 whereas moderate to heavy smokers exhibit negatively reinforced
addictive patterns maintaining smoking to avoid withdrawal.56 Thus, while some biological
pathways impacting susceptibility to smoking addiction may be common to all smokers
regardless of smoking intensity, there are likely some differences in pathways and differences in
the specific genes and SNPs that affect genetic susceptibilities in light-versus-heavy smokers.
2.1.5 Biological Mechanisms of Smoking Addiction (Figure 1)
The interplay of nicotine metabolism, nicotinic acetylcholine receptor (nAChR) and
mesolimbic dopamine (DA) pathways produces the biochemical effects of nicotine. Nicotine
inhaled via cigarette smoke is
quickly absorbed into brain tissue
and binds to nAChRs, a family of
multi-subunit neurotransmitter
receptors which typically bind
endogenous acetylcholine. Upon
binding, nAChRs are activated stimulating the release of several neurotransmitters, including
dopamine.57 Thus, nAChRs play an important role in regulating the mesolimbic dopamine (DA)
pathway. Nicotine is metabolized by the liver and cleared from the body with most (75-80%)
nicotine metabolized to cotinine.58 The speed at which nicotine is metabolized influences the
rate at which serum nicotine decreases and faster metabolism diminishes nicotine levels more
quickly freeing nAChRs for binding.59 The increase in nAChR binding availability contributes to
onset and severity of withdrawal symptoms60 if homeostasis is not maintained through
continued nicotine intake.
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Smoking addiction is further mediated by these pathways through neuroadaptations
which influence nicotine response. Nicotine binding causes a longer nAChR activation period
than acetylcholine leading to desensitization of nAChRs to prevent harm to the nerve.
Desensitized nAChRs fail to respond to either acetylcholine or nicotine.57 Chronic smoking
leads to protracted periods of receptor desensitization61 and a corresponding increase in the
number of nAChRs (upregulation) is observed.57 This upregulation and desensitization of
nAChRs produce craving, withdrawal, and tolerance.61 Upon discontinuation of nicotine intake,
receptors regain functionality within 27 hours.61 At this stage, the receptor may be more
sensitive to both nicotine and acetylcholine57 leading to a heightened response if nicotine is
reintroduced.
In addition to causing nAChR neuroadaptation, chronic smoking causes adaptation of
the DA system through repeated stimulation leading to acute deficits in DA function upon the
withdrawal of nicotine. DA deficits can be exacerbated by anxiety and stress during quit
attempts aggravating withdrawal symptoms and increasing relapse susceptibility.62 Relapse is
reinforced by a heightened DA response when nicotine is reintroduced during early abstinence,
a phenomenon similar that observed of nAChRs during early nicotine withdrawal.63 This
heightened response in both nAChR and DA pathways could partially explain relapse of heavy
smokers and may play a key role in persistent light smoking as light smokers tend to be
motivated by the “boost” received from smoking a cigarette (e.g. positive reinforcement).9
The nAChR and DA pathways not only contribute to craving, withdrawal, drug tolerance
and a heightened biochemical response, they also work in concert to influence conditioned
behavior further reinforcing continued smoking or relapse. Smokers can become conditioned to
experience a physiological response when presented with smoking-specific sensory stimuli with
or without nicotine administration.64 Nicotine-induced adaptations in the nAChR and DA
pathways as well as genetically driven properties of nAChRs (e.g. degree of natal expression,
14

ratio of sub-unit types and binding affinity) and the DA pathway (e.g. receptor density and
binding capacity), could facilitate and strengthen cue-primed drug seeking behavior and
frequent relapse. Several nAChRs are implicated in associative learning65,66, memory67, and
negative occasion setting68, with nicotine inducing improvements in these areas of cognitive
functioning. Associative learning is reinforced by the DA pathway when nicotine induces
increased dopamine levels and DA signaling62,63 which links smoking-related sensory input,
such as taste and feel of cigarette smoke, with reward.62
Additionally, there is a strong relationship between inhibitory control, the DA pathway,
and addiction.69,70 Decreased dopamine receptor activity has been linked to poor inhibitory
control70,71 and increased risk of smoking relapse72; increased brain reactivity in response to
smoking-specific cues is also predictive of smoking relapse.73 Higher connectivity may increase
inhibitory control response to cravings, cues, and withdrawal.74,75 An interplay of nAChR and DA
pathways in terms of cue-primed conditioning and inhibitory response to cues could explain why
smoking relapse rates remain high long after biochemical withdrawal.5
2.1.6 Genetic Associations Throughout Adulthood
Despite what is known about pathways influencing the biochemical, neurocognitive, and
behavioral aspects of smoking addiction, a clear understanding of the role of genetics within
these pathways in cessation failure and relapse has not been achieved. Contributing to the lack
of clear understanding are the small sample sizes, short-term follow-up periods and crosssectional measurements used in most genetic studies of smoking cessation. Studies have not
quantified the pattern of multiple quit attempts and relapse episodes throughout adulthood that
many smokers experience, important aspects of smoking phenotypes which have considerable
public health impact. Sustained cessation is key to improving public health and examining
genetic susceptibility from the perspective of lifetime smoking patterns is needed to improve
understanding of the genetics of persistent smoking, smoking cessation and relapse.
15

In addition, differences in genetic risk factors by sex are too often overlooked in studies of
smoking cessation and relapse. Inclusion of both sexes in genetic studies without a priori
planning for consideration of these potential differences may confound those genetic
associations that in fact do differ by sex. However, the few studies of women typically focus on
smoking during pregnancy. Our approach not only accounts for unique smoker phenotypes
indicative of variability in smoking behavior throughout adulthood that have not previously
examined but does so specifically in two large cohort studies of women.

16

3.0 Methods Background
3.1 Quality control of existing genotype data
We identified two large prospective cohort studies, the Nurses’ Health Study (NHS) (N =
121,700) and NHS-2 (N = 116,429), with existing genotype data and smoking behavior data
collected every 2 years from participants beginning in 1976 for NHS and 1989 for NHS-2.76
Genome-wide association study (GWAS) data was collected for several nested case-control
studies with 18,527 and 8,276 participants in the NHS and NHS-2 cohorts, respectively,
currently having quality controlled consented GWAS data available. This existing GWAS data
was obtained from DNA collected from cheek cells or blood samples. Genotyping on samples
was conducted on at least one of five genome-wide array platforms for NHS (Affymetrix,
HumanCore, Illumina, OmniExpress, and OncoArray) and at least one of three platforms for
NHS-2 (HumanCore, Illumina, and OncoArray). Some participant samples have been
genotyped using arrays on more than one platform and some have been genotyped with more
than one array on a single platform.
For each separate GWAS study, standard quality control procedures, such as testing for
Hardy-Weinberg Equilibrium and setting call rate filters, were conducted.77 To expand the utility
of the genetic data beyond the individual GWAS studies, the GWAS data for each genome-wide
array platform have been merged. To assure quality control during merging, ambiguous SNPs
and those that were not present in all studies being merged were removed as were SNPs with a
call rate <95%. In addition, strands were flipped where necessary to ensure homogeneity. One
record of expected duplicates (e.g. participants genotyped more than once) was retained and
other duplicates removed. In the case of unexpected duplicates (e.g. different participant IDs
with >0.999 agreement in GWAS data), all records were removed. Principal component
analysis was then used to identify pairs of related individuals and one member of each pair
removed. Lastly, differential ascertainment and genotyping of controls across case-control
17

studies can lead to systematic bias in allele frequencies when controls are combined.78 This
bias can lead to spurious associations among controls. To identify SNPs with these potentially
spurious associations, the “cases” were excluded from each merged platform dataset to conduct
analyses on the remaining controls in several cohort-specific analyses. For example, “controls”
for the NHS breast cancer study were analyzed as “cases” and compared to all other “controls”
in the dataset; SNPs reaching GWAS significance (p < 10-8) were removed for suspected
spurious associations.77 After this extensive quality control, the datasets for each assay
platform were separated into subsets by chromosome and submitted to the University of
Michigan Imputation Server to impute approximately 47 million genetic markers using the 1000
Genomes Phase 3 reference panel. The Michigan Imputation Server also applies its own
standards of quality control checks.77 To validate the imputation process, two “proof of
principle” GWAS were conducted using the imputed GWAS datasets.77
Per Channing School of Public Health guidance on data use, the imputed GWAS data
from the different platforms can be combined for analysis when testing associations for specific
selected SNPs; however, merging should be avoided in genome-wide association studies.
Access to the NHS data via the Channing Division of Network Medicine (CDNM) cluster,
managed by Harvard University’s Channing School of Public Health, has been approved
through August 31, 2022, with an option for extension. Of those with consented genotype data,
there are 10,049 former or current smokers, inclusive of light smokers, at baseline in the NHS
cohort and 2,804 in the NHS-2 cohort.
3.2 Preliminary evaluation of NHS and NHS-2 data
Initial evaluation of the NHS and NHS-2 data included a visual examination of participant
smoking profiles throughout the follow-up period. Figure 2 depicts a sample of six NHS
participant smoking status profiles, including both former and current smokers at baseline.
Examination of the profiles confirms that cross-sectional comparisons of former versus current
18

smoking status often fails to capture key smoking phenotype characteristics. For example,
Figure 2. Smoking profiles for a sample of Nurses’ Health Study (1976-2014) participants

analysis of former versus current smoking status at a later timepoint would classify all the
sampled participants identically, ignoring the variability observed between the participants
throughout adulthood. The profiles in figure 2 display the proportion of the follow-up time spent
in relapse showing that former smokers at the end of follow-up have wide variability in degree of
relapse. Given that all smoking-caused diseases are dose-dependent, variability in degree of
relapse has important health implications but has not been measured in previous studies.
In addition to assessing smoking status profiles, we conducted a preliminary crude
analysis of one single nucleotide polymorphism (SNP), rs16969968 of chromosome 15, which
has been previously studied in association with nicotine addiction. We examined the
association of the SNP with smoking cessation over time (calendar year of each questionnaire)
in both the NHS and NHS-2 cohorts. Using generalized estimating equations and a codominant
genetic model, the probability of being a non-smoker over time was modeled adjusted for
19

baseline age. In both the NHS and NHS-2 cohort, participants with two copies of the minor
allele had significantly reduced odds of having quit smoking over time compared to those with
zero copies of the minor allele. Figure 3 shows the odds ratio of being a former smoker by
genotype and how the association changed over time. The association is stronger in the NHS-2
cohort and the association attenuates with time in the NHS cohort.
Though tobacco policies varied over time, all participants at a given time were generally
impacted by the same policies; thus, we hypothesized that the advanced aging of the NHS
cohort compared to that of the more recent NHS-2 cohort contributed to the cohort differences
and the attenuation with time in NHS. The challenges to smoking cessation that smokers <65
years of age face can be considerably different compared to smokers ≥65 years of age.79,80 For

Figure 3. Preliminary analysis SNP rs16969968. Relative odds of having quit in each year comparing
homozygous minor allele genotypes to homozygous common allele genotypes among ever-smokers at baseline
in a) the Nurses’ Health Study, 1976-2014 and b) the Nurses’ Health Study II, 1989-2015. Generalized
estimating equations statistical model modeling likelihood of being a former smoker at each timepoint. A
codominant genotype model was used in the model. Comparison of 1 vs. 0 copies of the minor observed similar
trends with weaker associations that were rarely statistically significant.

example, behavioral change to quit smoking after onset of a new chronic condition is more likely
in older smokers.80 Such differences could be a major contributor to the much lower smoking
prevalence in adults >65 years of age compared to the prevalence in those 45-64 years.81
Furthermore, on average smoking can reduce life expectancy by 15 years.82 These factors
could explain why there may be different population genetic risk between those <65 and those
over 65 years of age. Descriptive statistics for the first and last timepoints in NHS and NHS-2
20

as well as an intermediate timepoint for NHS are shown in Table 1. This demonstrates that the
more recent NHS-2 cohort in 2015 and the NHS cohort in 1998 were comparable in terms of
mean age and the proportion of participants censored due to death. Thus, we deemed it
appropriate to stratify the population between those <65 and ≥65 years of age to evaluate
potential differences in genetic risk factors between these age groups and to enable more direct
comparison of the NHS and NHS-2 cohorts.
Nurses’ Health Study
(1976 – 2014)

Table 1.
Year
Mean Age (yrs)
[SD]
Age Range (yrs)
% Censored
(death)

Nurses’ Health Study 2
1989 – 2015)

1976

1998

2014

1989

2015

43.0 [6.7]

64.9 [6.7]

36.3 [4.26]

62.1 [4.24]

29 – 55

51 – 79

79.1
[6.27]
67 – 95

24 - 43

50 – 69

0.00%

2.97%

30.45%

0.00%

3.92%
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4.0 INNOVATION AND SIGNIFICANCE
Prior studies have not quantified the pattern of multiple quit attempts and relapse
episodes throughout adulthood that many smokers experience, important aspects of smoking
phenotypes which have considerable public health impact. Furthermore, despite the differences
in risk factors for smoking cessation failure or relapse between men and women, studies have
rarely focused on women smokers outside of pregnancy. In addition, genetic studies of
smoking cessation almost always exclude light smokers, thus difference in genetic susceptibility
between light and moderate-to-heavy smokers with respect to cessation failure and relapse
have not been previously examined. The goal of this research was to identify genetic variants
within pathways influencing nicotine addiction that are associated with the 1) probability of
smoking cessation over adulthood and 2) the degree of relapse in adulthood among women
while accounting for factors such as menopausal status and HRT use that may impact women
trying to quit smoking. The secondary goal was to examine heterogeneity in these genetic
associations between light and moderate-to-heavy smokers. This is an important line of inquiry
due to the growing prevalence of light smokers in the U.S. population.
We used a systemic review of the evidence to direct a gene and single nucleotide
polymorphism (SNP) selection process. This SNP selection methodology allowed us to strike a
balance between limiting the focus to a few SNPs already featured in the literature and an
agnostic approach taken by genome-wide association studies. Thus, we were able to both
reproduce and validate previous genetic findings and expand those findings in terms of longterm outcomes considering follow-up throughout adulthood, while also maintaining statistical
power to identify novel genetic risk factors.
Thus, the innovative features of our approach are that it 1) investigated associations with
smoking behavior throughout adulthood, 2) focused on women, and 3) examined heterogeneity
in genetic factors between light and heavy smokers. These innovative features combined with
22

the large sample, length of follow-up, and quantity of repeated measurements used in this
research offer considerable insight into genetic factors associated with persistent smoking in
women throughout adulthood, and differences in these factors by smoking intensity. This insight
is crucial for informing and implementing tailored smoking cessation interventions for
sustainable abstinence.
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6.1 Abstract
6.1.1 Introduction: Identifying genetic factors associated with smoking cessation could inform
precision cessation interventions. Of major interest is genetic variation in nicotine metabolism,
largely predicted by CYP2A6 variations.
6.1.2 Methods: We conducted a systematic literature review to summarize the populationbased evidence of the association between CYP2A6 and smoking cessation.
In the 12 studies meeting the inclusion criteria, the known functional metabolic effect of CYP2A6
variants was used to classify nicotine metabolism as normal (>75% metabolic activity),
intermediate (50.1 - 75% activity), slow (25 - 50% activity), and poor (<25% activity). Summary
odds ratios of smoking cessation were calculated across metabolic groups, stratified by
ancestry and whether participants received pharmacotherapy or placebo/no treatment.
6.1.3 Results: Among untreated people of European ancestry (n = 4 studies), those with
CYP2A6 reduced metabolism were more likely to quit smoking than those with normal
metabolism [Summary OR = 2.05, 95% CI 1.23 – 3.42] and the likelihood of cessation increased
as nicotine metabolism decreased. Nicotine replacement therapy attenuated the association at
end-of-treatment, while bupropion modified the association such that intermediate/slow
metabolizers were less likely to quit than normal metabolizers [Summary OR = 0.86, 95% CI
0.79 – 0.94]. Among untreated Asian people (n = 3 studies), results differed compared to those
with European ancestry: those with slow metabolism were less likely to have quit smoking than
normal metabolizers [Summary OR = 0.52, 95% CI 0.38 – 0.71]. Evidence for people of African
ancestry (n = 1 study) suggested the CYP2A6 association with cessation may differ compared
to those of European ancestry.
6.1.4. Implications: Most studies included in this review were of European ancestry
populations; these showed slower nicotine metabolism was associated with increased likelihood
of smoking cessation in a dose-related manner. Pharmacotherapy appeared to attenuate or
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modify this association among people of European ancestry, but it is unclear whether the
change in the association remains consistent after treatment ceases. This finding has
implications for precision medicine cessation interventions. Based on only a few studies of
people of Asian or African ancestry, the association between CYP2A6 variants and cessation
may differ from that observed among those of European ancestry, but more evidence is needed.
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6.2. Introduction
Twin studies suggest nicotine dependence, withdrawal symptoms, and smoking
behaviors are between 31% and 60% heritable12,71-73 providing evidence of underlying genetic
risk factors for cessation failure or relapse. Identifying these risk factors can advance the
understanding of precision medicine approaches to smoking cessation. A pathway of major
interest for understanding genetic susceptibility to smoking addiction is nicotine metabolism, a
key factor influencing nicotine addiction. Most (75%) nicotine is metabolized to cotinine by the
cytochrome P450 2A6 (CYP2A6) enzyme46 which is encoded by CYP2A6. Cotinine is also
metabolized by CYP2A6 to 3’-hydroxycotinine (3-HC), and the ratio of 3-HC to cotinine, referred
to as the nicotine metabolite ratio (NMR), is a biomarker of CYP2A6 enzyme activity and of
nicotine metabolism rate, with higher ratios indicative of faster nicotine clearance/metabolism.
Variations in nicotine metabolism have been attributed in part to CYP2A6 variants74 which
predict enzyme activity and resulting nicotine metabolite ratio (NMR) levels.75 Of note, CYP2A6
variant allele frequencies can vary by ancestral background.76 The interplay of nicotine
metabolism with the nicotinic acetylcholine receptor (nAChR) pathway plays a large role in the
biochemical response to nicotine.
Through coaction with nAChR binding and activation, the rate of nicotine metabolism
contributes to the onset of and severity of withdrawal symptoms and cravings.47,48 Nicotine
inhaled through tobacco smoke is absorbed quickly into brain tissue77 where it binds to and
activates nAChRs, a family of multi-subunit neurotransmitter receptors which typically bind
endogenous acetylcholine.78 Faster nicotine metabolism reduces serum nicotine levels more
quickly freeing nAChRs for binding,47 and could contribute to craving and withdrawal
symptoms48,79 if homeostasis is not maintained through continued nicotine intake. Thus,
smokers with faster nicotine metabolism may need to smoke more cigarettes per day (CPD) to
maintain stable serum nicotine levels.80
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Variation in the rate of nicotine metabolism influences smoking behavior.81 Earlier
evidence reviews suggested that slower versus faster nicotine metabolism, as measured by the
nicotine metabolite ratio (NMR), is associated with smoking fewer CPD, higher quit rates on
nicotine replacement therapy (NRT), and similar quit rates on bupropion.82,83 A recent (2019)
systematic review examined evidence of the association between NMR and smoking cessation
from two randomized controlled trials again showing NRT may be more effective for those with
slow nicotine metabolism.84 These reviews demonstrate the importance of understanding the
relationship between nicotine metabolism and smoking cessation.
Though NMR is influenced by genetic, hormonal, and environmental factors85, evidence
shows CYP2A6 variants are the strongest predictors of nicotine metabolism.75,86 Thus,
identifying CYP2A6 associations with smoking cessation is a promising line of inquiry with
potential relevance to precision medicine strategies in designing and implementing interventions
to increase the rates of successful long-term smoking cessation. For these reasons, the
objective of this investigation was to perform a systematic review of the epidemiological
evidence of CYP2A6 variants in relation to smoking cessation or smoking relapse.
6.3 Methods
This systematic review addressed the question “Are CYP2A6 variants associated with
smoking cessation in smokers?” The independent variable was thus defined as variants in
CYP2A6. The dependent variable was smoking cessation measured as abstinence from
smoking either continuously or at a point in time.
6.3.1 Inclusion criteria. To be eligible for inclusion, a study had to be in humans and present
data for ≥1 CYP2A6 variant in relation to smoking cessation measured as either continuous or
point abstinence, number of quit attempts, or time to cessation. Studies with prospective followup were included comprising randomized controlled trials, open label trials, cohort studies, nested
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case-control studies, and studies that analyzed pooled data. Cross-sectional studies relying on
a single measurement of smoking status (former vs. current) were also included. Only studies
published in peer-reviewed journals and in English were included.
6.3.2 Exclusion criteria. Articles were excluded if they met one or more of the following criteria:
1) did not have a smoking cessation or relapse outcome, 2) not published in English, 3) did not
test a genetic exposure, 4) non-human subjects, 5) news, commentary, or letter to the editor, 6)
review paper, 7) heritability study such as twin/family studies or linkage studies, and 8) studies
evaluating notification of genetic susceptibility to disease on motivation to quit smoking.
6.3.3 Literature Search. A search of both the PubMed and Scopus databases was conducted
for evidence of the association between CYP2A6 variants and smoking cessation (Figure 1).
These two databases were searched for journal articles published between January 1990 and
February 7, 2020. An alert was set to provide notification of articles meeting the search criteria
that were published online after February 7, 2020 through October 31, 2020. The PubMed
database was searched using MESH search terms “tobacco use cessation” OR “smoking
cessation” AND “genetic variation” OR “genetics” OR “precision medicine.” The Scopus database
was searched for article titles with the terms “gene*” OR “snp” OR “polymorphism*” OR “telomer*”
OR “mutation*” OR “precision medicine” and was then further limited to titles that also included
the terms “smoking” OR “tobacco” OR “cessation” OR “quit” OR “nicotine” OR “cigarette” AND the
terms “cessation” OR “quit” OR “quitting” OR “stop” OR “stopping” OR “abstin*” OR “relapse” and
human and English only studies.
The PubMed search yielded 625 citations and the Scopus search yielded 353 citations,
from which 137 duplicate records present in both databases were removed (Figure 1). The titles
and abstracts of the remaining 841 articles were screened using the inclusion and exclusion
criteria, leaving 15 articles for full-text review. Upon full-text review, 3 of the 15 remaining articles
were excluded based on inclusion/exclusion criteria.
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6.3.4 Data extraction. The data extracted from the 12 included articles constituted effect size
measures and confidence intervals, study design, sample size, study inclusion/exclusion criteria
(e.g. participant ages, CPD cut-offs excluding or including light smokers), ancestry and sex of
participants, and, if relevant, intervention types and protocols and any pharmacogenomic
analysis. Some articles had relevant data but the comparisons presented in the published
manuscript or supplementary data did not align with the methodology of other studies (e.g.
results reported were stratified by genotype or metabolism phenotype versus results reported
stratified by pharmacotherapy intervention). In these instances, we contacted the
corresponding authors to obtain the relevant results so the studies could be included in the
review.
6.3.5 Statistical Analysis. The methods for categorizing metabolism varied across studies.74,87
Nine of the twelve studies categorized participants’ nicotine-to-cotinine metabolism function by
the presence of variants predominantly known to impair CYP2A6 enzyme activity and tested the
association of these nicotine metabolism categories with smoking cessation. The three
remaining studies tested the association of individual CYP2A6 variant genotypes with cessation
outcomes. To harmonize these findings that were presented differently across studies, we
separately determined nicotine metabolism categories based on the known loss of function and
decrease of function effects of CYP2A6 variants on metabolic activity described in Table 1. We
designated the following nicotine metabolism categories: normal metabolism (NM) (>75%
metabolic activity, e.g. wild type), intermediate metabolism (IM) (50.1 - 75% activity), slow
metabolism (SM) (25 - 50% activity), and poor metabolism (PM) (<25% activity). The specific
CYP2A6 variants from Table 1 that were available in each study to designate these metabolic
categories are listed in Table 2. When data on multiple variants were available, nicotine
metabolism was categorized based on the estimated combined effect of the variants (e.g. 1
decrease of function variant = IM whereas 2 decrease of function variants = SM). It was
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possible to categorize the comparison for all studies except for the study by Stevens et al. that
tested a CYP2A6 variant with unknown metabolic effects.88 Metabolic categories were
evaluated on their own if the study data available made it possible to distinguish each category.
Some studies did not have data available to enable separating participants with slow
metabolism from those with poor or intermediate metabolism; in this case, the categories were
grouped together as having at least slow metabolism but possibly poor (PM/SM) or having at
least intermediate metabolism but possibly slow metabolism (SM/IM).
Studies were stratified by ancestry of the study population to address differences in
allelic frequencies between ancestral groups. Results were further stratified according to
whether participants received a smoking cessation pharmacotherapy (e.g. NRT, varenicline,
bupropion) or received placebo or no intervention. The Laird and DerSimonian estimators for
the fixed effects, the log odds of abstinence, within each strata of studies were obtained using
the %METAANAL SAS macro, which also tested for between-study heterogeneity.89,90 Random
effects pooling was assumed, weighting the studies proportionate to the inverse of the study
variance plus the between-studies variance.
6.4 Results
Of the twelve studies identified examining CYP2A6 genetic variation and smoking
cessation (Table 2), the participants were comprised of people of European or predominantly
European ancestry in eight studies, Asian ancestry in three studies, and African ancestry in one
study. Among the studies of European populations, four were trials of pharmaceutical
interventions of bupropion, nicotine replacement therapy (NRT) or varenicline; two of the trials
included a placebo arm. Inclusion criteria for these four trials were similar: adult smokers
consuming 10 or more CPD. Three of the remaining studies of people of European ancestry
were prospective cohort studies, two that included no pharmacotherapy, and one that included a
subset of participants from a smoking assistance program cohort who reported using
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varenicline. These cohorts did not report using a CPD cutoff for inclusion/exclusion. The cohort
using varenicline recruited adult smokers (≥18 years of age), and one other cohort also included
adult smokers 29-65 years old. The third cohort was comprised of adolescents (12-17 years
old). The remaining study of people of European ancestry was a nested case-control study of
participants 50-79 years old who had smoked 10 or more CPD for at least 25 years. The sample
sizes of these eight studies ranged from 70 to 5,277. All three studies of people of Asian
ancestry were predominantly male (91.7-93.1% male) and were cross-sectional studies relying
on smoking status at the time of recruitment; in two of these studies the participants were of
Japanese ancestry and in the other the participants were of Han Chinese ancestry. Among the
studies of people of Japanese ancestry, one included only participants that were at least 50
years old who had smoked at least 10 pack-years, whereas the other study included adult ever
smokers, but did not define cut-offs for determining ever smoker status. The study of people of
Han Chinese ancestry included participants at least 20 years old who were ever-smokers,
defined as smoking at least 100 lifetime cigarettes. The sample sizes of these three studies
ranged from 96 to 1,328. The remaining study of adult (≥18 years old) people of African
ancestry was a randomized controlled trial of 588 smokers which tested the efficacy of NRT
compared with placebo and limited inclusion to only light smokers (<10 CPD).
6.4.1 European ancestry - Placebo/No pharmaceutical intervention (n = 4 studies). The
results of studies of populations of European ancestry with no pharmacotherapy intervention
showed that slower nicotine metabolism was associated with increased likelihood of smoking
cessation. The results of a cohort study22, from the placebo arm of two trials25,91, and a nested
case-control study92, showed those with at least some reduction in nicotine metabolism activity
were significantly more likely to quit smoking compared to those with normal metabolism
[Summary OR = 2.05, 95% CI 1.23 - 3.42] (Figure 2 (a)). Significant heterogeneity was present
across these studies, likely due to the differences in metabolism phenotype comparisons.
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Assessing the dose-related relationship of decreasing nicotine metabolism, the summary ORs
compared with normal metabolism were 1.25 for intermediate metabolism [95% CI 0.93 -1.68],
2.26 for slow or poor metabolism [95% CI 1.28 - 3.99], and 5.92 for poor metabolism [95% CI
2.40 - 4.63]. These associations were consistent with a dose-related relationship showing
increased odds of smoking cessation with slow nicotine metabolism. The dose-related
comparisons eliminated the significant heterogeneity between studies. (Q statistics, I2, and pvalues resulting from tests for heterogeneity between studies are available in Supplementary
Figure 1).
A study in the American Cancer Society’s Cancer Prevention Study 3 (CPS 3) cohort
found those carrying the rs8192729 G>A minor (A) allele were more prone to relapse than noncarriers.88 This study could not be included in the meta-analysis because neither this variant’s
impact on nicotine metabolism nor its association with CYP2A6 functional variants are known.
6.4.2 European ancestry – Pharmaceutical interventions (n = 5 studies) Figure 2(b).
In studies of populations of European ancestry who were administered an NRT intervention (n =
4 studies), those with reduced metabolism (IM, SM, or PM) had greater odds of smoking
cessation but the association was not statistically significant (Summary OR = 1.38, 95% CI 0.91
– 2.11).25,27 There was significant heterogeneity among these studies due to one outlying result
from Verde et al. which observed that reduced metabolizers (IM or SM) had 3.86 [95% CI 1.94
– 7.72] the odds of abstinence compared to normal metabolizers.93 This outlier could be due to
several factors such as the extremely small sample size (n=36), the open label nature of the
trial, or the 12 months post-treatment abstinence outcome. In sensitivity analysis with this study
removed, the association was substantially attenuated [Summary OR = 1.13, 95% CI 0.94 –
1.37] and there was no longer significant heterogeneity across studies. Null findings comparing
reduced metabolizers (IM or SM) to normal metabolizers were also observed among study
participants receiving varenicline (n = 2 studies) [Summary OR = 0.94, 95% CI 0.73 – 1.22].91,94
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Among people of European ancestry administered bupropion (n = 2 studies), reduced
metabolizers (IM or SM) were significantly less likely to quit smoking compared to normal
metabolizers at end-of-treatment [Summary OR = 0.86, 95% CI 0.79 – 0.94].91,93
6.4.3 Asian ancestry – Cross-sectional studies (n = 3 studies) – Figure 2 (c). In contrast to
findings in those of European ancestry, three studies of Asian people95-97 suggest slow nicotine
metabolism may be associated with reduced odds of abstinence in untreated populations
[Summary OR = 0.52, 95%CI 0.38 – 0.71].
6.4.4 African ancestry (n = 1 study) – Figure 2 (d). In the sole study of people of African
ancestry, among participants randomized to placebo, no significant difference in odds of
abstinence was found between slow and normal metabolizers [OR = 0.78, 95%CI 0.38 – 1.61].
However, among women in the NRT arm, those with slow metabolism were more likely to be
abstinent at the end of eight weeks than those with normal metabolism [OR = 2.54, 95%CI 1.28
– 5.02].26 This association was not found in men; however, the odds ratio and specific p-value
were not reported.
6.5 Discussion
Given the important role of CYP2A6 in nicotine metabolism, this systematic review
aimed to synthesize the evidence of the potential role of CYP2A6 variants in smoking cessation
and relapse. The bulk of the evidence stems from studies of populations of European ancestry,
all of which used prospective follow-up to evaluate changes in smoking status. Among
untreated people of European ancestry, a monotonic dose-related relationship provided
convincing evidence that the likelihood of smoking cessation increases as the rate of CYP2A6
predicted nicotine metabolism decreases. The dose-related relationship, the strength of the
association, and prospective follow-up provide robust evidence that among smokers of
European ancestry, slow nicotine metabolism increases the likelihood of smoking cessation.
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The results in those of European ancestry also suggest the use of pharmacotherapy smoking
cessation interventions may attenuate or modify the CYP2A6 genetic association with smoking
cessation but that the change in the association may depend upon which pharmacotherapy is
administered. The administration of NRT or varenicline attenuated the association such that the
difference in likelihood of smoking cessation between intermediate or slow metabolizers and
normal metabolizers in these treatment groups was not statistically significant. However, the
use of bupropion appeared to significantly reverse the direction of the association. Due to the
differences in CYP2A6 variants genotyped and the corresponding nicotine metabolism
classifications across the limited number of studies, it was not feasible to look for the doserelated relationship within each treatment group.
In addition to insufficient data to test for the dose-related relationship within
pharmacotherapy groups, it was also unclear if the mitigation of the associations observed in
these groups remains consistent long-term after pharmacotherapy use has ceased. The studies
suggest the difference in cessation outcomes between slow and normal metabolizers is
attenuated during NRT administration because NRT may more effectively promote end of
treatment abstinence in fast metabolizers than in slower metabolizers.25,27 For example, Chen et
al. found that end of treatment abstinence among those randomized to placebo was significantly
lower among fast metabolizers compared to poor metabolizers; among poor metabolizers,
abstinence was similar in both the placebo and NRT arms. However, among participants
randomized to NRT, abstinence rates were higher among fast metabolizers so that the rate was
similar to that observed among the poor metabolizers. We would expect to observe the largest
pharmacotherapy effect on smoking cessation during and at the end-of-treatment and some
attenuation in the effect long-term, but the studies with a 12-month follow-up found contradictory
results. These contradictory results make it difficult to infer the degree to which associations
observed at end of treatment would be observable long-term. Verde et al. observed that 1241

months after NRT use ended, slow/intermediate metabolizers had increased odds of abstinence
compared to normal metabolizers93, whereas Lerman et al. observed no statistically significant
difference in abstinence 12-months post-cessation between slow/intermediate and normal
metabolizers who had received either standard (8 weeks) or extended (6 months) NRT.27 The
fact that Verde et al. evaluated only 36 smokers receiving NRT may help explain the disparate
findings. More research is needed to fully understand these associations.
The results also suggested bupropion pharmacotherapy may be less effective or not
effective for slow nicotine metabolizers. These findings were observed during either 6- or 12month follow-up implicating that the effect may be present long-term. Though based on only
two studies, these results are supported by a previous study that based nicotine metabolism on
NMR quartiles, with results showing that bupropion was effective over placebo for smoking
cessation among those with faster nicotine metabolism but had little to no impact on cessation
over placebo for those with slower metabolism.98 The association between CYP2A6 genotype
and smoking cessation among smokers using a bupropion intervention could be due to genegene interactions between CYP2A6 and CYP2B6 variants.99,100 The CYP2B6 gene encodes for
an enzyme that metabolizes bupropion. The role of CYP2B6 on nicotine metabolism is likely
minor, but some CYP2B6 variants may increase nicotine metabolism and the degree of
increase may be larger in those with reduced function CYP2A6 variants.99,100
Though studies of people of non-European ancestry were few, and often used crosssectional study designs, the evidence suggested variation in the association of CYP2A6 with
smoking cessation by ancestry. In the single study of people of African ancestry, CYP2A6
genotype was not associated with abstinence in the placebo arm; however, the contrasting
results could be due to the study population being light smokers26, the difference in allelic
frequencies between ancestral groups101, or a combination of these, or other, factors. Among
untreated people of Asian ancestry, a strong association in the opposite direction as that
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observed in people of European ancestry was present such that, slow metabolizers were
significantly less likely to have quit smoking than normal metabolizers. All three studies of Asian
people used cross-sectional measurement of smoking status (former vs. current smoker) at the
time of recruitment into the study whereas the studies of populations of European ancestry
evaluated prospective changes in smoking status. These differences in study design could
contribute to the discordant findings between people of Asian ancestry compared to people of
European ancestry. The disparate findings could also be due to significantly greater
frequencies of loss or reduced function CYP2A6 alleles among populations in China and
Japan.101 Further complicating comparisons, China and Japan have a higher prevalence of
heavy smokers, those consuming ≥20 CPD, than the United States or Europe101,102 and East
Asian smokers express lower interest in quitting103 compared to smokers in the United States.104
This phenomenon may be partially explained by social or cultural factors within these East
Asian populations such as the importance of smoking as part of social and familial networking in
mainland China103,105 or lower perceived health risks of cigarette smoking in East Asia.106,107
The social acceptance of cigarette smoking and decreased motivation to quit among East Asian
populations may confound detection of genetic associations with smoking cessation.
None of the studies of people of Asian ancestry examined pharmacotherapy
interventions, thus it remains unknown if the effects of pharmacotherapy would differ in these
populations compared to those observed among people of European ancestry. The findings
among people of African ancestry who were light smokers receiving NRT is the opposite of
those observed among populations of European ancestry: NRT gum appeared to be more
effective in promoting end-of-treatment abstinence in slow metabolizer genotypes26, but this
association was found only among the females. The disparate findings between ancestral
groups may be due to differences in CYP2A6 allelic frequencies between populations of African
ancestry compared with European ancestry101; however, the results among women of African
43

ancestry are consistent with the study of people of European ancestry by Verde et al.93 in which
the study population was predominantly female. Though the endpoint in Verde et al. was not at
end-of-treatment with NRT but rather 12-months post-treatment, it is plausible that there may be
sex differences in the effectiveness of NRT by CYP2A6 predicted nicotine metabolism. Support
for potential sex differences in the effectiveness of NRT is found in a meta-analysis of 14
randomized controlled trials of transdermal nicotine patch interventions for smoking cessation
which found that the nicotine patch increased abstinence 6-months post-cessation in both men
and women, but the patch was less effective among women compared to men.108 CYP2A6 is a
strong determinant of nicotine metabolism, but additional factors such as the endogenous
hormone estrogen also contribute to nicotine metabolism and may partially explain the
differences between men and women.85
In addition to allelic frequencies and sex differences, the different results could also be
an artifact of the inclusion of only light smokers in the study of people of African ancestry and
the exclusion of light smokers in studies of populations of European ancestry. Further
complicating the comparison is that the study of people of African ancestry used NRT gum,
whereas the trials of people of European ancestry used transdermal patches or combined NRT
methods such as patches and lozenges. Smokers with faster rate of nicotine metabolism not
only tend to smoke more CPD80, but likely experience more severe and earlier onset of
withdrawal symptoms47,48 and thus require more robust NRT delivery to combat the greater
severity of the symptoms and cravings. For light smokers with less severe withdrawal, NRT
gum may be effective. Consequently, the use of different NRT products may complicate
comparisons across studies.
In summary, most genetic studies of CYP2A6 and smoking cessation are of populations
of European ancestry and these studies show a dose-related relationship that the likelihood of
smoking cessation increases as the rate of CYP2A6 predicted nicotine metabolism decreases.
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The use of pharmacotherapy appeared to attenuate associations between nicotine metabolism
and cessation among people of European ancestry, but this was based on relatively few studies
that used different designs and pharmacotherapy interventions. In addition, the few studies of
Asian people have all used a cross-sectional design, often with small sample sizes (e.g., n =
96), and at this time only one study of people of African ancestry is available. Thus, there is a
need for more large prospective studies and randomized controlled trials, especially of
ancestrally diverse populations, to enrich understanding of the relationship between CYP2A6
and smoking cessation. Additionally, because NMR is a biomarker of CYP2A6 enzyme activity,
a future systematic review synthesizing the evidence related to NMR and smoking cessation will
provide valuable complementary evidence to the present systematic review to provide a more
complete understanding of CYP2A6 in relation to smoking cessation.
6.6 Conclusion
The evidence to date suggests that among smokers of European ancestry not receiving
pharmacotherapy those with CYP2A6 reduced metabolism genotypes are more likely to quit
smoking than those with normal metabolism genotypes. Support for this association is
strengthened by the finding of a dose-related relationship showing that the likelihood of quitting
increases as metabolism decreases. Among people of European ancestry, findings also
suggest NRT may reduce the higher likelihood of cessation among those with CYP2A6 slow
metabolism; however, it remains unclear if such attenuation has long term effects after the NRT
intervention ends. Further research to understand the long-term effectiveness of NRT
interventions by nicotine metabolism genotype will help to inform precision medicine strategies.
Though evidence suggests the association between CYP2A6 and cessation among
people of Asian ancestry and African ancestry may differ from the associations observed among
those of European ancestry, this inference is based on only three cross-sectional studies of
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Asian people and one randomized clinical trial of people of African ancestry. Nonetheless,
differences in associations by ancestry are plausible and may be due to differences in social
acceptance and perceived risk of smoking, variation in allelic frequencies between ancestral
groups, and differences in smoking topography, such as depth of inhalation and cigarettes per
day. More research is needed to gain an understanding of the association between CYP2A6
and smoking cessation among diverse populations.
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Identification

6.7 Figures

Records identified in
database search
(n = 978)

Screening & Eligibility

Duplicate records removed
(n = 841)

Title & Abstract Review:
Step 1: Exclusion screening
(n = 167)

Included

Title & Abstract Review:
Step 2: Inclusion screening
(n = 15)

Exclusion Criteria
No smoking behavior/cessation outcome (n = 422)
No Genetic Exposure (n = 99)
Non-English or non-human (n = 4)
News, Commentary, or letter (n = 34) or Review paper (n = 78)
Heritability or linkage study (n = 18)
Efficacy of genetic notification on motivation (n = 19)

Inclusion Criteria
Independent variable = variant of CYP2A6 (n = 15),

Exclusion Criteria
CYP2A6: no cessation/relapse outcome (n = 3)

Included
CYP2A6 (n = 12)

Figure 1. Summary of search process in systematic review of CYP2A6 variation in relation to smoking
cessation in observational studies and clinical trials of smoking cessation interventions.

47

48

Figure 2. CYP2A6 results. a) European ancestry with no pharmaceutical treatment or in a placebo arm, b) European ancestry in pharmaceutical treatments groups, c) Asian
ancestry, d) African ancestry (results are for women). NM = Normal Metabolism, IM = Intermediate Metabolism, SM = Slow Metabolism, PM = Poor Metabolism, EOT =
End of Treatment, NRT = Nicotine Replacement Therapy, * = significant heterogeneity
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Supplementary Figure 1. Summary odds ratios and test of heterogeneity across studies (Q statistic and p-value)

6.8 Tables
Table 1. CYP2A6 alleles and functional effect on nicotine metabolism
Decreased function alleles reducing metabolic activity to <75% of normal (wild type) level†
CYP2A6 allele Identifying variant(s)
Genotype
Ref.
20,27,47,48
CYP2A6*9
rs28399433 (possibly rs4803381)
heterozygotes
20,47,49
CYP2A6*12
Partial gene deletion
heterozygotes
50
CYP2A6*23
rs56256500
heterozygotes
Decreased or Loss of function alleles reducing metabolic activity to <50% of normal (wild type) level†
CYP2A6 allele Identifying variant(s)
Genotype
Ref.
20,39,51
CYP2A6*2
rs1801272
heterozygotes
20,39,51
CYP2A6*4
Gene deletion
heterozygotes
39,51
CYP2A6*5
rs5031017
heterozygotes
39,52
CYP2A6*7
rs5031016
heterozygotes
20,27,47,48
CYP2A6*9
rs28399433 (possibly rs4803381)
homozygotes
39
CYP2A6*10
rs5031016, rs28399468
heterozygotes
20,47,49
CYP2A6*12
Partial gene deletion
homozygotes
50,53
CYP2A6*17
rs28399454
heterozygotes
54
CYP2A6*20
rs28399444
heterozygotes
Loss of function alleles reducing metabolic activity to <25% of normal (wild type) level †
CYP2A6 allele Identifying variant(s)
Genotype
CYP2A6*2
rs1801272
homozygotes
CYP2A6*4
Gene deletion
homozygotes
CYP2A6*5
rs5031017
homozygotes
CYP2A6*7
rs5031016
homozygotes
CYP2A6*10
rs5031016, rs28399468
homozygotes
CYP2A6*17
rs28399454
homozygotes
CYP2A6*20
rs28399444
homozygotes
CYP2A6*23
rs56256500
homozygotes

Ref.
20,39,51
20,39,51
39,51
39,52
39
50,53
54
50

† The CYP2A6 *1 allele is considered normal (wild type) level metabolism. The *1 variant includes both *1A and *1B when
differentiated.

50

51

Crosssectional
Crosssectional
Prospective
Cohort
Nested case
control
Prospective
Cohort

IM: 1 copy of decreased function
variant (*9).
SM: 2 copies of decreased function
variant (*9) or 1 copy of loss of function
variant (*4, *5, *7, or *10)
PM: 2 loss of function variants
SM: 1 or 2 copies of *4 loss of function
variant

SM: 1 or 2 copies of *4 loss of function
variant

rs8192729 (unknown effect on
metabolic activity)

SM: 1 or more copies of *2, *4, or *9
variants
*2 allele (rs1801272) (<50% activity)

*9 allele (rs28399433) (<70% activity)

SM: 1 or 2 copies of *2 variant, or IM: 1
copy of *9 variant

SM vs. NM
and IM vs.
NM

PM/SM vs.
IM/NM

SM/IM vs NM

PM vs. NM,
SM vs. NM,
IM vs. NM

SM vs. NM

SM vs. NM

N/A

SM/IM vs.
NM
SM vs. NM

IM vs. NM

SM/IM vs.
NM

Chenoweth
(2013)

Ho (2009)

Lerman
(2010)

Liu (2011)

Minematsu
(2003)

Ohmoto
(2014)

Stevens
(2017)

Styn (2013)

IM: 1 copy of decreased function
variant (*9 or *12).
PM/SM: 2 copies of loss of function (*2,
*4, *17, *20, *23-27, *35) or 1 copy of
loss of function and 1 copy of decreased
function (*9 or *12)
*2, *9, *12, *4 CYP2A6 haplotypes

Open label
trial

Crosssectional

RCT

N = 70 (77%
women)

N = 878 (52%
female)
N = 167 (57.2%
female)

N = 5,277
(75.6% female)

European
(Spanish)

92%
European
83%
European

European

Asian
(Japanese)

Asian
(Japanese)

N = 203 (93.1%
male)
N = 96 (91.7%
male)

Asian (Han
Chinese)

European

African

N = 1328
(92.4% male)

N = 471 (58%
male)

N = 588 (67.5%
female)

European

European

N = 709 (58.7%
female)
N = 308 (63.7%
female)

European

Ancestry

N = 2,499
(56.1% female)

Sample Size

≥ 18 years old, > 10
CPD, > 10 pack-years

29-65 years old, ever
smoker – ≥1 CPD for 1
year
50-79 years old, ≥ 10
CPD for ≥ 25 years
≥ 18 years old

Point abstinence at 1-year
post-treatment

9+ failed quit attempts vs.
1 quit attempt and
abstinent > 1 year)
30-day abstinence at 1 year follow-up
6-months continuous
abstinence

Current vs. Former
Smokers (quit for at least
6-months)
Current vs Former smoker
(quit for at least 1-year)

≥ 50 years old, ≥ 10
pack-years
>18 years old,
ever smoker*

Current vs Former smoker
(self-reported quit and
abstinent at time of
interview)

Point prevalent abstinence,
at EOT (8-weeks)

18-65 years old, ≥ 10
CPD
≥ 20 years old, ever
smoker - 100 lifetime
cigarettes

point prevalent abstinence,
at EOT (8-weeks)

≥ 18 years old, < 10
CPD, interested in
quitting within 2 weeks

12-17 years old, ever a
puff of a cigarette, no
CPD requirement
1-year abstinence

Point prevalent abstinence,
at EOT (8-12 weeks) & 26weeks
Relapse 90-days postcessation

≥ 18 years old, ≥ 10 CPD

≥ 18 years old, ≥ 10 CPD

Outcome/follow-up
timepoint

Key eligibility criteria

transdermal NRT or
bupropion

Varenicline

None

None

None

None

None

Transdermal NRT

NRT (Females only, n
= 200)

NRT gum/Placebo

None

Placebo, bupropion,
NRT, bupropion +
NRT, varenicline
Placebo, Bup, NRT,
Bup + NRT

Treatment

NM = Normal metabolism (>75%), IM = Intermediate metabolism (50.1-75%), SM = Slow metabolism (25-50%), PM = Poor Metabolism (<25%). The CYP2A6 *1 allele is considered normal (wild type)
level metabolism. The *1 variant includes both *1A and *1B when differentiated. EOT = End of Treatment. * = “ever smoker” was not defined by Ohmoto et al.

Verde
(2014)

Tomaz
(2019)

Prospective
Cohort

IM: 1 copy of decreased function
variant (*9 or *12).

PM vs.IM/NM

Chen
(2014)

RCT

RCT (Pooled
data from 8
RCT)
RCT

rs4803381 & rs1137115 (reduced
activity, may be associated with *9
haplotype, <70% activity)
PM: bottom 25% of CYP2A6 activity
based on *2, *9, *12, and *4 variants

IM vs. NM

Bergen
(2015)

SM: 2 copies of decreased function
variant, or 1 or 2 copies of loss of
function variant (*2 or *4)

Study
Design

Variants used to predict metabolism

Metabolism
Comparison

Study

Table 2. Description of studies of CYP2A6 and smoking cessation included in the review
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7.1 Abstract
7.1.1 Background: Nicotine produces its effects by binding to nicotinic acetylcholine receptors
(nAChRs). Several genes encode for properties of these receptors, making variants in these
genes excellent candidates for affecting the likelihood of smoking cessation.
7.1.2 Methods: A systematic review was conducted to summarize evidence of associations
between single nucleotide polymorphisms (SNPs) of nAChR genes and smoking cessation.
From 22 articles meeting inclusion criteria, summary odds ratios (ORs) for associations between
nine SNPs and smoking cessation were calculated stratified by gene, ancestry, study design,
and pharmacotherapy; SNPs in linkage disequilibrium were pooled.
7.1.3 Results: People of European ancestry with the minor alleles of CHRNA5 rs16969968 and
CHRNA3 rs1051730 had longer time to cessation [HR = 0.90, 95% CI 0.88 – 0.92) (n = 2
studies)] and lower odds of cessation [OR = 0.88, 95% CI 0.80 – 0.97 (n= 5 cohort studies), OR
= 0.64, 95% CI 0.45 – 0.90 (n = 4 placebo arms)]. The risk of persistent smoking associated
with these minor alleles was attenuated in smokers receiving nicotine replacement therapy
(NRT), whereas recipients of bupropion alone or with NRT with these alleles had higher, though
not statistically significant, odds of cessation. Results for CHRNA5 rs588765 and rs680244
were similar to those observed for rs16969968/rs1051730. Evidence was limited with respect to
other SNPs and ancestral populations.
7.1.4 Conclusion: Evidence consistently indicates the minor alleles of four SNPs within
CHRNA3 or CHRNA5 are risk alleles for cessation failure. Analysis by pharmacotherapy
revealed that bupropion may be the most efficacious intervention for people with these alleles.
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7.2 Introduction
Less than 8% of U.S. adult smokers who attempt to quit smoking each year are
successful1, and 25% or more of those who quit relapse after two to five years of abstinence.2
Precision medicine approaches to smoking cessation and relapse prevention hold promise for
improving rates of long-term cessation. Identification of genetic variants associated with
cessation is needed to inform such approaches.
Nicotine delivery via cigarette smoke binds to nicotinic acetylcholine receptors
(nAChRs), a family of multi-subunit neurotransmitter receptors, stimulating the release of
several neurotransmitters, including dopamine.3 This interplay between nAChRs and the
mesolimbic dopamine (DA) pathway produces biochemical effects of nicotine that contribute to
the onset of craving, withdrawal and tolerance as well as conditioned drug-seeking behavior.4,5
Furthermore, several nAChRs are implicated in associative learning6,7, memory8, and negative
occasion setting9, with nicotine enhancing these areas of cognitive functioning. Genetically
driven properties of nAChRs (e.g. degree of natal expression, ratio of sub-unit types and binding
affinity) influence nicotine response and could facilitate conditioned drug seeking behavior, thus
variants within genes encoding for nAChRs are excellent candidates for smoking cessation
research because of their translational potential for clinical precision medicine approaches.
Each nAChR is a pentameric structure consisting of five subunits. Twelve genes encode
for the nAChR subunits expressed in the brain, CHRNA2-10 encode the α-2 – α10 subunits and
CHRNB2-4 encode the β2 – β4 subunits.10 Genetic variation within these genes influences
various properties of nAChR receptors, such as the degree of natal expression, binding affinity,
and the α-to-β receptor subunit ratio that contributes to nicotine sensitivity.11 The primary
subunits expressed in the brain are α7 and β2. The α7 subunit comprises homomeric nAChRs
and has not yet been linked to nicotine-induced reward or conditioned behavior in animal
models10,12 In contrast, the β2 subunit, which contributes to the structure of several heteromeric
nAChRs, has a high affinity for nicotine and is directly involved in dopamine activation.10 The β2
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subunit is seen alongside the α4 subunit in two of the major nAChR subtypes influencing
nicotine addiction, the (α4)2(β2)2α5, and (α4)3(β2)2 receptors.13 Other major subtypes
contributing to nicotine dependence are the (α3)2(β4)2α5 and (α3)2(β2)2α5.14 Thus, genetic
variants within the genes encoding for the α3, α5, and β4 subunits along with the β2 and α4
subunits are excellent candidates for genetic research of nicotine addiction and smoking
behavior.
This review aimed to examine the population-based evidence in relation to variants
within nAChR genes and smoking cessation outcomes. Though a 2017 systematic review15 of
genetics and smoking cessation synthesized evidence for four nAChR SNPs, three within
CHRNA5 and one within CHRNA3, this prior review concentrated on pharmacogenomic
analysis, limiting the evidence to randomized controlled trials identified in a search of clinical
trial registries and genetic databases. As such, it did not reflect the wide variety of study
designs and approaches, including observational studies, open label trials, and randomized
controlled trials, used for genetic research into smoking cessation. An examination of the
totality of the evidence from this broader range of studies promises to further the understanding
of genetic factors associated with smoking cessation. This approach provided additional
evidence for the four SNPs identified in the prior pharmacogenomic review as well as enabled
the synthesis of existing findings for five additional nAChR SNPs within CHRNA3, CHRNA4,
CHRNB2, or CHRNB4.
7.3. Methods
The aim of this systematic review was to investigate evidence of associations between
genetic variants within nAChR genes and smoking cessation. The independent variable was
defined as single nucleotide polymorphisms (SNPs) within genes encoding for nAChR subunits.
The dependent variable was smoking cessation measured as time to smoking cessation or by
abstinence from smoking, the latter measured at the end of treatment for smoking cessation
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interventions or at the primary follow-up endpoint for prospective cohort studies. For crosssectional studies, abstinence outcome was determined via participant recall per the study
design.
7.3.1 Inclusion criteria. To be eligible for inclusion, the study had to be of humans, available in
English, and report on the association of one or more SNPs within a nAChR gene with a
smoking cessation outcome, defined as point abstinence, continuous abstinence, quit attempts
required to achieve abstinence, or time to cessation. Randomized-controlled trials, nonrandomized trials, open label trials, cohort studies, and cross-sectional studies were all
included.
7.3.2 Exclusion criteria. Studies were excluded if they did not have a smoking cessation
outcome or used a genetic risk score as the independent variable. Also excluded were news
stories, commentaries, letters to the editor, review papers, heritability or linkage studies, studies
with ≤ 1-month follow-up, studies that used the same data and tested the same SNPs as
another study16,17, and one study reporting results for novel and intergenic SNPs and haplotypes
of nAChR genes.18
7.3.3 Literature search. We searched the PubMed and Scopus databases for evidence of
associations between SNPs within nAChR genes and smoking cessation (Figure 1). The
original search was conducted on February 7, 2020 for journal articles published from January
1, 1990 through February 7, 2020, and alerts were set to identify articles meeting search criteria
published from February 7, 2020 through September 14, 2021. The PubMed and Scopus
searches retrieved 625 and 353 records, respectively, for a total of 841 unique articles
(removing duplicates) for evaluation of exclusion/inclusion criteria. (Search terms are detailed in
Appendix 1).
7.3.4. Article screening and data extraction. Of the 841 articles, 809 were excluded after
abstract screening (Figure 1). After full text review of the remaining 32 articles, 10 records were
excluded leaving 22 articles included in the systematic review. For these 22 articles, data were
60

extracted for study design, sample size, participant ancestry, intervention protocols, SNP
associations with smoking cessation, and pharmacogenomic analysis results.
Two articles reported results from the University of Wisconsin Transdisciplinary Tobacco
Use Research Center (UW-TTURC) randomized controlled trial19,20; the results from the most
recent analysis19 were used in the evidence synthesis when both articles reported results for the
same SNP (CHRNA5 rs16969968) and treatment group (placebo and NRT arms). Two other
articles included in the review were meta-analyses of pooled data; one pooled data from eight
clinical trials and the other pooled data from 24 consortia or cohort studies. When relevant
results for a SNP from the same study were presented in both a study-specific publication and a
meta-analysis, the results from the meta-analyses were used for the present systematic review
(CHRNB2 rs207166121 and CHRNA5 rs1696996820).
7.3.5 Statistical analysis. Associations of nAChR SNPs with smoking cessation were
organized by gene, study design, ancestry, and pharmacotherapy. Study results for SNPs in
linkage disequilibrum (D’ = 1.00 and r2 = 1.00) were pooled and summary measures were
obtained using the %METAANAL SAS macro, which produced the Laird and DerSimonian fixed
effect estimators and tested for between-study heterogeneity.22,23 Random effects pooling was
assumed weighting the studies proportionate to the inverse of the study variance plus the
between-study variances.
7.4 Results
The review identified 22 articles reporting results from 26 studies: 10 randomized trials, 5
open label trials, 1 meta-analysis of data pooled from eight trials, 8 cohort studies, 1 crosssectional study, and 1 meta-analysis of data pooled from 24 datasets (Table 1). The sample
sizes of the fifteen trials ranged from 233 to 1,073. Most trials were of European ancestry
populations (n = 10) or predominantly European ancestry populations (n = 3), and two of the
trials were of people with African ancestry. The meta-analysis of pooled trial data comprised
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people of European ancestry and had a total sample size of 2,633. The sample sizes of the
cohort studies ranged in size from 901 to 5,216 and all cohorts comprised people of European
ancestry. The sole study of Han Chinese people was cross-sectional with a sample size of 819.
The largest study included in the review was a meta-analysis of data pooled from 24 datasets.24
Data for this meta-analysis included people of European ancestry and were pooled mostly from
the International Lung Cancer Consortium (ILCCO), Genetic Associations and Mechanisms in
Oncology (GAME-ON), Genetic Epidemiology of COPD study (COPDgene), Collaborative
Genetic Study of Nicotine Dependence (COGEND), the Multi-ethnic Study of Atherosclerosis
(MESA), ARIC study, and the Study of Addiction: Genetics and Environment (SAGE).
The evidence for associations between nine SNPs with results reported in the included
studies and the likelihood of smoking cessations were synthesized. Of the nine SNPs, seven
are located in the chromosome 15 CHRNA5-A3-B4 gene cluster, one within CHRNA4 on
chromosome 20, and one within CHRNB2 on chromosome 1. A summary of the results follows
below.
7.4.1 SNPs within the CHRNA5-A3-B4 cluster.
7.4.1.1 CHRNA5 rs16969968 and CHRNA3 rs1051730. Most studies (n = 21) reported results
for CHRNA5 SNP rs16969968 and/or CHRNA3 SNP rs1051730. These SNPs are in linkage
disequilibrium (D’ = 1.00, r2 = 1.00) in European ancestry populations; thus, results are
summarized together in Figure 2. The results for studies comprising people of European
ancestry (n = 18) are summarized before considering the results for other ancestral groups.
The minor alleles were associated with longer time to smoking cessation in two studies24,25
[Summary HR = 0.90, 95% CI 0.88 – 0.92]. Five cohort studies26-30 showed that the minor
alleles were associated with reduced odds of cessation [Summary OR = 0.88 95% CI 0.80 –
0.97], as did the placebo arm of four smoking cessation intervention studies19,31,32 [Summary OR
= 0.64, 95% CI 0.45 – 0.90].
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The evidence suggested the type of pharmacotherapy may alter the association of these
SNPs with end-of-treatment abstinence. Among recipients of nicotine replacement therapy
(NRT; n = 6 studies)19,31-35 or varenicline (n = 3 studies)19,31,32 the association of the minor allele
with reduced odds of abstinence was weaker than the association for the placebo [NRT:
Summary OR = 0.93, 95% CI 0.79 – 1.11; varenicline: Summary OR = 0.92 95% CI 0.69 –
1.23]. The associations were approximately equal to that seen in observational studies but
were not statistically significant. In contrast, among recipients of bupropion alone (n = 1 study)31
[OR = 1.33, 95% CI 0.66 – 2.69] or combined with NRT (n = 3 studies)31,33 [Summary OR =
1.10, 95% CI 0.92 – 1.31], the associations with cessation were not statistically significant but
were in the opposite direction as seen in the placebo arm so that the minor allele was
associated with increased odds of abstinence.
Two studies administered various pharmaceutical treatments based on physician/patient
consultation. Because it was not feasible to distinguish between intervention type, results are
reported individually (Figure 2). In one of the studies, a non-randomized open label trial36,
participants were provided with varenicline, bupropion, NRT, or NRT plus bupropion.
Participants with at least one copy of the minor allele of rs16969968 were less likely to be
abstinent 3-months post-cessation [OR = 0.71, 95% CI 0.50 – 1.04], but the association was not
statistically significant. In the second study, a clinic-based cohort in which participants received
varenicline, varenicline plus bupropion, bupropion plus NRT, or NRT only37, no association was
observed between either allele and six-months of continuous abstinence [OR = 1.02, 95% CI
0.75 – 1.40].
The evidence is limited but suggests these associations are not consistently observed
across other ancestral populations. In a cross-sectional study of Han Chinese men38, those with
at least one copy of the minor allele of rs16969968 had increased odds of having quit smoking
for at least 2 years [OR = 1.60, 95% CI 0.87 – 2.92], but the association was not statistically
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significant. People of African ancestry with at least one copy of the minor allele in the combined
placebo arms of two cessation trials39 also had increased odds of abstinence [OR = 1.68, 95%
CI 0.88 – 3.19], but the association was not statistically significant. One of the trials evaluated
the efficacy of bupropion, whereas the other tested NRT. Within the bupropion arm, the
association was weaker than with the placebo arms [OR = 1.42, 95% CI 0.59 – 3.43]; in
contrast, a statistically significant inverse association was observed in the NRT arm [OR = 0.27,
95% CI 0.08 – 0.92].
7.4.1.2. CHRNA3 rs578776. Six studies of people of European ancestry, including five
cessation trials31,33,35,40 and one cohort study25, tested associations between CHRNA3 SNP
rs578776 and cessation. No statistically significant associations were observed in the placebo
or pharmacotherapy arms of trials or in the cohort study, Figure 3(a). In contrast, in a crosssectional study of Han Chinese men38, those homozygous for the A allele (AA) were more likely
to have been abstinent for at least two years than men with at least one copy of the G allele [OR
= 1.30, 95% CI 1.04 – 1.61]. A similar though not statistically significant point estimate was also
observed within the placebo arms of two trials of people of African ancestry39 [OR = 1.27, 95%
CI 0.78 – 2.08].
7.4.1.3. CHRNA5 rs588765 and rs680244. Within European populations, CHRNA5 SNPs
rs588765 and rs680244 are in linkage disequilibrium (D’ = 1.00, r2 = 1.00), thus, the results are
pooled in Figure 3(b). People of European ancestry with at least one copy of the minor allele in
the placebo arms from three trials31,32,41 were less likely to have quit smoking [Summary OR =
0.65, 95% CI 0.45 – 0.94]. The risk of persistent smoking associated with the allele was weaker
and not statistically significant among smokers who received varenicline [n = 2 studies;
Summary OR = 0.85, 95% CI 0.56 – 1.30]31,32, and no association was observed between the
allele and cessation in NRT recipients [n = 3 studies; Summary OR = 1.02, 95% CI 0.79 –
1.32].31,32,35 In contrast, the alleles were associated with higher odds of cessation among
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recipients of bupropion alone31 [n = 1 study; OR = 1.35 (0.70 – 2.58)] or combined with NRT31,33
[n = 3 studies, Summary OR = 1.18 (0.67 – 2.07)], but these associations were not statistically
significant.
The minor allele was also associated with increased risk of cessation failure among Han
Chinese men in a cross-sectional study38 [OR = 0.73, 95% CI 0.57 – 0.84]. A similar though not
statistically significant association was observed in the combined placebo arms from two
randomized trials of people of African ancestry39 [OR = 0.85, 95% CI 0.54 – 1.35]. Among
people of African ancestry receiving either NRT or bupropion the minor allele was associated
with increased odds of cessation, but the association was not statistically significant.39
7.4.1.4. CHRNB4 rs3813567 and rs12914008. Five studies, all of European ancestral
populations, reported results for SNPs within CHRNB4 (Figure 3(c)); four of the studies,
including one cohort study and three trials, reported results for rs3813567. Results from the
cohort study showed the minor allele of rs3813567 was not associated with time to smoking
cessation [HR = 1.02, 95% CI 0.89 – 1.18].25 One trial randomized participants to selegiline or
placebo and found a significantly increased odds of end-of-treatment abstinence for participants
in the treatment arm who had at least one copy of the minor allele [OR = 6.16, 95% CI 1.67 –
22.7] but no association between the minor allele and end-of-treatment abstinence for those in
the placebo arm [OR = 1.09, 95% CI 0.35 – 3.40].42 The other two trials, treating all participants
with a combined NRT and bupropion intervention, found those with at least one copy of the
minor allele were less likely to be abstinent at end-of-treatment, though the association was not
statistically significant [Summary OR = 0.75, 95% CI 0.53 – 1.06].33
The two trials in which all participants received combined NRT plus bupropion also
reported results for rs12914008. Participants with at least one copy of the minor allele were
more likely to be abstinent at end-of-treatment, but the association was not statistically
significant [Summary OR = 1.24, 95% CI 0.63 – 2.44].33 In an open label trial that provided all
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participants with NRT, people with at least one copy of the minor allele of rs12914008 had lower
odds of abstinence [OR = 0.29, 95% CI 0.04 – 2.20]43, but the association was not statistically
significant.
7.4.2. CHRNA4 SNP rs2236196. The association between CHRNA4 SNP rs2236196 and
smoking cessation was evaluated in five studies, including four trials of people of European
ancestry21,36,44,45 and one cross-sectional study of people of Han Chinese ancestry38 (Figure 4).
The use of pharmacotherapy varied among the four studies of people of European ancestry;
only one trial testing the efficacy of bupropion for smoking cessation had a placebo arm21. In
this randomized trial, those with the minor allele had 9% increased odds of abstinence [95% CI
0.53 – 2.23] in the placebo arm, and 37% increased odds of abstinence [95% CI 0.76 – 2.46] in
the bupropion arm; however, neither association was statistically significant. In two open label
trials in which all participants received NRT44,45, those with the minor allele had increased odds
of abstinence [Summary OR = 1.15, 95% CI 0.81 – 1.63], but the association was not
statistically significant. In the fourth trial, participants were provided with varenicline, bupropion,
NRT, or NRT plus bupropion, but the results were not stratified by pharmacotherapy.36 Among
those receiving these various pharmacotherapies, the minor allele was not associated with odds
of abstinence [OR = 0.95, 95% CI 0.66 – 1.30]. In the sole study of people of non-European
ancestry, Han Chinese people with the minor allele had lower odds of having been abstinent for
at least two years [OR = 0.83, 95% CI 0.66 – 1.08] but the association was not statistically
significant.38
7.4.3 CHRNB2 SNP rs2072661. The associations between CHRNB2 SNP rs2072661 and
smoking cessation were evaluated in four studies, three of people of European ancestry31,36,45
(Figure 4). People of European ancestry with at least one copy of the minor allele were less
likely to be abstinent at end of treatment if assigned to the placebo arm [n = 1 study; OR = 0.68,
95% CI 0.37 – 1.22]31; however, the association was not statistically significant. A nearly
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identical association with lower odds of abstinence three-months after cessation was found in
people of European ancestry given NRT, bupropion, or NRT plus bupropion, based on physician
recommendation [OR = 0.68, 95% CI 0.44 – 1.10].36 Yet, no association with odds of end of
treatment abstinence was observed among recipients of NRT alone [n = 2 studies; Summary
OR = 0.96, 95% CI 0.75 – 1.23]31,45 or varenicline [n = 1 study; OR = 1.00, 95% CI 0.69 –
1.46].31 An association with higher odds of abstinence was observed among recipients of
bupropion alone [n = 1 study; OR = 1.30, 95% CI 0.82 – 2.04]31 or combined with NRT [n = 1
study; OR = 1.27, 95% CI 0.78 – 2.06]31, but the associations were not statistically significant.
The only study of people of non-European ancestry, a cross-sectional study of Han Chinese
males38, found that rs2072661 may be associated with lower odds of having quit for at least two
years [OR = 0.90, 95% CI 0.73 – 1.11], but the association was not statistically significant.
7.5 Discussion
This systematic review examined the current evidence for associations between SNPs
within nAChR genes and smoking cessation and synthesized the results for the nine SNPs with
results published on this topic. Seven of the SNPs are located in the CHRNA5-A3-B4 gene
cluster: three SNPs in CHRNA5; two in CHRNA3; and two in CHRNB4. The eighth and ninth
SNPs are located in CHRNA4 and CHRNB2, respectively. The minor alleles of all three of the
CHRNA5 SNPs and one of the CHRNA3 SNPs were identified as risk alleles for cessation
failure. Further, the evidence synthesis points to bupropion as potentially the most effective
intervention for promoting abstinence among people with these alleles. In contrast, an allele of
the second SNP within CHRNA3 may be associated with increased likelihood of smoking
cessation. Less evidence was available for the two SNPs in CHRNB4, the third gene in the
chromosome 15 gene cluster, precluding inferences. Due to the importance of the α4β2 nAChR
subtype for nicotine response and dependence, CHRNA4 and CHRNB2 are expected to be
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linked to smoking cessation, but the evidence was limited and difficult to synthesize due to
varying study designs.
7.5.1 SNPs within the CHRNA5-A3-B4 gene cluster.
7.5.1.1 Risk alleles within CHRNA5 and CHRNA3. The minor alleles of four of the SNPs
encoding for α subunits, CHRNA3 SNP rs1051730 and CHRNA5 SNPs rs16969968, rs588765,
and rs680244, were found to be risk alleles for cessation failure. Due to high linkage
disequilibrium between loci, the results for SNPs rs1051730 and rs16969968 were combined,
as were the results for SNPs rs588765 and rs680244. Several studies, including cessation
trials and time to cessation or smoking cessation cohort studies, provide consistent evidence
that the minor alleles of rs16969968/rs1051730 are associated with lower odds of cessation in
people of European ancestry. Stronger associations were observed in the placebo arms of the
trials compared to the cohort studies, likely because trials have shorter follow-up and
participants selected based on motivation to quit. In this evidence synthesis, the results for
rs588765/rs680244 were similar to those for rs16969968/rs1051730 but were based on fewer
studies.
In people of European ancestry, pharmacotherapy interventions seemed to effectively
increase likelihood of smoking cessation at end of treatment in those with the minor alleles of
rs16969968 and rs1051730; however, the evidence synthesis suggests that bupropion may be
the most effective. The risk of lower likelihood of cessation associated with the minor alleles
was weaker in recipients of an NRT or varenicline intervention than those receiving the placebo,
whereas those with the minor alleles receiving bupropion with or without NRT had higher odds
of cessation. Notably, when those with the minor allele were compared to those homozygous
for the common allele in the NRT plus bupropion arm, the odds ratio of abstinence was
intermediate between the odds ratio for people in the NRT and bupropion only arms. This trend
in increasing odds ratios suggests that bupropion may be more effective than NRT, but that the
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effect of combining NRT and bupropion may not be synergistic in terms of increasing abstinence
among carriers of the minor alleles (Figure 5 depicts a summary of the change in genetic risk of
persistent smoking by type of pharmacotherapy). Though these findings were based on a single
study with a bupropion only arm and three studies with an NRT plus bupropion arm, one of
these studies pooled data from eight clinical trials lending strength to the findings.31
The studies included in this review suggest that NRT compared to placebo increases the
odds of smoking cessation in people of European ancestry with the minor alleles, but the effect
of NRT on smoking cessation is negligible compared to placebo among homozygous common
allele carriers.19 It is possible that those without the minor alleles of rs16969968/rs1051730 are
more prone to side effects from NRT46 and thus gain little benefit from these interventions. This
is biologically plausible as animal studies demonstrate α5-knockout mice and partial α3knockout mice (α3-knockout mice are not viable) do not experience or have lessened adverse
somatic effects from nicotine (e.g. nicotine-induced seizures).10 The diminished nAChR
response in carriers of the minor alleles leads to fewer adverse effects from nicotine but also the
need to smoke more CPD to increase dopamine levels. Thus, people with these minor alleles
tend to smoke more CPD and have higher levels of nicotine dependence.47 Bupropion inhibits
reuptake of dopamine to stabilize background dopamine levels.48 Thus, bupropion may be
more effective than NRT for maintaining dopamine levels in smokers with these minor alleles
explaining the better efficacy of bupropion for promoting abstinence in these smokers.
Bupropion also blocks nAChR binding48 and NRT binding may partially interfere with
bupropion’s mechanism of action. This interference could explain the lack of synergy when the
treatments are combined.
Like NRT, varenicline weakened the risk associated with the minor allele, but varenicline
seemed to significantly increase cessation rates among smokers with all genotypes.19
However, varenicline may do so to a greater extent among those with the minor allele of
rs16969968.40 This increased efficacy among those with the minor allele of rs16969968 may be
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due to the dual action of varenicline: it selectively binds to nAChRs causing activation of the
receptors and stable release of dopamine, but also competitively binds to nAChRs blocking the
receptors to nicotine binding.49
The sparseness of the data for people of non-European ancestry make it is difficult to
characterize these associations across ancestral groups. The limited studies available indicate
the minor allele of rs16969968 may not be predictive of cessation failure, but rather may be
associated with greater likelihood of cessation in people of Asian or African ancestry. More
evidence is needed given these findings were not statistically significant and are based on a
single cross-sectional study of people of Han Chinese ancestry and two trials of people of
African ancestry. However, discordance in associations between ancestral groups is possible
due to differences in minor allele frequencies (MAF) as rs16969968 is more prevalent in
European ancestral populations (MAF = 36.6%) than Han Chinese populations (MAF = 2.9%)
and populations of African ancestry in the Southwest United States (MAF = 7.4%). Differences
in genetic diversity and environmental factors among ancestral groups could also contribute to
disparate associations.
7.5.1.2 Potential protective allele within CHRNA3. A strong association between the A allele
of CHRNA3 SNP rs578776 and cessation of smoking for at least two years was observed in the
cross-sectional study of people of Han Chinese ancestry.38 Likewise, the point estimate for
odds of cessation observed among the combined placebo arms of two trials of people of African
ancestry was similar to that seen in Han Chinese people, though the association was not
statistically significant.39 The six studies of people of European ancestry included in this review
observed null associations between rs578776 and smoking cessation. However, in other
studies, the A allele was protective against both relapse50 and a heightened intrinsic reward
response to visual smoking cues.51 This protection against a heightened response to smoking
cues could explain why the A allele was associated with former smokers self-reporting that
quitting was “remarkably easy” rather than “extremely difficult”.52 Biological plausibility of a
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relationship with reward is supported by the presence of α-3 subunits in areas of the human
brain involved in reward and memory.13 Thus, there is evidence suggesting the A allele is
associated with increased likelihood of smoking cessation and may influence smoking through
intrinsic reward mechanisms. Those associations could be relevant across ancestral
populations. Notably, the A allele is considered the common allele for rs578776 among
populations of Asian or African ancestry, whereas the A allele is the minor allele among
populations of European ancestry. Moreover, the genotypes for rs578776 and rs16969968,
though not highly correlated (r2) due to differences in MAFs, are in linkage disequilibrium (D’);
thus, the protective genotype for rs578776 and the risk genotype for rs16969968 are rarely
inherited together.
7.5.1.3 Alleles within CHRNB4. Of the five studies concerning smoking cessation and SNPs
within CHRNB4, the third gene of the CHRNA5-A3-B4 cluster, four reported associations for
rs3813567 and three reported associations for rs12914008. However, due to varied designs
and treatment arms, synthesis of associations was difficult. Although most findings were null,
rs3813567 was strongly associated with end of treatment abstinence among trial participants
receiving selegiline42, a pharmaceutical agent that inhibits reuptake of dopamine. Additionally,
though rs12914008 was not associated with end of treatment abstinence (the primary endpoint
assessed in this review), the minor allele was associated with increased abstinence at the oneyear follow-up in one study (p-value = 0.0098).33
Although not included in the evidence synthesis due to the reporting of novel and/or
intergenic SNPs, a prior study found that the minor allele CHRNB4 SNP rs11072768 was
associated with increased odds of cessation in Korean people.18 This finding indicates further
investigation of CHRNB4 variants and smoking cessation holds promise, when taken together
with prior studies showing associations between CHRNB4 and nicotine dependence53 and
evidence from animal models that β4 subunits play a role nicotine withdrawal10 and selfadministration.54
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7.5.2 SNPs within CHRNA4 or CHRNB2. Of the studies included in this review, five reported
SNP associations with smoking cessation for CHRNA4 SNP rs2236196 and four reported
associations for CHRNB2 SNP rs2072661. These genes are likely candidates for smoking
cessation research because the α4β2 nAChR subtypes are abundant in the brain, have high
nicotine binding affinity, and play an important role in mediating the brain’s dopaminergic reward
system.10 Animal studies demonstrated α4- or β2-knockout mice did not self-administer nicotine,
likely due to the inability of nicotine to stimulate the dopaminergic system in these animals.10,12
Thus it was unexpected that no statistically significant associations emerged for these variants
from the evidence in this review. However, the variety of pharmacotherapy interventions and
study designs made integrating the genetic associations for these SNPs difficult.
Notwithstanding the null associations in this review, other scientific findings related to
these genes and SNPs indicate more investigation is necessary to determine SNP associations
with smoking cessation. For example, prior studies indicate that CHRNB2 variants may not be
sufficient on their own to influence nicotine addiction55,56, but may interact with variants of
CHRNA4 to do so.57 Moreover, nicotine dependence has been found to have a significant
association with the the interplay between rs2236196 and rs2072661.57 Other research showed
strong associations between rs2236196 and nicotine dependence in people of African, Chinese,
and European ancestry55,56, and the minor allele of rs2236196 was associated with higher
binding in α4β2 receptors in an examination of postmortem brain tissue.44 Additionally, when
data from one of the trials pooled by Bergen et al.31 were separately analyzed in two different
articles, the minor allele of rs2072661 was strongly associated with lower odds of abstinence
both at end of treatment16,21 and, to a greater extent, six-months after cessation.16 This minor
allele has also been associated with significantly lower odds of initial short-term quit success 0
to 4 days post-cessation.58 Thus, more evidence is needed about links between these SNPs
and smoking cessation, particularly in relation to potential interactions between SNPs of
CHRNA4 and CHRNB2.
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7.6 Conclusion
Although more evidence is needed to determine associations with smoking cessation for
variants within CHRNB4, CHRNB2, and CHRNA4, and to explore SNP and gene interactions, a
consistent body of evidence suggests that SNPs rs16969968/rs1051730 and
rs680244/rs588765 are risk alleles for smoking cessation failure. While NRT, bupropion, and
varenicline pharmacotherapies effectively increased end of treatment abstinence mitigating the
risk associated with these alleles, the evidence indicates that bupropion alone may be the most
effective smoking cessation intervention for people with these minor alleles. Improving end of
treatment abstinence outcomes is important for reducing smoking prevalence and reducing
smoking-caused health risk. However, short-term abstinence outcomes are just one piece of a
complex topic that should also include longer term approaches to prevent relapse and increase
sustained abstinence rates. More research is needed to fully understand genetic risk factors
for persistent smoking and the pharmacogenomic implications for cessation interventions, but
the current evidence highlights the translational potential of these lines of inquiry for precision
medicine approaches to smoking cessation.
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7.7 Figures and Table

Records remaining after
duplicate records removed
(n = 841)
-674

Title & Abstract Review:
Step 1: Exclusion screening
(n = 167)
-135

Title & Abstract Review:
Step 2: Inclusion screening
(n = 32)

Included

-10

Step 3: Full-text review
Included (n = 22)

Exclusion Criteria (n = 674)
No smoking behavior/cessation outcome (n = 422)
No Genetic Exposure (n = 99)
Non-English or non-human (n = 4)
News, Commentary, or letter (n = 34) or Review paper (n = 78)
Heritability or linkage study (n = 18)
Efficacy of genetic notification on motivation (n = 19)

Fail to meet Inclusion Criteria (n = 135)
Independent variable ≠ variant of nAChR gene

Exclusion Criteria for Full-text review (n = 10)
No cessation/abstinence outcome (n = 3)
Genetic risk score exposure (n = 1)
Novel/intergenic SNPs and haplotypes (n = 1)
Duplicate data used other papers, same SNP (n = 2)
Follow-up for outcome ≤ 1 month (n = 2)
Hospitalized, NRT ≤ 7 days, follow-up ≤ 1 month (n = 1)

Figure 1. Summary of search process in systematic review of variation within nAChR genes in relation to
smoking cessation in observational studies and clinical trials of smoking cessation interventions.
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Figure 2. Results for CHRNA5-A3-B4 SNPs: CHRNA5 rs16969968 and CHRNA3 rs1051730 in linkage disequilibrium (r2 = 1.00, D’ = 1.00). † rs10517030. NRT = nicotine replacement therapy, HR =
hazard ratio, OR = odds ratio, CI = confidence interval

Figure 3. Results for CHRNA5-A3-B4 SNPs: (a) CHRNA3 rs578776, (b) CHRNA5 rs588765 or rs680244 (D’ = 1.00, r2 = 1.00 in European ancestry
populations, thus these SNPs are in perfect linkage disequilibrium and shown together, and (c) CHRNB4 rs3813567 and rs12914008. NRT = nicotine
replacement therapy, HR = hazard ratio, OR = odds ratio, CI = confidence interval
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Figure 4. Results CHRNB2 and CHRNA4 SNPs. NRT = nicotine replacement therapy, OR = odds ratio, CI = confidence interval.

Figure 5. Figure 5. Summary of the CHRNA5 rs16969968/CHRNA3 rs1051730 and CHRNA5
rs588765/rs680244 associated odds of smoking cessation by type of pharmacotherapy. The
type of pharmacotherapy altered the odds of smoking cessation associated with these minor
alleles. NRT and varenicline appear to attenuate the risk of persistent smoking (lower odds of
smoking cessation), whereas recipients of bupropion with these minor alleles were more likely
to have quit smoking. * The genetic association with odds of smoking cessation was statistically
significant in the placebo arm only.
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European
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N = 5,216
N = 1,073
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(TRIUMPH)
RCT**
RCT
Pooled metaanalysis***
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RCT

Ray (2010)
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Cohort (CPS-3)
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Cross-sectional

RCT

Spruell (2012)

Stevens (2017)

Tomaz (2018)

Tyndale (2015)

Wang (2016)

Zhu (2014)
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N = 231

EOT (8-weeks)
1-year follow-up after index MI
hospitalization
EOT (8-weeks)
Abstinence weeks 9-12 of treatment

Point abstinence
Former/current
smoker
Point abstinence
Continuous
abstinence
Time to cessation

6-weeks

Point abstinence

African

Point abstinence

EOT (7-weeks)

EOT (8-weeks)

Abstinence >= 2 years

Continuous
abstinence

Han Chinese
(males)

EOT (11-weeks)

6-months

12-weeks
Easy = 1 quit attempt, abstinent for ≥ 1 year,
Difficult = not abstinent, ≤ 9 failed attempts

8-weeks

Point abstinence

Point abstinence
Easy vs Difficult
quitters
Continuous
abstinence

Point abstinence

11-weeks

EOT (8-weeks)

Point abstinence

Point abstinence

3-months

12-weeks post quit

12-weeks post quit

EOT (8-weeks)

EOT (8-weeks)

Point abstinence

Continuous
abstinence

Point abstinence

Point abstinence

Duration of pregnancy

European

(Brazilian)

European

European

European

European (77.1%)

European (78.4%)

European

European

Abstinence >12 months at any follow-up
1965 - 1990 (measures every 3 years)
Age of smoking cessation

Continuous
abstinence
Time to cessation

Age of smoking cessation

Age of initiation to age of reported cessation

Time to cessation

Quit during
pregnancy

CHRNA5 (rs16969968), CHRNA3 (rs1051730,
rs578776), CHRNB4 (rs3813567)

Abstinence >6 months at any follow-up 1988
- 2005 (measures every 4 years)

CHRNA5 (rs16969968, rs588765), CHRNA3
(rs578776)

CHRNA5 (rs16969968, rs588765), CHRNA3
(rs578776)
CHRNA3 (rs588765), CHRNA5 (rs578776,
rs16969968), CHRNA4 (rs2236196), CHRNB2
(rs2072661), CHRNB4 (rs3813567)

CHRNA5 (rs16969968), CHRNA3 (rs1051730)

CHRNA5 (rs16969968, rs588765)

CHRNB2 (rs2072661), CHRNA4 (rs2236196)

CHRNB4 (rs3813567)

CHRNB4 (rs3813567, rs12914008), CHRNA5
(rs16969968, rs680244), CHRNA3 (rs578776,
rs1051730)

CHRNA5 (rs16969968), CHRNB2
(rs2072661), CHRNA4 (rs2236196)
CHRNA3 (rs578776), CHRNA5 (rs16969968),
CHRNB4 (rs12914008)

CHRNA3 (rs1051730)

CHRNA4 (rs2236196)

CHRNA4 (rs2236196), CHRNB2 (rs2072661)

CHRNA3 (rs1051730)

CHRNA5 (rs16969968)

CHRNA5 (rs16969968)

CHRNA5 (rs16969968)

CHRNA5 (rs16969968, rs680244)

CHRNA3 (rs1051730)

CHRNA5 (rs16969968), CHRNA3 (rs1051730)

EOT (8-12 weeks)

Gene (SNP)
CHRNA3 (rs1051730, rs578776), CHRNA5
(rs588765), CHRNB2 (rs2072661)

Continuous
abstinence

Time

Point abstinence

Outcome

RCT = Randomized controlled trial, EOT = End of treatment, COMMIT = Community Intervention Trial for Smoking Cessation, ESTHER = Germany epidemiological study of elderly population, ARIC = Atherosclerosis Risk in Communities
study, TRIUMPH = Translational Research Investigating Underlying disparities in acute Myocardial Infarction Patients’ Health Status, ALSPAC = Avon Longitudinal Study of Parents and Children, EFSOCH = Exeter Family Study of Childhood
Health, CPS-3 = Cancer Prevention Study 3. * Data from one of the eight trials pooled for analysis by Bergen et al. was used by Heitjan et al., both studies report results for rs2072661. This review reports results for rs2072661 from Bergen
et al. to avoid duplication of results. ** University of Wisconsin Transdisciplinary Tobacco Use Research Center (UW-TTURC) RCT data used in both studies. Both studies reported results related to rs16969968, this review reports the
rs16969968 results from 2015 to avoid duplication. *** Chen et al. (2015) meta-analysis pools data from 24 datasets from ILCCO (International Lung Cancer Consortium), GAME-ON (Genetic Associations and Mechanisms in Oncology),
COPDgene (Genetic Epidemiology of COPD study), COGEND (Collaborative Genetic Study of Nicotine Dependence) consortia, as well as MESA (Multi-ethnic Study of Atherosclerosis), SAGE (Study of Addiction: Genetics and
Environment), and ARIC. ARIC was also used by Chen et al. (2012) and both studies report time to cessation for rs16969968. This review uses only the meta-analysis result for rs16969968 to avoid duplication of results.

RCT

Sarginson (2015)

Sarginson (2011)
N = 301

European (76.3%)

N = 337

Open label trial

Pintarelli (2017)

RCT

European

N = 692

RCT

Munafo (2011)

N = 817

Open-label trial

European

European

N = 353

Open-label trial

N = 436

RCT*

European

Hutchison (2007)

N = 2,241

European

European
European

N = 328
N = 790
N = 29,072

European

N = 1,451

Heitjan (2008)

Freathy (2009)

Chen (2015)

Chen (2015)

Chen (2014)

Chen L (2012)

European

N = 901

Cohort

European

Budulac (2012)

N = 1,553

Cohort (ESTHER)

European

European

Ancestry

Breitling (2009)

N = 1,157

N = 2,633

Sample Size

Cohort (COMMIT)

Study Design
Pooled analysis (8
clinical trials)*

Bousman (2012)

Bergen (2013)

Study

Table 1. Descriptive characteristics of included nicotinic acetylcholine receptor (nAChR) gene SNP studies

7.8 Appendix: Search Terms for Pubmed and Scopus

The PubMed database was searched using MESH search terms “Tobacco Use
Cessation” OR “Smoking Cessation” AND “Genetic Variation” OR “genetics” OR
“Precision Medicine” retrieving 625 journal articles.
We then searched the Scopus database for article titles with the terms “gene*” OR “snp”
OR “polymorphism*” OR “telomer*” OR “mutation*” OR “precision medicine”. The
Scopus search was further limited to titles that included the terms “smoking” OR
“tobacco” OR “cessation” OR “quit” OR “nicotine” OR “cigarette” AND the terms
“cessation” OR “quit” OR “quitting” OR “stop” OR “stopping” OR “abstin*” OR “relapse”.
Scopus was further limited to human and English only studies, producing 353 journal
articles.
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8.1 Abstract
8.1.1 Background: Nicotine produces its effects by binding to nicotinic acetylcholine receptors
(nAChRs) stimulating the release of dopamine. The release of dopamine activates the
mesolimbic dopamine pathway, a primary contributor to neurological reward. Dopamine
receptor binding transmits reward signals and the rate of metabolism of dopamine contributes to
stabilizing levels of dopamine in the brain. Thus, genes that encode for dopamine receptors or
enzymes that metabolize dopamine are excellent candidates for genetic research of smoking
addiction.
8.1.2 Methods: The goal of this research was to conduct a systematic review to summarize the
evidence of associations between single nucleotide polymorphisms (SNPs) of dopamine
receptor or dopamine metabolism genes and smoking cessation outcomes. From 29 articles
meeting inclusion criteria, summary odds ratios (ORs) for associations between four SNPs and
smoking cessation were calculated. Two of these SNPs were within the DRD2 dopamine
receptor gene; the remaining two SNPs were within the COMT or DBH genes, which encode for
dopamine metabolizing enzymes. The calculated summary ORs were stratified by ancestry,
pharmacotherapy, and biological sex where feasible.
8.1.3 Results: The minor allele of DRD2/ANKK1 SNP rs1800497 was associated with lower
odds of abstinence among people of European ancestry [Summary OR = 0.86, 95% CI 0.77 –
0.96, n= 14 studies]; this association was not observed among Japanese people [Summary OR
= 1.17, 95% CI 0.61 – 2.24, n = 3 studies]. Heterogeneity by biological sex in associations
between the minor allele of rs1800497 and cessation was indicated [Women: Summary OR =
0.80, 95% CI 0.66 – 0.97, n = 7 studies; Men: Summary OR = 1.16, 95% CI 0.87 – 1.55, n = 7
studies]. Recipients of nicotine replacement therapy (NRT) with the minor allele of DRD2 SNP
rs6277 were more likely to be abstinence at end of treatment [Summary OR = 1.43, 95% CI
1.06 – 1.92, n = 2 studies]. Similarly, recipients of NRT with the minor allele of COMT SNP
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rs4680 had increased odds of smoking abstinence [Summary OR = 1.61, 95% CI 1.11 – 2.35, n
= 3 studies]. Possible heterogeneity in associations between SNP rs4680 and smoking
cessation were observed as the minor allele was associated with lower odds of cessation in
combined sex studies [Summary OR = 073, 95% CI 0.57 – 0.93, n = 3 studies] and in one study
of men only [OR = 0.74, 95% CI 0.53 – 1.02, n = 1 study], but no association was observed
among women [Summary OR = 1.01, 95% CI 0.77 – 1.32, n = 5 studies]. The minor allele of
DBH SNP rs77905 was associated with increased odds of cessation [Summary OR = 1.79, 95%
CI 1.17 – 2.73, n = 2 studies] among people of European ancestry.
8.1.4 Conclusion: The association between the minor alleles of DRD2/ANKK1 SNP rs1800497
and COMT SNP rs4680these with smoking cessation may differ by biological sex. Limited
evidence also indicated some associations may differ in people of non-European ancestry.
More research is needed to fully understand potential differences by sex and ancestry in genetic
factors associated with smoking. The evidence also suggested that recipients of NRT with the
minor allele of either COMT SNP rs4680 or DRD2 SNP rs6277 may have higher odds of
abstinence after treatment. These SNPs could help identify smokers who may benefit from
NRT interventions.
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8.2 Introduction
Though the prevalence of smoking among U.S. adults declined from 21% in 2005 to
14% in 2019, cigarette smoking continues to be a leading cause of premature death and
preventable illness.1,2 Smoking rates decreased by only 1% from 2015 to 2019 (15% to 14%)1
among U.S. adults, a possible indication of slowing of the progress toward reducing the public
health burden of cigarette smoking. The addictiveness of nicotine delivered through cigarette
smoking poses a significant barrier to smoking cessation. Each year more than half of U.S.
adult smokers make a quit attempt and more than 90% relapse within 6-months.3,4 Among
those who reach 12-months of abstinence, half will eventually relapse to smoking.5
Precision medicine approaches to smoking cessation interventions and relapse
prevention could improve the rates of successful quit attempts. Identifying risk factors
associated with smoking cessation failure can inform the development of precision approaches.
Family and twin studies have shown considerable heritability (23 to 70%) of several smoking
phenotypes such as the severity of nicotine dependence and withdrawal symptoms, as well as
the likelihood of persistent smoking.6 Thus, genetic susceptibility plays a significant role in
smoking cessation. Identifying specific genetic variants associated with cessation holds
promise for informing precision medicine interventions.
Nicotine, the primary psychoactive substance in tobacco7, binds to and activates
nicotinic acetylcholine receptors which stimulates the release of dopamine.8 The release of
dopamine activates the mesolimbic dopamine pathway, a primary contributor to both
neurological reward and impulsivity9 and conditioned drug seeking behavior.10 Dopamine
receptor binding transmits dopaminergic signals; thus, the five dopamine receptor genes:
DRD1, DRD2, DRD3, DRD4, and DRD5, which encode the D1, D2, D3, D4, and D5 receptors,
respectively10, are potential candidates for genetic studies of nicotine addiction. In addition,
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dopamine levels are partially regulated by the breakdown of dopamine into both inactive and
active metabolites making dopamine metabolism genes additional candidate genes for smoking
research. Three genes encode enzymes responsible for dopamine metabolism: COMT, DBH,
and MAOA.11
Of the five dopamine receptor genes, DRD2 and DRD4 have been predominantly
studied in relation to nicotine addiction. In relation to smoking behavior, DRD2 is the most
prolifically researched dopamine receptor gene with the bulk of studies focused on the
DRD2/ANKK1 SNP rs1800497, sometimes referred to as Taq1A. The Taq1A SNP has been
associated with heavy use of alcohol, cigarettes,12 and heroin13. Furthermore, the strength of
the association of Taq1A with alcoholism is correlated with the medical severity of alcoholism.14
Research related to DRD4 and smoking has largely focused on a variable number tandem
repeat (VNTR)15 with limited smoking-related research on single nucleotide polymorphism
(SNPs). Regarding SNPs within dopamine metabolism genes and nicotine addiction, research
has focused largely on variants within COMT or DBH.
In this systematic review, we aimed to synthesize the evidence related to associations of
Taq1A and other less studied SNPs withing DRD2, COMT, and DBH with smoking cessation.
We herein give special consideration to differences by ancestry and biological sex where
feasible. The goal of this research was to identify what is known in relation to dopamine
receptor and metabolism SNPs and smoking cessation outcomes and to identify gaps and
areas for future exploration.
8.3 Methods
The independent variable of this systematic review was defined as SNPs within
dopamine receptor and metabolism genes. The specific genes of focus were DRD2, COMT,
and DBH due to a dearth of studies examining SNPs within other dopamine receptor or
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metabolism genes. The dependent variable was smoking cessation. Smoking cessation was
measured in various ways, including time to smoking cessation, abstinence from smoking at a
study endpoint for prospective studies, or by former versus current smoking status for crosssectional studies.
8.2.1. Inclusion criteria. To be eligible for inclusion, the study had to be of humans,
available in English, and report on the association of one or more SNPs within a dopaminergic
gene with a smoking cessation outcome, defined as point abstinence, continuous abstinence,
former versus current smoker status, or time to cessation. Randomized-controlled trials, nonrandomized trials, open label trials, cohort studies, case-control studies, and cross-sectional
studies were all eligible for inclusion.
8.2.2. Exclusion criteria. Studies were excluded if they did not have a smoking cessation
outcome or used a genetic risk score as the independent variable. Also excluded were news
stories, commentaries, letters to the editor, review papers, heritability or linkage studies, trials
with < 1-month follow-up, and studies reporting results for novel SNPs or haplotypes. Published
reports that used the same data from the same study population and tested the same SNPs as
another published report were also excluded. One of these excluded studies utilized data from
a placebo-controlled bupropion trial16; however, this trial data was pooled with a second
bupropion trial for use in another study17 that was included in this review. Two other studies
utilized the same study population to test associations between Taq1A and cessation18; the
study with a primary aim of testing for the Taq1A interaction with a serotonin genetic variant was
excluded.19 Another three studies were excluded for using the same study population as
another study. Two studies that used Patch II trial data to test associations between COMT
SNP rs468020 and ANKK1/DRD2 SNP rs180049721 and cessation, along with a third study
using Patch-in-Practice trial data to test associations between rs4680 and time to relapse22 were
excluded because a fourth citation included the associations between these SNPs and
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abstinence from smoking in both the Patch II and Patch-in-Practice trials23. Because this later
study reported the combined sex results for both studies, two exceptions to the use of duplicate
data were made for articles that stratified results reported from the Patch-in-Practice trial24 and
the Patch II trial25 by biological sex. The combined results from these trials were used in the
primary systematic review synthesis and the studies stratifying results by sex were used for
synthesis of results by biological sex.
8.3.1. Literature search. We searched the PubMed and Scopus databases for evidence of
associations between SNPs within dopaminergic genes and smoking cessation (Figure 1). The
original search was conducted on February 7, 2020 for journal articles published from January
1, 1990 through February 7, 2020, and alerts were set to identify articles meeting search criteria
published from February 7, 2020 through September 14, 2021. The PubMed and Scopus
searches retrieved 625 and 353 records, respectively; after removing duplicate citations, a total
of 841 unique articles remained for evaluation of exclusion/inclusion criteria. (Search terms are
detailed in Appendix 1).
8.3.2. Article screening and data extraction. Of the 841 articles, 793 were excluded after
abstract screening (Figure 1). After full text review of the remaining 48 articles, 25 citations
were excluded. Based on references in the originally identified citations, we added an additional
6 articles that met inclusion criteria for a total of 29 included articles. For each included article,
data were extracted for study design, sample size, participant ancestry, intervention protocols,
SNP associations with smoking cessation, and results of any pharmacogenomic analysis.
8.3.3. Statistical analysis. Associations of SNPs with smoking cessation were organized
by gene, study design, ancestry, biological sex, and pharmacotherapy. Summary measures
were obtained using the %METAANAL SAS macro, which produced the Laird and DerSimonian
fixed effect estimators and tested for between-study heterogeneity.26,27 Random effects pooling
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was assumed weighting the studies proportionate to the inverse of the study variance plus the
between-study variances.
8.4 Results
The 29 included articles reported results from 30 unique studies: 12 randomized trials, 5
open label trials, 5 cohort studies, 4 case-control studies, 4 cross-sectional studies (Table 1).
The sample sizes of the 12 randomized trials ranged from 76 to 2,374. Eleven of these trials
comprised populations that were entirely or predominantly (85 - 98.9%) of European
ancestry17,23,25,28-38 and one was of people of Chinese ancestry that was also 93.6% male39. Of
the five open label trials three were of European populations comprised of 371 to 804
people18,35,40, one comprised of 225 Korean men34, and the fifth stratified results by ancestry for
the 178 women of European ancestry and 112 women of African ancestry32 included in the trial.
All five cohort studies were of people of European ancestry with sample sizes ranging from 419
to 5,115.41-45 Two of the four case-control studies stratified results by ancestry: one stratified by
women of European ancestry (n = 541) and women of African ancestry (n = 241)32, whereas the
other stratified by Mexican ancestry (n = 59) and African ancestry (n = 72)46. Two other casecontrol studies studied 881 people47 and 283 people48 of European ancestry. The four crosssectional studies were all conducted in people of Asian ancestry, three were studies of
Japanese people49-51 and one was a study of Chinese men52; these ranged in size from 96 to
359 people.
There was enough evidence available to conduct meta-analyses for four SNPs with the
likelihood of smoking cessation. Two of the SNPs, DRD2/ANKK1 SNP rs1800497 G>A and
DRD2 SNP rs6277 G>A, are associated with D2 dopamine receptor density.53,54 The other two
SNPs, COMT SNP rs4680 and DBH SNP rs77905, are within dopamine metabolism genes.

93

8.4.1 DRD2/ANKK1 SNP rs1800497 (Figure 2)
8.4.1.1 Associations with smoking cessation among European ancestral populations.
Among 14 studies of people of European ancestry)17,18,23,25,29-38,45,47,48, those with at least one
copy of the minor allele of SNP rs1800497 (commonly annotated as the A1 allele) had lower
odds of smoking cessation [Summary OR = 0.86, 95% CI 0.77 - 0.96] compared to those with
homozygous common allele genotypes (commonly annotated as A2/A2 genotypes) (Figure 2,
part a). In some of these 14 studies, at least some of the participants received a
pharmaceutical intervention; however, in these cases, the smoking cessation outcome was
assessed at least 3 months and up to 3 years after the intervention ended.
For four trials of people of European ancestry, it was feasible to stratify the SNP
associations with abstinence at end of treatment by intervention arm (Figure 2, part b). In the
two studies with a placebo arm17,23, those with at least one copy of the minor allele had higher
odds of smoking cessation at end-of-treatment (10-12 weeks post-cessation) [Summary OR =
1.37, 95% CI 0.70 – 2.70], but the association was not statistically significant. Although the test
for heterogeneity between these two studies was not statistically significant (p = 0.09), the
findings between the two studies were inconsistent [David et al. (2011) OR = 0.96, 95% CI 0.54
– 1.7223, whereas David et al. (2007) OR = 1.92, 95% CI 1.13 – 3.2817]. There was no
association between SNP rs1800497 genotype and end-of-treatment abstinence among
recipients of nicotine replacement therapy (NRT) [Summary OR = 1.11, 95% CI 0.79 – 1.54 (n =
2 studies)]23 or bupropion [OR = 0.91, 95% CI 0.59 – 1.40] (n = 1 study)].17
8.4.1.2 Associations with smoking cessation among non-European ancestral populations
(Figure 2, part c). Korean men with the A1 allele who received bupropion in an open label trial
had significantly lower odds of smoking cessation than men without the minor allele [OR = 0.56,
95% CI 0.32 - 0.99 (n = 1 study)].34 Japanese people with the A1 allele had increased odds of
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smoking cessation but the association was not statistically significant [Summary OR = 1.17,
95% CI 0.61 – 2.24 (n = 3 studies)].49-51 Some heterogeneity between these three crosssectional studies of Japanese people was indicated (test for heterogeneity p = 0.07) because
one study50 observed an association between the A1 allele and the likelihood of former versus
current smoker status that was in the opposite direction of the other two studies. Synthesis of
the two studies in agreement showed a strong association between the A1 allele and increased
likelihood of being a former smoker [Summary OR = 1.64, 95% CI 1.09 – 2.49].49,51 In contrast,
the third study found those with the A1 allele had lower, though not statistically significant, odds
of being a former smoker [OR = 0.65, 95% CI 0.32 – 1.29].50 One study evaluated SNP
rs1800497 associations with smoking cessation among people of African or Mexican ancestry
finding no genetic association among either population [African ancestry OR = 1.03, 95% CI
0.40 – 2.66, Mexican ancestry OR = 1.03, 95% CI 0.31 – 3.43].46
8.4.1.3 Stratification of SNP rs1800497 associations by biological sex (Figure 3). The
association between SNP rs1800497 and smoking cessation may differ by biological sex.
Women with the A1 allele had lower odds of smoking cessation [Summary OR = 0.80, 95% CI
0.66 - 0.97, n = 7 studies].18,24,25,37,38,49,50 The association was similar when the results were
limited to populations of European ancestry [Summary OR = 0.80, 95% CI 0.63 – 1.02, n = 5
studies].18,24,25,37,38 In contrast, men with the A1 allele had increased odds of smoking cessation
[Summary OR = 1.16, 95% CI 0.87 - 1.55, n = 7 studies],18,24,25,37,49-51 but the association was
not statistically significant. No association was observed when considering only studies of men
of European ancestry [Summary OR = 1.06, 95% CI 0.85 – 1.33].18,24,25,37
8.4.2 DRD2 SNP rs6277 (Figure 4). Five studies, all of people of European ancestry, reported
associations between DRD2 SNP rs6277 and smoking cessation. People with the minor allele
who did not receive a pharmaceutical intervention for cessation had lower odds of cessation
[Summary OR = 0.89, 95% CI 0.63 - 1.24, n = 3 studies],23,36,47 but the association was not
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statistically significant. Among those who received NRT, the minor allele was associated with
increased odds of cessation [Summary OR = 1.43, 95% CI 1.06 – 1.92, n = 3 studies].23,35 In
the only study with a bupropion arm, no association was observed between SNP 6277 and
smoking cessation [OR = 1.05, 95% CI 0.64 - 1.72].35
8.4.3 COMT SNP rs4680 (Figure 5).
8.4.3.1 Associations among people of European ancestry. Among people of European
ancestry, no association between the minor allele of COMT SNP rs4680 and the age of smoking
cessation [HR = 0.97, 95% CI 0.83 – 1.12, n = 1 study]41 or the likelihood of smoking cessation
[Summary OR = 0.94, 95% CI 0.73 - 1.22, n = 6 studies]23,32,38,42-44 was observed.
Heterogeneity across the six studies of smoking cessation was significant (p = 0.001). After
removing the three studies with all-female study populations from the meta-analysis23,42,44, we
no longer observed significant heterogeneity across the remaining studies (p = 0.31) (the allfemale studies were analyzed separately below). Among the studies of both men and women
that remained, those with the minor allele of SNP rs4680 had significantly lower odds of
smoking cessation compared to those with homozygous common allele genotypes [Summary
OR = 0.73 95% CI 0.57 - 0.93, n = 3 studies].
Among people of European ancestry receiving bupropion, no association between SNP
4680 and end-of-treatment abstinence was observed [OR = 1.09, 95% CI 0.86 - 1.38, n = 1
study]33 (Figure 5, part b). The association between the minor allele of SNP rs4680 and
smoking cessation among recipients of NRT was in the opposite direction [Summary OR = 1.61,
95% CI 1.11 - 2.35, n = 3 studies]23,32 to that observed in untreated people with carriers of the
minor allele more likely to be abstinent at end of treatment.
8.4.3.2 Associations among people of non-European ancestry (Figure 5, part c). Five
studies of non-European ancestral populations reported associations between SNP rs4680 and
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smoking cessation: two studies of women of African ancestry32, one study of Korean men34,
and two predominantly male studies of Chinese people39,52. No association was observed
among women of African ancestry who did not receive a pharmaceutical intervention [OR =
1.08, 95% CI 0.51 – 2.29, n = 1 study], whereas among women receiving NRT, those with the
minor allele had increased odds of smoking cessation at end of treatment [OR = 2.02, 95% CI
0.84 – 4.85, n = 1 study] but the association was not statistically significant.32 Among people of
Chinese ancestry, those with the minor allele of SNP rs4680 had higher, but not statistically
significant, odds of smoking cessation than those with homozygous common allele genotypes
[Summary OR = 1.48, 95% CI 0.94 - 2.32, n = 2 studies]. The combined study population of
these two studies was 96.9% male. In contrast, Korean men with the minor allele of SNP
rs4680 receiving bupropion in an open label trial had significantly lower odds of smoking
cessation [OR = 0.49, 95% CI 0.28 - 0.84, n = 1 study].
8.4.3.3 Stratification of SNP rs4680 associations by biological sex (Figure 6). To assess
the association among women, we evaluated the association of SNP rs4680 with smoking
cessation using results from the five all-female studies and from one study with results available
stratified by biological sex. Among the five studies without a pharmaceutical intervention, no
association between SNP rs4680 and cessation was observed [Summary OR = 1.01, 95% CI
0.77 - 1.32, n = 5 studies]32,44,55, though there was significant heterogeneity between these
studies (p = 0.006). After removing the study by Omidvar et al.44, a study of older people aged
≥55 years at recruitment and followed for 12 years, no significant heterogeneity between studies
was observed (p = 0.13) and those with the minor allele had slightly, but not statistically
significant, increased odds of smoking cessation [Summary OR = 1.13, 95% CI 0.90 - 1.42, n =
4 studies]. Among women receiving an NRT intervention, those with the minor allele were
significantly more likely to quit smoking than those without the minor allele [Summary OR =
1.95, 95% CI 1.07 – 3.57, n = 2 studies].32
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In addition to the aforementioned results observed within studies of male or
predominantly (97%) male populations of Asian ancestry, it was feasible to obtain SNP rs4680
associations among men from two studies of European ancestry populations. Among
untreated, older men (55+ years of age at recruitment) of European ancestry, those with the
minor allele were less likely to quit smoking during the 12-years follow-up [Summary OR = 0.74,
95% CI 0.53 – 1.02, n = 1 study].44 No association between SNP rs4680 genotype and
abstinence was observed among men of European ancestry receiving NRT in an open label trial
[Summary OR = 1.08, 95% CI 0.53 – 2.18, n = 1 study].32
8.4.4 DBH SNP rs77905 (Figure 7). Three studies, all of people of European ancestry,
reporting associations between SNP rs77905 and smoking cessation were included in the
review. Among those who did not receive a pharmaceutical intervention, the minor allele was
associated with increased odds of smoking cessation [Summary OR = 1.79, 95% CI 1.17 - 2.73,
n = 2 studies]23,29; however, no association between SNP rs77905 and smoking cessation was
observed for those receiving NRT [Summary OR = 0.95, 95% CI 0.66 - 1.36, n = 2 studies].23
8.5 Discussion
In this systematic review, we synthesized the available evidence for associations
between DRD2/ANKK1 SNP rs1800497 (Taq1A), DRD2 SNP rs6277, COMT SNP rs4680, and
DBH SNP rs77905. We found that the minor allele of DRD2/ANKK1 Taq1A was associated with
smoking cessation but that the direction of the association may differ by ancestry and biological
sex. Evidence was limited for the second DRD2 variant, SNP 6277, but suggested that the
minor allele may be useful for predicting the efficacy of NRT for smoking cessation. Similar to
results for Taq1A, the COMT SNP rs4680 was found to be associated with smoking cessation,
but the association may differ by biological sex and ancestry. Lastly, though based on only
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three studies, findings suggest that the minor allele of DBH SNP rs77905 may be associated
with increased odds of smoking cessation.
8.5.1 DRD2/ANKK1 SNP rs1800497 (Taq1A)
The present systematic review showed that the A1 allele was associated with lower odds
of cessation in people of European ancestry, but that this association may not be consistent by
biological sex and ancestry. We found that the A1 allele was associated with lower likelihood of
having quit smoking among women when considering both Asian and European ancestral
populations together and when studies were limited to women of European ancestry. In
contrast, among men of European ancestry, no association was observed with smoking
cessation. Though some studies indicated that Asian men with the A1 may be more likely to be
former versus current smokers, significant heterogeneity in studies of Asian men made it difficult
to determine associations.
Specifically, two of the studies of Japanese men showed the A1 allele was associated
with increased odds of former smoker status whereas a third study found an inverse
association. We observed that the heterogeneity in studies of Japanese smokers was present
only in the results for the male participants. Upon closer evaluation, two of the studies with
disparate results both recruited from first-visit patients to the Aichi Cancer Center. Even though
the study population samples were taken from the same location and within temporal proximity,
the prevalence of current, former, and never smokers specifically among the men recruited for
these two studies differed. Specifically, in Hamajima et al.49, 48% of men were current smokers
whereas 31% and 21% were former or never smokers, respectively. In contrast, among men in
Yoshida et al.50, the prevalence of current, former, and never smokers were 34%, 33%, and
33%, respectively. The disparate prevalence indicates a potential systematic difference
between the study populations and possible selection bias, although the source of such bias is
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not clear. Prevalence of smoking in a population can affect the relative contribution of genetic
heritability to a phenotype6, and this phenomenon may explain the disparate results.
Two previous meta-analyses also observed an association among people of European
ancestry.56,57 These two previous reviews found no association between Taq1A and smoking
cessation among people of Asian ancestry; however, they also observed significant
heterogeneity in studies of Asian people. Importantly, neither study considered cessation
treatment or biological sex, and other potential sources of bias were present. For example, one
prior review synthesized results from two studies of Japanese people together with a study of
Korean schizophrenia patients in which comorbid mental illness may bias smoking outcomes.57
In addition, due to the exclusion of former smokers from the study of patients with
schizophrenia, current smokers were compared to never smokers.58 The other review
conducted a meta-analysis for three cross-sectional studies of Japanese people together with a
study examining short-term smoking abstinence (4- and 10-weeks post cessation) among
Korean men receiving bupropion. We also examined these four studies but did so considering
the study of Korean men receiving bupropion therapy for cessation separately. The results from
examining end of treatment abstinence in cessation trials in the present review as well as a prior
meta-analysis of Taq1A associations with abstinence after bupropion or NRT therapy59 suggest
the genetic associations with end of treatment may differ from those observed over longer
follow-up or in untreated people.
Despite some heterogeneity in studies of Japanese people, differences in genetic
associations by ancestry are plausible and could be partially due to differences in the minor
allele frequencies (MAF). The MAF for the A1 allele is 0.2020 for Americans of European
decent (CEU) and 0.3894 for the Japanese population (JPT) according to the 1000 Genomes
Project.60 In addition, interactions between genetic variants may play a role in the Japanese
ancestral populations as the Taq1A variant is part of a large haplotype block60 among those of
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Japanese ancestry indicating high linkage with other potentially functional variants. Figure 8
depicts linkage disequilibrium plots for both CEU and JPT and demonstrates that the haplotype
block for JPT is larger than that observed in CEU.
Notwithstanding the aforementioned results and biological plausibility, several additional
factors complicate the full understanding of associations by ancestry and biological sex. The
gap between smoking prevalence by sex is greater in Asian countries such as Japan (age
standardized prevalence in 2019 among women = 10.2%, among men = 33.4%) compared to
the United States (age standardized prevalence in 2019 among women = 15.3%, among men =
19.9%).61 Societal attitudes toward smoking in Japanese culture differs between men and
women; smoking is more acceptable as part of social etiquette among men, whereas it is more
likely to be considered aberrant behavior for women.62 Previous studies have suggested that
Japanese men more moderately inhale cigarette smoke in comparison to American men of
European ancestry, but that no difference in inhalation is indicated between these groups of
women.63 In addition to the differences between men and women, smokers in East Asia
express lower interest in quitting than the United States or Europe.3,64-66 Genetic risk may be
moderated by these and other environmental and cultural factors which may explain the
different findings by ancestry and sex.
8.5.2 DRD2 SNP rs6277.
Evidence was limited for SNP rs6277 but indicated no association between genotype
and likelihood of smoking cessation among people of European ancestry. However, among
recipients of NRT, the minor allele was associated with increased odds of smoking cessation.
More research is needed to confirm this inference, but these findings suggest the minor allele
could be used to identify smokers that could highly benefit from using NRT.
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No studies have examined associations between this SNP and smoking cessation in
non-European ancestry populations. The minor allele frequency of SNP rs6277 is much lower
in people of either Asian or African ancestry (6% for both) compared to the frequency in people
of European ancestry (50% for Utah residents with European ancestry). Thus, differences in
associations by ancestry are likely to exist and should be researched. In addition, no studies
have examined differences in genetic associations between SNP rs6277 and smoking cessation
by biological sex. Both Taq1A and SNP rs6277 have been associated with the density of D2
dopamine receptors.53,54,67 Since both SNPs appear to functionally affect the same biological
mechanism, SNP rs6277 associations with smoking cessation may differ between men and
women in a manner similar to that observed for Taq1A. This line of inquiry could help further
the understanding of how genetic and biological mechanisms influencing smoking behavior vary
between men and women.
8.5.3 COMT SNP rs4680
Functionally, the minor allele of COMT SNP rs4680 is linked to lower catechol-omethyltransferase (COMT) enzyme activity, resulting in slower dopamine metabolism and
higher levels of dopamine in the prefrontal cortex.68 Sex differences in COMT enzyme activity
have been identified, possibly due to the role of estrogen in downregulating activity.68 The
results of this review indicated that the association of SNP rs4680 with smoking cessation may
differ by biological sex. The evidence showed that the minor allele of SNP rs4680 was not
associated with cessation among women. In contrast, within studies of both men and women,
the minor allele was associated with lower odds of cessation. Only two studies were available
to evaluate associations specifically among men of European ancestry, one of older men (age
55 years or older at recruitment) and one of men receiving NRT. The results of these limited
studies suggested that the minor allele is associated with lower odds of cessation in men but
that the risk associated with the allele is attenuated in recipients of NRT. In contrast, within two
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studies of Chinese men, the association appeared to be in the inverse direction with the allele
associated with increased likelihood of smoking abstinence. Though more evidence is needed,
the results suggest possible differences in associations by both sex and ancestry.
Though the minor allele was not associated with cessation among women, significant
heterogeneity across studies of women was observed. One study was of older women, aged 55
years or older at recruitment; these women were found to have significantly lower odds of
smoking cessation during the 12-years follow-up. When this study was removed, significant
heterogeneity was no longer observed among women. In addition, in the meta-analyses of the
remaining all-female studies the direction of the association, though not significant, was in the
opposite direction. Due to the role of estrogen in downregulating COMT activity68, it could be
that associations between SNP rs4680 and smoking cessation may differ between older and
younger women due to changes in sex hormones between pre-, peri-, and post-menopause.
Among people receiving NRT, those with the minor allele were more likely to be
abstinent from smoking indicating that NRT may be more effective in aiding smoking cessation
for people with the minor allele of rs4680. This association was stronger among women, while
among men receiving NRT no association between SNP 4680 and abstinence at end of
treatment was observed. Though caution is warranted due to the limited number of studies (two
studies of women and one of men), these findings provide further evidence of potential
differences by biological sex.
The effect of estrogen on COMT enzyme activity may partially explain the potential
difference in genetic associations between men and women. However, the role of COMT and
SNP rs4680 in smoking addiction is likely very complex. Higher dopamine levels from low
enzyme activity could plausibly minimize the reward experienced as a result of nicotinestimulated dopamine release. In addition, SNP rs4680 also impacts cognitive control.
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Specifically, people with the minor allele of rs4680 have been found to have improved executive
control function and lower risk of attention deficit hyperactivity disorder.69 Based on the
potential reduction in nicotine reward and improvement in executive control, we might expect
the minor allele of SNP rs4680 to be protective against persistent smoking. Though the
association with persistent smoking (failure to quit smoking) was weakly in the protective
direction among women, the results of this review suggested the association was in the
opposite direction in men. This could be related to the fact that the minor allele is also
associated with increased risk for some psychiatric disorders, such as obsessive-compulsive
disorder for which the association is stronger among men.69,70
The associations between SNP rs4680 and phenotypes related to nicotine reward,
cognitive control, and compulsive behavior could impact smoking behavior in varying degrees
depending on biological sex. In the Nicotine Dependence Syndrome Scale, a multidimensional
measure of nicotine dependence, men score higher in measures of continuity and stereotypy of
smoking behavior, indicating consistency in smoking behavior. 71 However, women have been
shown to score significantly higher in the negative reinforcement and cue response subscales of
the Wisconsin Inventory of Smoking Dependence Motives, another multidimensional measure of
nicotine use.71 These scores indicate women are more likely to smoke to improve negative
mood and in response to environmental smoking cues. The difference in scores between men
and women in these multidimensional measures suggests it is plausible men may be impacted
by factors associated with repetitive, consistent behavior, whereas women may be more
responsive to factors which improve mood (e.g. nicotine reward) and behavioral control in
response to cues.
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8.5.4 DBH SNP rs77905.
Though the evidence is limited to three studies, the findings of this review show that the
minor allele of SNP rs77905 is associated with increased odds of abstinence from smoking.
However, no association between SNP genotype and smoking cessation was observed at end
of treatment for those receiving NRT. This suggests that NRT may be more effective for those
with the common allele genotype, but more evidence is needed since this is based on two
studies of NRT. No studies of non-European ancestral populations have evaluated these
genetic associations and differences by biological sex have not been assessed, thus it is
unknown if these findings are generalizable to other populations and if differences between men
and women exist.
8.6 Conclusion
The majority of the studies of associations between SNPs within dopaminergic genes
and smoking cessation have reported results for DRD2/ANKK1 SNP rs1800497 (Taq1A) and/or
COMT SNP rs4680. The results of this review found that the minor alleles of these two SNPs
are associated with lower odds of abstinence in people of European ancestry, but that these
associations may differ by biological sex. In addition, the limited evidence suggests that
associations differ in people of non-European ancestry. The two other SNPs of dopaminergic
genes that emerged in the literature search were DRD2 SNP rs6277 and DBH SNP rs77905;
however, each of these SNPs had limited evidence concentrating on people of European
ancestry without consideration of potential differences by biological sex. Despite the limited
number of studies, the evidence suggests these SNPs could be important indicators of smoking
cessation intervention efficacy. Thus, genetic research of dopaminergic genes and smoking
cessation holds promise for informing precision medicine approaches to smoking cessation
interventions. Yet to fully understand the impact of genetic variation in dopaminergic genes on
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smoking cessation and to effectively develop precision medicine approaches, the potential
differences in dopaminergic function by ancestry and biological sex must be considered.
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8.7 Figures and Tables
Records remaining after
duplicate records removed
(n = 841)
-674

Included

Screening & Eligibility

Title & Abstract Review:
Step 1: Exclusion screening
(n = 167)
-119

Title & Abstract Review:
Step 2: Inclusion screening
(n = 48)

Exclusion Criteria (n = 674)
No smoking behavior/cessation outcome (n = 422)
No Genetic Exposure (n = 99)
Non-English or non-human (n = 4)
News, Commentary, or letter (n = 34) or Review paper (n = 78)
Heritability or linkage study (n = 18)
Efficacy of genetic notification on motivation (n = 19)

Fail to meet Inclusion Criteria (n = 119)
Independent variable ≠ variant of dopaminergic gene (n = 114)
Genetic variable not a SNP (n=5)

-25

Exclusion Criteria for Full-text review (n = 25)
No cessation/abstinence outcome (n = 3)
Genetic risk score exposure (n = 2)
Novel SNPs and haplotypes (n = 7)
Duplicate data used other papers, same SNP (n = 5)
Hospitalized, NRT ≤ 7 days, follow-up ≤ 1 month (n = 1)
Smoking-related illness diagnosed study population (n = 1)
Review meta-analysis (n = 6)

+6

Records added (n = 6)
Referenced in originally identified articles (n = 6)

Step 3: Full-text review
Included (n = 29)

Figure 1. Summary of search process in systematic review of variation within dopaminergic genes in
relation to smoking cessation in observational studies and clinical trials of smoking cessation interventions.
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European (91.8%)
European
African
European
African
European (98.9%)
European
European
European
European
Chinese
Japanese
Korean
European
European
European (89%)
European
European
Japanese
European
Unknown
European (85%)
European
Chinese
European
European
European (93%)
European
Mexican
African
Japanese
European

N = 134 (49.3% male)
N = 541 (0% male)
N = 241 (0% male)
N = 178 (0% male)
N = 112 (0% male)
N = 536 (51.5% male)
N = 722 (47.9% male)
N = 755 (41% male)
N =792 (41% male)
N = 736 (47% male)
N = 269 (100% male)
N = 359 (75.8% male)
N = 225 (100% male)
N = 405 (46% male)
N = 371 (54% male)
N = 2,161 (50.2% male)
N = 804 (48% male)
N = 2,001 (0% male)
female)
= 96 (92.7% male)
N
N = 2,928 (62.5% male)
N = 283 (54.8% male)
N = 419 (41% male)
N = 881 (48% male)
N = 249 (93.6% male)
N = 416 (38% male)
N = 621 (63.3% male)
N = 593 (0% male)
N = 76
N = 59 (76% male)
N = 72 (68% male)
N = 134 (80.6% male)
N = 752 (41% male)

RCT
Case-control (crosssectional analysis)
Open-label trial
Cohort
RCT (2 pooled)
RCT
Open label trial
RCT (2 pooled)
Cross-sectional
Cross-sectional
Open label trial
RCT
Open label trial
Randomized trial
Open label trial

Colilla (2005)

David (2002)
David (2007)
David (2011)

Case-control
Cohort
Nested Case Control
RCT
Open-label trial
Randomized
clustered trial
RCT
Pilot study
Case-control (crosssectional analysis)
Cross-sectional
RCT

Spitz (1998)
Stapleton (2011)
Styn (2009)
Sun (2012)
Swan (2005)
Tashkin (2012)

rs1800497

6-weeks NRT, venlafaxine or
placebo weeks 3-18
None
NRT
None
bupropion or placebo
NRT vs placebo
NRT
bupropion or placebo
None
None
bupropion
bupropion or placebo
NRT
None
All received NRT
None
None
None

Former vs. Current smoker
EOT (8-weeks)
Former vs. Current smoker
Abstinence EOT (10-12
weeks)
Abstinence EOT (12weeks)
EOT (12Abstinence
weeks)
EOT (10-12
Abstinence
weeks) vs. Current smoker
Former
Former vs. Current smoker
Abstinenct EOT (4-weeks)
Abstinence EOT (10weeks)
Abstinencet EOT (12weeks) vs. Current smoker
Former
Point abstinence
Smoking during pregnancy
Former vs. Current smoker
Point abstinence at 3
follow-ups
Former vs. Current smoker
Abstinence weeks 3 & 4
Abstinence at 1-year
Abstinence EOT (8-weeks)
Abstinence 1-year
Abstinence over 5-years
(annually assessed)
Continuous abstinence 6months
EOT - 10Abstinence
weeks vs. Current smoker
Former

None*
rimonabant & placebo
None

None
All received NRT
None
NRT or placebo
8-weeks bupropion
None

rs1800497

beflaxatone and placebo

Abstinence last 4-weeks of
3-month treatment period
Abstinence (over 1-year)

rs1800497, rs4680
rs1800497
rs1800497

rs1800497

rs1800497
rs1800497
rs1800497, rs6277
rs4680

rs4680
rs1800497
rs4680

rs1800497, rs6277
rs1800497

rs4680
rs1800497
rs1800497, rs6277,
rs77905, rs4680
rs4680
rs4680
rs1800497
rs1800497, rs4680
rs6277

rs4680

rs1800497, rs77905

physician offices randomized
to training & reimbursement

Abstinence 1-year

population.

Yoshida (2001)
Yudkin (2004)

Former vs. Current smoker None
rs1800497
Abstinence EOT (12NRT vs placebo
rs1800497
1 Also reported results for SNP rs1800497 but were not included in this review because results for this SNP stratified
weeks)
by treatment arm were reported by David et al. 2007 using the same data and study

Ton (2007)
Wilcox (2011)
Wu (2000)

Cohort
Cross-sectional
Cohort study

Munafo (2011)
Ohmoto (2014)
Omidvar (2009)

Morton (2006)
Munafo (2009)

David (2013)1
Guo (2007)
Hamajima (2002)
Han (2008)
Lerman (2006)

Cinciripini (2004)

European (85%)

N = 595 (48% male)

RCT

Berlin (2005)

German

Randomized
clustered trial

Breitling (2010)

N = 562 (48% male)

Table 1. Studies included in the systematic review (RCT = Randomized controlled trial, NRT = nicotine replacement therapy,*treatment administered 3-years prior to outcome
measure)
Study
Study Design
Sample Size
Population
Outcome
Treatment
SNP
Breitling (2009)
Cohort study
N =1,443 (78% male)
European
Time to cessation
None
rs4680
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Figure 2. Results for DRD2 SNP rs1800497 by ancestry and treatment arm. RCT = randomized controlled trial, NRT = nicotine replacement therapy,
*pharmaceutical intervention ended 3 months to 3 years prior to outcome assessment.
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Figure 3. DRD2 SNP rs1800497 results stratified by biological sex, includes only those studies where data allowed stratification. EOT, = end of
treatment, NRT = nicotine replacement therapy, *pharmaceutical intervention stopped 3 months to 3 years prior to endpoint.
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Figure 4. DRD2 SNP rs6277 associations with smoking cessation. EOT = end of treatment, NRT = nicotine replacement
therapy, RCT = randomized controlled trial
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Figure 5. COMT SNP rs4680 associations with smoking cessation by ancestry and treatment arm. EOT = end of treatment, NRT =
nicotine replacement therapy, RCT = randomized controlled trial
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Figure 6. COMT SNP rs4680 association with smoking cessation by biological sex. EOT = end of treatment, NRT = nicotine
replacement therapy, RCT = randomized controlled trial
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Figure 7. DBH SNP rs77905 association with smoking cessation. EOT = end of treatment, NRT = nicotine replacement therapy, RCT
= randomized controlled trial

Figure 8. Haplotype blocks for DRD2 SNP rs1800497 (Taq1A) for Americans of European
ancestry (CEU 1000 Genomes population) (top plot) and Japanese people (JPT 1000
Genomes population) (bottom plot).
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8.8 Appendix: Search Terms for Pubmed and Scopus

The PubMed database was searched using MESH search terms “Tobacco Use
Cessation” OR “Smoking Cessation” AND “Genetic Variation” OR “genetics” OR
“Precision Medicine” retrieving 625 journal articles.
We then searched the Scopus database for article titles with the terms “gene*” OR “snp”
OR “polymorphism*” OR “telomer*” OR “mutation*” OR “precision medicine”. The
Scopus search was further limited to titles that included the terms “smoking” OR
“tobacco” OR “cessation” OR “quit” OR “nicotine” OR “cigarette” AND the terms
“cessation” OR “quit” OR “quitting” OR “stop” OR “stopping” OR “abstin*” OR “relapse”.
Scopus was further limited to human and English only studies, producing 353 journal
articles.
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9.1 Abstract
Genetic studies of smoking cessation have been limited by short-term follow-up or crosssectional design. This study tests genetic associations with cessation during long-term followup throughout adulthood. Associations between 10 SNPs in CHRNA5, CHRNA3, CHRNB2,
CHRNB4, DRD2, and COMT and the probability of smoking cessation over time were evaluated
in two longitudinal cohort studies of female nurses, the Nurses’ Health Study (NHS) (n =10,017)
and NHS-2 (n = 2,793). Participant follow-up ranged from 2 to 38 years with data collected
every 2 years. Women with the minor allele of either CHRNA5 SNP rs16969968 or CHRNA3
SNP rs1051730 had lower odds of cessation throughout adulthood [OR = 0.93, p-value =
0.003]. Women had increased odds of cessation if they had the minor allele of CHRNA3 SNP
rs578776 [OR = 1.17, p-value = 0.002] or CHRNB4 SNP rs12914008 [OR = 1.14, p-value =
0.0363]. The minor allele of DRD2 SNP rs1800497 was associated with lower odds of
cessation in moderate/heavy smokers [OR = 0.92, p-value = 0.0183] but increased odds in light
smokers [OR = 1.24, p-value = 0.096]. Identification of SNPs associated with cessation over
decades of follow-up could inform precision medicine approaches for smokers who may benefit
from long-term cessation management.
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9.2 Introduction
Most U.S. adult smokers attempt to quit smoking each year, but only a small proportion
achieve sustained cessation1,2 as 50% of those who quit relapse within 12 months.3
Understanding factors associated with smoking cessation can lead to improved intervention
approaches, increasing long-term cessation rates. Smoking cessation is more than 50%
heritable4, emphasizing the importance of research to identify genetic variants associated with
cessation because of their value for refining precision medicine approaches to smoking
cessation.
Nicotinic acetylcholine receptor (nAChR) and dopaminergic genes are strong candidates
for genetic studies of smoking cessation due to their influence on nicotine response. Nicotine
binds to nAChRs,5 a family of neurotransmitter receptors,5 stimulating dopamine release
producing neurological reward and reinforcing smoking behavior.6 Continued nicotine intake
causes neuroadaptations within nAChRs7 producing craving, tolerance, and dependence.8,9
Furthermore, nAChRs are implicated in memory and associative learning10 that are reinforced
by increased dopamine levels and signaling.11 This leads to cue-primed behavior,12 drugseeking in the absence of contextual biological need.13 Dopamine-driven inhibitory control
mechanisms also contribute to addictive behaviors.14-16 Cue-primed behavior and inhibitory
control are behavioral factors that contribute to relapse risk long after nicotine withdrawal. 3
Depending on smoking intensity, the nAChR and dopaminergic pathways may influence
addiction through varying degrees of biochemical and behavioral mechanisms. Light smokers
(≤5 cigarettes/day (CPD)) experience low or no nicotine dependence yet still smoke for an
average of 19 years.17 Light smokers report smoking for the “boost” in mood or concentration18,
thus, for light smokers, persistent smoking may be driven by positive reinforcement and
corresponding behavioral conditioning.18 Conversely, nicotine dependence predominates in
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heavy smokers via a negative reinforcement mechanism of addiction (e.g. withdrawalavoidance).1,19
Addiction mechanisms may also differ by biological sex. Women are more likely to
respond to sensory stimuli of cigarette smoking, smoke to regulate mood, and have increased
cue-reactivity.20-22 Conversely, men are more sensitive to nicotine content and craving.20,21,23
Despite the plausible differences in factors associated with smoking intensity and differences by
biological sex, most genetic studies of smoking cessation have excluded light smokers and the
few studies of women focused on pregnancy24,25. Thus, studies examining differences in
genetic risk by smoking intensity and studies focused on women are needed. Furthermore,
most evidence of genetics and smoking cessation is from studies measuring abstinence 2-6
months post-cessation. Studies are needed to understand genetic markers that are associated
with long-term smoking outcomes. Using data from two all-female cohort studies with up to 38
years of repeated smoking status measures, the primary aim of this study was to examine
associations between single nucleotide polymorphisms (SNPs) within nAChR and dopaminergic
genes and the likelihood of smoking cessation throughout adulthood in women. In addition,
because prior genetic studies of older smokers are limited, this study also stratifies SNP
associations with smoking cessation by <65 and 65+ years of age. The secondary study aim
was to examine heterogeneity of genetic associations between light versus moderate-to-heavy
smokers.
9.3 Methods
9.3.1 Study population
The study population (Figure 1) included a subset of participants from the Nurses’ Health Study
(NHS) (N = 121,700) and NHS-2 (N = 116,429), two prospective cohort studies of female
registered nurses that have been previously described.26. Data were collected every 2 years
beginning in 1976 for NHS and 1989 for NHS-2 and were available up to 2014 for NHS and
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2015 for NHS-2. The final study population includes self-reported white participants with
quality-controlled, consented genotype data27,28 who were former or current smokers at
baseline. This resulted in 10,017 participants from the NHS and 2,793 participants from the
NHS-2.
9.3.2 SNP selection
A literature review identified 10 SNPs within nAChR or dopaminergic genes with findings
suggesting an association with short-term smoking cessation or cross-sectional smoking status.
Six SNPs were located within the CHRNA5-A3-B4 gene complex on chromosome 15, encoding
for the α-5, α-3, and β-4 nAChR subunits: CHRNA5 SNPs rs16969968 G>A25,29-32, rs680244
T>C25,33, rs588765 T>C34-36; CHRNA3 SNPs rs1051730 G>A24,35,37 and rs578776 G>A34; and
CHRNB4 SNP rs12914008 G>A33. An additional nAChR variant, CHRNB2 SNP rs2072661
G>A,38,39 was also identified; CHRNB2 encodes for the β-2 nAChR subunit. Three
dopaminergic variants were identified. Two SNPs of DRD2, encoding for D2 dopamine
receptors: SNPs rs1800497 G>A40-45 and rs6277 G>A46; and one SNP of COMT, encoding for
an enzyme regulating brain dopamine levels: SNP rs4680 G>A47-49.
9.3.3 Variables
The dependent variable was smoking status dichotomized for each subject at each follow-up
time as former or current. Follow-up time was treated as continuous with the baseline
designated as year 0. At each follow-up, participants reported former or current ordinal CPD
data with the following categories: 1–4, 5–14, 15–24, 25–34, 35–44, 45+, and unknown.
Smoking intensity was classified so that participants who reported smoking 1-4 CPD throughout
the follow-up were categorized as light smokers and all others were classified as
moderate/heavy smokers. This variable definition captures lifetime light smokers and prevents
misclassifying moderate/heavy smokers who reported reducing smoking to <5 CPD as light
smokers50.
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Additional relevant variables included baseline age, early age of smoking initiation51,
menopausal status52, hormone replacement therapy (HRT) use53-55, and body mass index
(BMI).53 Due to differences between cohorts in data collection, early age of smoking initiation
was defined as participants who reported smoking prior to age 16 years for NHS and those who
reported smoking prior to age 15 years for NHS-2. To account for changes during follow-up,
time-varying dichotomized variables were used for menopausal status and HRT use and a
continuous time-varying variable was used for BMI.
9.3.4 Statistical analysis
Generalized estimating equation (GEE) models were used to evaluate the association between
the 10 SNPs and the probability of smoking cessation over time using repeated smoking status
measurements. These models account for the proportion of observations each participant was
a former smoker determining if SNP associations with cessation persist throughout the follow-up
instead of focusing on smoking status at a single timepoint. An autoregressive covariance
structure was assumed to account for the correlation between repeated measures for each
participant. Codominant, dominant, recessive, and additive genetic models were considered for
SNPs with minor allele frequencies (MAF) > 0.05, whereas the dominant model was assumed if
MAF ≤ 0.05. The association between each SNP and the probability of smoking cessation over
time was modeled with fixed effects for baseline age, year, and genotype and considering fixed
effects for potential confounders (smoking intensity, early initiation of smoking, menopausal
status, HRT use, and BMI). Analyses were stratified on age <65 years at the time of follow-up
assessments to account for documented differences in smoking prevalence and cessation
attempts between adults aged <65 years and those aged >65 years.56-60 Age stratification also
enabled more valid comparison between NHS and the more recent NHS-2 which had
insufficient sample size of participants aged >65 years for longitudinal analysis.
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A false discovery rate (FDR) < 0.05 was used to control for testing multiple SNPs and genetic
models. Statistical analyses were conducted using SAS 9.4 statistical software and model
assumptions were checked graphically. The best genetic model for each SNP was selected
based on QIC score and consistency with inheritance patterns.61 To accomplish the secondary
goal of the study of evaluating heterogeneity of genetic associations between moderate/heavy
and light smokers, a genotype by smoking intensity interaction was then considered.
Each cohort was analyzed separately. Results were combined via meta-analysis using the
%METAANAL SAS macro to produce fixed effects estimators and test for between-study
heterogeneity.62 Random effects pooling was assumed.
9.4 Results
Participant characteristics are summarized in Table 1. At baseline, the average NHS eversmoker was 43 years old (SD 6.7 years) with a BMI of 23.7 kg/m2 (SD 4.0) and the average
NHS-2 ever-smoker was 36.3 years old (SD 4.3 years) with a BMI of 24.0 kg/m2 (SD 4.7). At
the beginning of follow-up, 32.0% of NHS participants were post-menopause and 9.2% used
HRT whereas only 6.1% of NHS-2 participants were post-menopause and 5.3% used HRT.
The prevalence of early initiation of smoking was similar in both cohorts (13.0% NHS, 14.1%
NHS-2), whereas the prevalence of light smokers was higher (p-value < 0.001) in NHS-2
(16.8%) compared to NHS (5.7%). Genotype frequencies are reported in Supplementary Table
1.
9.4.1 Associations in participants aged <65 years
Among NHS and NHS-2 participants aged <65 years, associations with cessation were not
observed for five of the ten SNPs: CHRNA5 SNPs rs588765 and rs680244, CHRNB2 SNP
rs2072661, DRD2 SNP rs6277, and COMT SNP rs4680. Three SNPs, two nAChR and one
dopaminergic, were associated with reduced odds of cessation and two nAChR SNPs were
associated with increased odds of cessation. The odds ratios (ORs) and 95% confidence
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intervals (CIs) under the best genetic model for each SNP are presented in Figure 2.
Associations (ORs, 95% CIs) for all SNPs and genetic models are shown in Supplementary
Table 2.
The nAChR SNPs associated with reduced odds of cessation, CHRNA5 rs16969968
and CHRNA3 rs1051730, are nonrandomly associated loci or in linkage disequilibrium (LD) (r2 =
1.00, D’ = 1.00) in populations with European ancestry. Thus, findings are nearly identical with
participants having 7% lower odds of quitting smoking with each additional copy of the minor
allele [rs16969968 95% CI 0.89 – 0.98, rs1051730 95% CI 0.89 – 0.97]. Among dopaminergic
SNPs, those with at least one copy of the minor allele DRD2 rs1800497 were less likely to quit
smoking than those homozygous for the common allele [Summary OR = 0.93, 95% CI 0.87 –
1.00]. This association was not statistically significant after adjusting for multiple testing.
The nAChR SNPs associated with increased odds of cessation were CHRNA3 rs578776 and
CHRNB4 rs12914008. Within European ancestry populations, these SNPs are in LD (D’ =
0.999) but low correlation (r2= 0.12). Participants with at least one copy of the minor allele of
rs578776 had increased odds of smoking cessation compared to homozygous common allele
carriers [Summary OR = 1.17, 95% CI 1.06 – 1.29]. A weaker association that was not
statistically significant after adjusting for multiple testing was observed for rs12914008
[Summary OR = 1.14, 95% CI 1.01 – 1.28].
9.4.2 Associations in NHS participants, ≥ 65 years of age
The associations were not statistically significant in NHS participants aged ≥ 65 years; however,
the point estimates were similar or slightly weaker compared to those found in NHS participants
aged <65 years. (Figure 3)
9.4.3 Associations by smoking intensity in participants aged <65 years
Examining SNP associations under the best genetic model by smoking intensity, the genotype
by smoking intensity interactions were not statistically significant. However, in both cohorts,
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there was heterogeneity for some SNPs in the direction of the genetic association between light
and moderate/heavy smokers. (Figure 4)
The strongest heterogeneity was for DRD2 rs1800497. Among moderate/heavy
smokers, those with at least one copy of the minor allele were less likely to quit smoking than
those homozygous for the common allele [Summary OR = 0.92, 95% CI 0.86 – 0.99].
Conversely, among light smokers, minor allele carriers had increased odds of quitting [Summary
OR = 1.24, 95% CI 0.96 – 1.59].
Similar heterogeneity in the direction of the association was observed for SNPs
rs16969968 and rs1051730. In moderate/heavy smokers, the odds of smoking cessation were
reduced 8% per copy of the minor allele of either SNP [95% CI 0.88 – 0.97], whereas, in light
smokers the odds of smoking cessation increased 8% per copy of the minor allele of either SNP
[95% CI 0.89 – 1.29].
9.4.4 Post-hoc analysis
We conducted post-hoc analyses testing associations between rs578776/rs16969968
haplotypes and smoking cessation (Supplementary Figure 1). Compared to participants with
GG/AA haplotypes, participants with (AG + AA)/GG haplotypes [Summary OR = 1.33, 95% CI
1.10 – 1.61] or (AG + AA)/AG haplotypes [Summary OR = 1.19, 95% CI 1.06 – 1.33] had higher
odds of smoking cessation throughout adulthood. The (AG + AA)/AA haplotypes were rare
(NHS: n = 3; NHS-2: n = 0), and thus were not examined.
9.5 Discussion
This study focused on ten selected SNPs in relation to smoking cessation, with methods
and results that expand upon prior evidence. The innovative study characteristics include a
long-term longitudinal design, a focus on smoking cessation in women, a large sample size to
investigate the genetic associations by smoking intensity, and data on elderly individuals for
whom evidence is sparse. Each of these pieces of evidence are discussed below.
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This study provides important proof-of-principle that some SNPs associated with shortterm smoking cessation remain associated with cessation during long-term follow-up, whereas
other SNP associations may not persist long-term. These findings could help identify high-risk
smokers who may benefit from long-term smoking cessation management. In this study, five of
the ten SNPs tested were associated with smoking cessation throughout adulthood
documenting that these genetic associations persist during long-term follow-up in white women.
The minor alleles of CHRNA5 rs16969968 and CHRNA3 rs1051730 were associated with lower
likelihood of quit smoking throughout adulthood among women aged <65 years. Though some
null findings for either SNP have been reported32,33,63,64, the present findings are consistent with
several prior studies with much shorter follow-up.24,25,29,31,35,37
The present study also found that the minor alleles of CHRNA3 rs578776 and CHRNB4
rs12914008 were associated with increased odds of smoking cessation throughout adulthood.
The findings for rs12914008 are consistent with those previously observed in a short-term
smoking cessation trial33, but the present association was weak and could be an artifact of the
LD with rs578776. The results for rs578776 were robust and consistent with those observed
among Han Chinese males.34 To our knowledge this is the first study to observe this
association with cessation in a population of European ancestry as previous studies reported
null associations.35,64 The minor allele was previously shown to be protective against relapse
during the first 90-days post-cessation 65 and may influence smoking cessation through
cognitive-behavioral mechanisms as smokers with the minor allele are less likely to have a
heightened intrinsic reward response to visual smoking cues.66 This may partially explain the
strong association observed in the present all-female study as women are more likely than men
to respond to sensory stimuli of cigarette smoking.21
Concerning dopaminergic SNPs evaluated in this study, the minor allele of DRD2
rs1800497 was weakly associated with lower likelihood of smoking cessation throughout
132

adulthood in women aged <65 years. The direction of this association is consistent with
previous studies41,67,68, but the association was stronger in prior studies with a higher proportion
of males.41 The weaker association we observed in this study could be due to biological sex
because the minor allele is associated with reductions in D2 dopamine receptor density and
binding capacity69 that are more pronounced in males.70
The present study also extends current research by examining differences in genetic
associations by smoking intensity. Smoking intensity is an important tobacco control issue
because the proportion of U.S. adult smokers who are light smokers is growing.71 Evidence of
this increase was observable in the study as the proportion of light smokers increased from
5.7% in NHS to 16.8% in NHS-2. This study’s large sample size and long-term follow-up are
notable strengths for investigating whether SNP associations with smoking cessation differ by
smoking intensity. Consistent heterogeneity in the direction of the associations with smoking
cessation by light versus moderate-heavy smokers were observed for rs1800497, rs16969968,
and rs1051730. The minor alleles of these SNPs were inversely associated with persistent
smoking among light smokers but associated with increased risk of persistent smoking among
moderate/heavy smokers. Despite the heterogeneity in ORs, inferences are limited because
the tests for statistical interaction were not statistically significant, though this may be due to the
relatively low prevalence of light smokers. Nevertheless, these findings are biologically
plausible. The reduced D2 receptor density and binding capacity associated with the minor
allele of rs1800497 could lead to decreased positive reinforcement, and thereby protect against
persistent light smoking. The rs16969968 and rs1051730 SNPs are associated with nicotine
dependence,72-75 and thus could lead to persistent heavier smoking because of the key role of
withdrawal-avoidance in heavier smoking.
Another strength of the present study was the data to examine genetic associations over
time in women aged ≥65 years. Genetic studies of smoking cessation of elderly populations are
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rare as the mean age of study populations have typically been 37.7 - 57.3 years.25,32,35
Compared to women aged <65 years, observed associations were weaker and were not
statistically significant among women aged ≥65 years, but the point estimates of the ORs were
consistent across age strata suggesting the associations are relevant among older women.
These results provide insights into smoking cessation in elderly populations, but also highlight
challenges to this research area. The lower prevalence of smoking and quit attempts among
older women smokers increases the difficulty of detecting genetic associations in this
population.
In summary, this study revealed some of the CHRNA5-A3-B4 and DRD2 SNPs
previously associated with short-term smoking cessation were also associated with long-term
cessation. The clinical implications of these results include the potential use of genetic markers
to identify smokers who may benefit from long-term cessation/relapse management.
Furthermore, comparison of the results from this all-female study to findings from studies
including both sexes suggests the strength of some associations may differ by biological sex.
Understanding genetic differences by biological sex could fine-tune precision medicine
cessation approaches.
This study provided limited evidence that genetic associations differ by smoking
intensity, a challenging research area due to the low prevalence of light smokers. Similarly,
determining genetic factors associated with cessation among elderly smokers can be difficult;
however, the results suggested associations among younger smokers may be relevant for the
elderly. Identifying how genetic factors predictive of long-term cessation differ by smoking
intensity and their relevance to elderly smokers holds promise for high-precision tailoring of
long-term smoking cessation/relapse management.
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9.6 Figures

Figure 1. Study population

NHS = Nurses’ Health Study, NHS-2 = Nurses’ Health Study 2
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Figure 2. SNP associations with odds of smoking cessation, timepoints where participants are <65 years
old.

SNP = single nucleotide polymorphism, NHS = Nurses’ Health Study, NHS-2 = Nurses’ Health Study 2.
Controlling for year, age, smoking intensity (<5 or ≥5 cigarettes per day), early initiation of smoking (NHS = <16
years of age, NHS-2 = <15 years of age), menopausal status, use of hormone replacement therapy, body mass
index.
† FDR < 0.05, accounting for multiple comparisons for all genetic models and SNPs analyzed.
‡ FDR < 0.05, accounting for multiple comparisons of the selected genetic model for all 10 SNPs.
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Figure 3. SNP associations with odds of smoking cessation, NHS participants <65 and ≥65 years old.

Controlling for baseline age, year, smoking intensity (<5 or ≥5 cigarettes per day), early initiation of
smoking (<16 years of age), menopausal status (for <65 years of age), and hormone replacement
therapy use. SNP = Single Nucleotide Polymorphism, NHS = Nurses’ Health Study.

137

Figure 4. Genetic associations with odds of smoking cessation by smoking intensity

SNP = single nucleotide polymorphism, NHS = Nurses’ Health Study, NHS-2 = Nurses’ Health Study 2.
Light smoking <5 cigarettes per day (CPD), Moderate/Heavy smoking ≥5 CPD).
Adjusted for year, age, smoking intensity, genotype x smoking intensity interaction, early initiation of smoking
(NHS = <16 years of age, NHS -2 = <15 years of age), menopausal status, use of hormone replacement therapy,
and body mass index. Assessing timepoints in which participants are <65 years of age.
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Supplementary Figure 1. Single nucleotide polymorphisms rs578776 and rs16969968
haplotype comparisons.
NHS = Nurses’ Health Study, NHS-2 = Nurses’ Health Study
* includes n = 3 NHS participants with AA genotype for rs16969968
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9.7 Tables

Table 1. Descriptive statistics of Nurses' Health Study (NHS) and Nurses' Health Study 2 (NHS-2)
cohorts. Baseline status data were collected in 1976 for NHS and 1989 for NHS-2.
NHS
NHS-2
1976 - 2014
1989 - 2015
(N = 10,017)
(N = 2,793)
Age (years),
baseline

mean, (SD)

43.0 (6.7)

36.3 (4.3)

(kg/m2),

29-55

24-43

mean, (SD)

23.7 (4.0)

24.0 (4.7)

n (%)

10,017 (100)

2,793 (100)

n (%)

10,017 (100)

2,793 (100)

Postmenopausal,
baseline
HRT use, baseline

Yes, n (%)

3,208 (32.0)

171 (6.1)

Yes, n (%)

923 (9.2)

148 (5.3)

Early initiation of
smoking (<16 years
old in NHS, <15
years old in NHS-2_
Lifetime light
smoker (<5
cigarettes/day)

Yes, n (%)

1,305 (13.0)

393 (14.1)

574 (5.7)

471 (16.8)

BMI
baseline
Female

Race, White

Range

n (%)

Participants
<65 years of
age
10,017

Participants
≥65 years of
age
9,788

Participants
<65 years of
age
2,793

Participants
≥65 years of
age
N/A

114,487

75,169

36,387

N/A

# of repeated measures per
2 - 20
1 - 15
participant
BMI = body mass index, HRT = hormone replacement therapy

5 – 14

N/A

# of participants, N
Total # of observations
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Supplementary Table 1. Study population genotype frequencies
Nurses' Health Study
10,017)
SNP
SNP rs16969968 G>A

SNP rs588765

SNP rs680244

SNP578776

SNP rs1051730

T>C

T>C

G>A

G>A

SNP rs12914008
G>A
SNP rs1800497

SNP rs2072661

SNP rs6277

SNP rs4680

G>A

G>A

G>A

G>A

(N =

Nurses' Health Study 2
2,793)

n

%

n

%

GG

4,356

43.5

1,201

43.0

AG

4,458

44.5

1,251

44.8

AA

1,203

12.0

341

12.2

TT

2,398

23.9

651

23.3

CT

4,895

48.9

1,373

49.2

CC

2,724

27.2

769

27.5

TT

2,401

24.0

651

23.3

CT

4,907

49.0

1,373

49.2

CC

2,709

27.0

769

27.5

GG

5,214

52.0

1,496

53.6

AG

4,038

40.3

1,089

39.0

AA

765

7.6

208

7.4

GG

4,346

43.4

1,203

43.1

AG

4,466

44.6

1,243

44.5

AA

1,205

12.0

347

12.4

GG

9,236

92.2

2,553

91.4

AG

759

7.6

239

8.6

AA

22

0.2

1

0.0

GG

6,588

65.8

1,856

66.4

AG

3,100

30.9

837

30.0

AA

329

3.3

100

3.6

GG

5,588

55.8

1,581

56.6

AG

3,785

37.8

1,040

37.2

AA

644

6.4

172

6.2

GG

2,500

25.0

791

28.3

AG

4,915

49.0

1,355

48.5

AA

2,602

26.0

647

23.2

GG

2,486

24.8

688

24.6

AG

5,008

50.0

1,410

50.5

AA

2,523

25.2

695

24.9

(N =
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Supplementary Table 2. Odds ratio (95% confidence interval) of smoking cessation for all genetic models tested for the 10 single nucleotide polymorphisms
evaluated (<65 years of age)
SNP
Statistical
Study
Additive
Recessive
Dominant
Codominant
Model
Aa vs. AA
aa vs (Aa + AA)
(aa + Aa) vs AA
Aa vs AA
aa vs. AA
rs16969968

Unadjusted

NHS
NHS-2

0.93 (0.88, 0.98)
0.87 (0.78, 0.96)

0.86 (0.78, 0.96)
0.80 (0.64, 1.00)

0.92 (0.86, 0.99)
0.84 (0.73, 0.97)

0.95 (0.88, 1.02)
0.87 (0.75, 1.02)

0.84 (0.75, 0.94)
0.75 (0.59, 0.94)

rs16969968

Adjusted

NHS
NHS-2

0.94 (0.89, 0.99)
0.90 (0.80, 1.00)

0.89 (0.80, 0.99)
0.84 (0.67, 1.05)

0.93 (0.87, 1.01)
0.88 (0.76, 1.02)

0.95 (0.88, 1.03)
0.91 (0.78, 1.06)

0.87 (0.77, 0.98)
0.80 (0.63, 1.01)

rs578776

Unadjusted

NHS
NHS-2

1.10 (1.04, 1.16)
1.26 (1.12, 1.41)

1.10 (0.97, 1.26)
1.42 (1.07, 1.89)

1.13 (1.05, 1.21)
1.31 (1.14, 1.51)

1.13 (1.05, 1.21)
1.27 (1.09, 1.48)

1.16 (1.01, 1.33)
1.56 (1.17, 2.09)

rs578776

Adjusted

NHS
NHS-2

1.09 (1.03, 1.16)
1.21 (1.08, 1.37)

1.08 (0.95, 1.24)
1.33 (0.99, 1.79)

1.13 (1.05, 1.21)
1.26 (1.08, 1.46)

1.12 (1.04, 1.21)
1.23 (1.05, 1.43)

1.14 (0.99, 1.31)
1.45 (1.07, 1.96)

rs1051730

Unadjusted

NHS
NHS-2

0.92 (0.88, 0.97)
0.87 (0.78, 0.97)

0.86 (0.78, 0.96)
0.80 (0.64, 0.99)

0.92 (0.86, 0.99)
0.85 (0.74, 0.98)

0.95 (0.88, 1.02)
0.88 (0.76, 1.03)

0.84 (0.75, 0.94)
0.75 (0.59, 0.94)

rs1051730

Adjusted

NHS
NHS-2

0.94 (0.89, 0.99)
0.90 (0.81, 1.00)

0.88 (0.79, 0.99)
0.84 (0.67, 1.04)

0.93 (0.87, 1.00)
0.89 (0.77, 1.03)

0.95 (0.88, 1.03)
0.92 (0.78, 1.07)

0.86 (0.77, 0.97)
0.80 (0.63, 1.01)

rs1800497

Unadjusted

NHS
NHS-2

0.96 (0.90 - 1.02)
0.93 (0.82, 1.05)

1.11 (0.92, 1.35)
1.13 (0.77, 1.67)

0.93 (0.87, 1.00)
0.89 (0.76, 1.03)

0.92 (0.85, 0.99)
0.87 (0.74, 1.01)

1.08 (0.89, 1.32)
1.08 (0.73, 1.60)

rs1800497

Adjusted

NHS
NHS-2

0.96 (0.90, 1.03)
0.94 (0.83, 1.07)

1.11 (0.91, 1.35)
1.11 (0.75, 1.65)

0.94 (0.87, 1.01)
0.90 (0.78, 1.05)

0.92 (0.86, 1.00)
0.89 (0.76, 1.04)

1.08 (0.88, 1.32)
1.07 (0.72, 1.59)

rs680244

Unadjusted

NHS
NHS-2

0.99 (0.94, 1.04)
1.00 (0.91, 1.11)

0.99 (0.91, 1.07)
0.97 (0.83, 1.14)

0.98 (0.90, 1.06)
1.04 (0.88, 1.23)

0.98 (0.90, 1.07)
1.06 (0.88, 1.26)

0.97 (0.88, 1.07)
1.01 (0.83, 1.23)

rs680244

Adjusted

NHS
NHS-2

0.97 (0.92, 1.02)
1.02 (0.92, 1.13)

0.96 (0.89, 1.05)
0.99 (0.84, 1.16)

0.96 (0.88, 1.05)
1.08 (0.91, 1.28)

0.97 (0.89, 1.06)
1.09 (0.91, 1.31)

0.94 (0.85, 1.05)
1.05 (0.85, 1.28)

rs588765

Unadjusted

NHS
NHS-2

0.99 (0.94, 1.04)
0.99 (0.90, 1.10)

0.99 (0.91, 1.07)
0.96 (0.82, 1.13)

0.98 (0.90, 1.06)
1.03 (0.87, 1.21)

0.98 (0.90, 1.07)
1.05 (0.88, 1.25)

0.97 (0.88, 1.07)
0.99 (0.81, 1.21)

rs588765

Adjusted

NHS
NHS-2

0.97 (0.92, 1.02)
1.01 (0.91, 1.12)

0.96 (0.89, 1.05)
0.98 (0.83, 1.15)

0.96 (0.88, 1.05)
1.07 (0.90, 1.26)

0.97 (0.89, 1.06)
1.08 (0.90, 1.30)

0.94 (0.85, 1.04)
1.03 (0.84, 1.27)

rs12914008

Unadjusted

1.13 (0.99, 1.29)
1.10 (0.84, 1.43)

rs12914008

Adjusted

1.14 (1.00, 1.31)
1.11 (0.85, 1.45)

rs2072661

Unadjusted

NHS
NHS-2

0.95 (0.90, 1.01)
0.98 (0.88, 1.10)

0.89 (0.78, 1.03)
1.06 (0.78, 1.43)

0.95 (0.87, 1.02)
0.96 (0.83, 1.11)

0.96 (0.90, 1.04)
0.95 (0.82, 1.10)

0.88 (.0.76, 1.01)
1.03 (0.76, 1.40)

rs2072661

Adjusted

NHS
NHS-2

0.96 (0.90, 1.02)
0.99 (0.88, 1.11)

0.93 (0.80, 1.07)
1.08 (0.79, 1.46)

0.95 (0.89, 1.03)
0.96 (0.83, 1.12)

0.96 (0.89, 1.04)
0.95 (0.81, 1.11)

0.91 (0.79, 1.05)
1.05 (0.77, 1.43)

rs6277

Unadjusted

NHS
NHS-2

0.99 (0.94, 1.03)
1.02 (0.92, 1.12)

0.98 (0.91, 1.05)
1.05 (0.89, 1.25)

0.98 (0.91, 1.06)
1.00 (0.86, 1.17)

0.99 (0.91, 1.08)
0.98 (0.83, 1.16)

0.97 (0.89, 1.06)
1.04 (0.85, 1.27)

rs6277

Adjusted

NHS
NHS-2

0.98 (0.94, 1.03)
1.02 (0.92, 1.13)

0.97 (0.89, 1.04)
1.04 (0.88, 1.24)

0.98 (0.90, 1.06)
1.01 (0.86, 1.19)

0.99 (0.91, 1.08)
1.00 (0.84, 1.18)

0.96 (0.88, 1.05)
1.04 (0.85, 1.27)

rs4680

Unadjusted

NHS
NHS-2

0.97 (0.92, 1.02)
0.99 (0.90, 1.08)

0.93 (0.86, 1.01)
1.02 (0.87, 1.19)

0.98 (0.90, 1.05)
0.94 (0.80, 1.11)

1.00 (0.92, 1.09)
0.93 (0.78, 1.11)

0.94 (0.85, 1.03)
0.97 (0.80, 1.18)

rs4680

Adjusted

NHS
0.96 (0.92, 1.01)
0.92 (0.85, 1.00)
0.97 (0.89, 1.05)
0.99 (0.91, 1.08)
NHS-2
0.97 (0.88, 1.07)
1.00 (0.85, 1.18)
0.92 (0.78, 1.08)
0.91 (0.76, 1.08)
A = Major allele, a = minor allele, AA = homozygous for major allele, aa = homozygous for minor allele, Aa = heterozygous

0.92 (0.84, 1.02)
0.94 (0.77, 1.15)
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10.1 Abstract
10.1.1. Background: Seven genes were selected that influence nicotinic acetylcholine
receptors (CHRNA3, CHRNA5, CHRNB2, CHRNB4), dopaminergic function (DRD2 and DBH),
and nicotine metabolism (CYP2A6). These genes are good candidates for associations with the
likelihood of smoking cessation due the influence on biological mechanisms that influence
smoking behavior and prior indications of gene associations with nicotine dependence. The
goal of this research was to conduct a candidate gene study of these genes to identify novel or
understudied single nucleotide polymorphisms (SNPs) that are associated with smoking
cessation.
10.1.2. Methods: Participants were from two all-female longitudinal cohort studies, the Nurses’
Health Study (NHS) (n = 10,017) and NHS-2 (n = 2,793), with repeated smoking behavior
measures collected every 2 years over up to 38-years follow-up. A three step process was
used to evaluate genetic associations: 1) Haploview software was used to select 108 tag SNPs
providing full coverage of CHRNA3, CHRNA5, CHRNB2, CHRNB4, DRD2, DBH and CYP2A6;
2) Generalized estimating equations (GEE) models evaluated SNP genotype associations with
the probability of having quit smoking over time in the NHS; 3) SNPs reaching statistical
significance (p < 0.05) within the NHS, were then evaluated in the NHS-2 using the same GEE
modeling approach with the additional implementation of a false discovery rate (FDR) < 0.05 to
control for multiple testing.
10.1.3. Results: Women with the minor alleles of six SNPs within the CHRNA3-A5-B4 gene
cluster, CHRNA5 SNPs rs637137, rs503464, and rs684513 and CHRNB4 SNPs rs11072774,
rs12441998, and rs12441088, had lower odds of having quit smoking throughout adulthood.
The minor alleles of two additional SNPs in this gene cluster, CHRNA3 SNP rs77478700 and
CHRNB4 SNP rs4887074, were associated with higher likelihood of abstinence from smoking
throughout adulthood in women who were moderate-to-heavy smokers. Women with the minor
150

alleles of two SNPs within CYP2A6, SNPs rs56113850 and rs56267346, had lower odds of
smoking cessation throughout adulthood.
10.1.4. Conclusion: For the first time, genetic variants within these candidates have been
shown to be significantly associated with the likelihood of smoking cessation throughout
adulthood. Identifying these long-term associations has important translational potential for
informing the implementation of long-term smoking cessation management interventions. The
validity of these findings is supported by the replication of the results in the two, well-designed
cohort studies, the NHS and NHS-2, with correction for multiple testing in the NHS-2 validation
cohort.
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10.2 Introduction
Addiction theory hypothesizes that greater levels of nicotine dependence result in
increased difficulty quitting smoking. Even so, though nicotine dependence has been shown to
be 70% to 75% heritable1,2, the severity of various withdrawal symptoms has been found to be
between 23% and 43% heritable.2 The heritability of persistent smoking and/or smoking
cessation is 50 - 54%.2 The variation in heritability of these different smoking phenotypes likely
indicates some shared and some unique genetic influences for these phenotypes. Candidate
gene studies of smoking addiction have more frequently focused on the nicotine addiction
phenotype than smoking cessation3, but it is important to evaluate genetic associations across
the spectrum of smoking phenotypes to identify shared and unique genetic contributions.
Genes that influence nicotinic acetylcholine receptors (nAChRs), dopaminergic function,
and nicotine metabolism are good candidates for associations with the likelihood of smoking
cessation. Genetic association studies of smoking cessation have largely focused on CHRNA5
SNP rs16969968 which has consistently emerged as a risk variant for nicotine addiction and
cessation failure. Variants within the CHRNA5-A3-B4 cluster, encoding for the α-5, α-3, and β-4
nAChR subunits, have been associated with Fagerström Test for Nicotine Dependence (FTND)
scores.1 Evidence in relation to other SNPs within CHRNA5-A3-B4 and associations with
smoking cessation is limited but there is some evidence other SNPs within this cluster may be
predictive of smoking cessation.4,5 In addition, although CHRNB2 has not been associated with
the degree of nicotine dependence6, a strong association between CHRNB2 SNP rs2072661
and smoking cessation was observed in one study.7
Similar associations with FTND scores and haplotypes of DBH, a gene that encodes the
enzyme that metabolizes dopamine to norepinephrine, have also been observed.8,9 Despite
associations with nicotine dependence, inconsistencies have been observed in associations
between variants of DBH with respect to cigarette consumption (cigarettes per day; CPD).10,11
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Similarly, associations between smoking phenotypes and the DRD2 Taq1A (rs1800497) SNP,
which is associated with D2 dopamine receptor density and binding12 and is one of the most
frequently studied genetic variants in smoking addiction, have shown links with nicotine
dependence, CPD10,13, and smoking cessation14 although the results have not all been
consistent.2
Variation between individuals’ nicotine-to-cotinine metabolism is predominantly
attributable to polymorphisms of the CYP2A6 gene.15 Faster nicotine metabolism, as measured
by the nicotine metabolite ratio, has been correlated with smoking more CPD16,17, and nicotine
metabolism predicted by CYP2A6 genotypes has been associated with likelihood of smoking
cessation.18 However, few studies have explored the association of individual CYP2A6 variants
and the likelihood of smoking cessation.
The goal of this research was to conduct a candidate gene study of CHRNA3, CHRNA5,
CHRNB2, CHRNB4, DRD2, DBH, and CYP2A6 to identify novel or understudied SNPs within
these genes that are associated with smoking cessation. Using data from two well-established
cohort studies of female, registered nurses with up to 38 years of repeated assessment of
smoking status, we examined associations between single nucleotide polymorphisms (SNPs)
providing full coverage of the selected genes and the likelihood of smoking cessation throughout
adulthood. The secondary study aim examined heterogeneity of genetic associations by
smoking intensity to identify potential differences between light and heavy smokers, as several
genes have shown potential associations with CPD.
10.3 Methods
10.3.1 Study population (Figure 1): The study populations used for discovery and validation
were obtained from subsets of participants from the Nurses’ Health Study (NHS) (N = 121,700)
and NHS-2 (N = 116,429), respectively. The NHS and NHS-2 are prospective cohort studies of
female registered nurses with data collected every 2 years beginning in 1976 for NHS and 1989
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for NHS-2 for up to 38 years of follow-up. Each cohort has been previously described in
detail.19 Those participants from each cohort who were former or current smokers at baseline,
who self-reported as European ancestry, and who had existing quality-controlled, consented
genotype data20,21 were included in the final study populations. This resulted in 10,017
participants from the NHS and 2,793 participants from the NHS-2 for the discovery and
validation datasets, respectively. The reason for exclusion based on ancestry was to prevent
confounding due to difference in genetic variability between ancestral groups.
10.3.2. Participant characteristics and variables: The dependent variable was smoking
status dichotomized within each subject at each follow-up time as former or current. Follow-up
time was treated as continuous with the baseline questionnaire designated as year 0. At each
follow-up, in addition to smoking status, both former and current smokers reported cigarettes
per day (CPD), captured ordinally with the following categories: 1–4, 5–14, 15–24, 25–34, 35–
44, 45+, and unknown. Smoking intensity was re-classified so that participants who reported
smoking 1-4 CPD throughout the follow-up were categorized as light smokers and all others
(i.e., ever smokers of 5+ CPD) were classified as moderate/heavy smokers. We used this
variable definition to avoid misclassifying participants reporting smoking <5 CPD at one followup while reporting smoking more at another follow-up22 as light smokers. This classification
captures lifetime light smokers to examine genetic associations with smoking cessation among
this understudied population of smokers.
Additional relevant variables included baseline age, early age of smoking initiation23,
menopausal status24, hormone replacement therapy (HRT) use25-27, and body mass index
(BMI).25 Due to differences between cohorts in data collection, early age of smoking initiation
was defined as participants who reported smoking prior to 16 years of age for NHS and those
who reported smoking prior to 15 years of age for NHS-2. To account for changes during
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follow-up, time-varying dichotomized variables were used for menopausal status and HRT use
and a continuous time-varying variable was used for BMI.
Follow-up time was limited to questionnaire assessments occurring at timepoint in which
participants were aged <65 years. This approach enabled more accurate comparison between
the NHS and the more recent NHS-2 because the younger baseline age and later study start for
NHS-2 yielded insufficient numbers of follow-up timepoints in which participants were >65 years
of age. In addition, differences have been noted in smoking prevalence, likelihood of making a
quit attempt, and challenges to smoking cessation success between adults >65 years of age
and those <65 years of age.28-32
10.3.3 Three-step approach to evaluate genetic associations: A three-step approach was
used to determine associations between SNPs within candidate genes and smoking cessation
throughout adulthood (Figure 2).
Step 1: SNP selection:
Haploview software was used to select tag SNPs, with minor allele frequencies >0.05
and not in linkage disequilibrium (R2<0.80), to provide full coverage of the following candidate
genes within nicotine addiction pathways: CHRNA5, CHRNA3, CHRNB4, CHRNB2, DRD2,
DBH, CYP2A6. The chromosome location of each gene and the selected tag SNPs within each
are available in Table 1.
Step 2: Discovery
Using the repeated smoking status measurements collected every 2 years in the NHS,
generalized estimating equations (GEE) models evaluated SNP genotype associations with the
probability of having quit smoking over time. These GEE models accounted for the proportion
of smoking status measurements each participant was a former smoker and thus allowed us to
determine SNP associations with smoking cessation throughout the follow-up time instead of at
a single timepoint. The correlation between repeated measures for each participant over time
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was accounted for assuming an autoregressive covariance structure. Genetic models
considered in the analysis included codominant, dominant, recessive, and additive models for
SNPs with MAF > 0.20; MAF < 0.20 was modeled using the dominant and additive models. The
association between each SNP and the probability of having quit over time was initially modeled
with minimal adjustment for baseline age, year, smoking intensity, and genotype. The
association was then then modeled adding fixed effects for other potential confounders: early
initiation of smoking, menopausal status, HRT use, and BMI.
Step 3: Validation
Those SNPs reaching nominal statistical significance (p < 0.05) with the likelihood of
having quit smoking throughout the follow-up within the NHS study population during the
discovery phase (Step 2), were then evaluated in the NHS-2. The same GEE modeling
approach used in discovery was used with the additional implementation of a false discovery
rate (FDR) < 0.05 to control for testing of multiple SNPs and genetic models.
All statistical analyses were conducted using SAS 9.4 statistical software and model
assumptions (e.g. linearity in the logit of continuous covariates) were checked graphically. The
best fitting genetic model for each SNP was selected based on QIC score and consistency with
inheritance patterns described by Thakkinstian et al.33 To test whether genetic associations
may differ between moderate-to-heavy and light smokers, stratification of associations by
smoking intensity was also considered.
10.4 Results
Baseline participants characteristics have been previously described and are
summarized in Table 2. Of the 108 SNPs examined in the NHS, 27 were identified as
associated with smoking cessation over time with nominal statistical significance (p < 0.05).
These 27 SNPs were then examined for validation in the NHS-2 study population; 10 of the 27
SNPs were found to be associated with having quit smoking throughout adulthood among
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women in the NHS-2 after correcting for multiple testing (FDR < 0.05; Figure 2). Eight of the ten
SNPs were within the CHRNA5-A3-B4 gene cluster located on chromosome 15 and the minor
alleles were associated increased odds of having quit smoking throughout adulthood in women.
The remaining two SNPs were within the CYP2A6 nicotine metabolism gene and the minor
alleles were associated with lower odds of having quit smoking over time.
10.4.1 CHRNA3-A5-B4 SNPs
Among the full NHS-2 study population, the minor alleles of six SNPs within the
CHRNA3-A5-B4 gene cluster were associated with the likelihood of quitting smoking after
correction for multiple testing (Figure 3). The minor alleles of CHRNA5 SNPs rs637137,
rs503464, and rs684513 and CHRNB4 SNPs rs11072774, rs12441998, and rs12441088 were
associated lower odds of having quit smoking throughout adulthood. Odds ratios with 95%
confidence intervals for both the discovery and validation steps for each SNP are shown in
Figure 2. Two additional SNPs, CHRNA3 SNP rs77478700 and CHRNB4 SNP rs4887074,
were nominally associated with smoking cessation (p < 0.05) in the full NHS-2 study population
but were not statistically significant after correcting for multiple testing. However, examination of
associations with smoking cessation over time stratified by smoking intensity (light versus
moderate-to-heavy smokers) suggested that the associations between these two SNPs and
cessation differed in direction by smoking intensity (Figure 4). Those with the minor alleles of
these SNPs were more likely to be abstinent from smoking throughout the follow-up if they were
moderate to heavy smokers. These associations within the moderate-to-heavy smoker strata
were statistically significant after correction for multiple testing. In contrast, light smokers with
the minor alleles of these SNPs had lower odds of being abstinent throughout the follow-up but
the associations were not statistically significant. The associations were consistently in the
inverse direction between light and moderate-to-heavy smokers in both the NHS and NHS-2
cohorts. However, the SNP rs77438700 genotype by smoking intensity interaction was only
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statistically significant in the NHS-2 [NHS: p = 0.15; NHS-2: p = 0.02], and the SNP rs4887074
by smoking intensity interaction was not statistically significant in either cohort study [NHS: p =
0.07; NHS-2: p = 0.12].
10.4.2 CYP2A6 SNPs
The minor alleles of two SNPs within CYP2A6, SNPs rs56113850 and rs56267346, were
associated with lower odds of smoking cessation throughout adulthood. The odds ratios and
95% confidence intervals for both the discovery and validation steps are shown in Figure 2.
10.4.3 Post-hoc analysis by birth cohorts
For SNPs that were statistically significantly associated with smoking cessation
throughout the follow-up, the associations were consistently stronger in NHS-2 compared to
NHS. To assess the possibility that the stronger results in the more recent cohort may be due
to cohort effects, a post-hoc analysis was conducted stratifying the analysis by year of birth
cohorts. Women in the NHS cohort were stratified by year of birth from 1921 to 1935 (n =
6,551) and from 1936 to 1946 (n = 3,466); and women in the NHS-2 cohort were stratified by
year of birth from 1946 to 1955 (n = 2,061) and from 1956 – 1964 (n = 732). Figure 4 shows the
odds ratios and confidence intervals for the year of birth stratum for the eight SNPs associated
with smoking cessation over time in the full cohorts. An increase in the strength of the
association was consistently observed for all eight SNPs across the 1921 – 1935 through the
1946 – 1955 cohorts. Some inconsistency in the trend of the association for the 1956 – 1964
birth cohort was observed across the eight SNPs.
10.5 Discussion
Prior genetic studies of smoking cessation have typically either been cross-sectional or
focused on relatively short-term follow-up of six months to one year. The unique feature of this
candidate gene study of 108 SNPs within CHRNA5-A3-B4, CHRNB2, DRD2, DBH, and
CYP2A6 is that it investigated whether genetic associations in relation to the long-term
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likelihood of smoking cessation. This research was carried out in two cohorts of women with
long-term follow-up of up to 38 years. The results showed 10 SNPs, 8 within the CHRNA5-A3B4 cluster and 2 within CYP2A6, were associated with smoking cessation throughout adulthood.
We characterize the relevant details of these findings in relation to the SNPs and gene regions
below. Since these SNPs were selected as tag SNPs, attention was also given to any previous
findings in relation to variants in high linkage disequilibrium with the selected SNPs.
The major finding of this study is the documentation for the first time that genetic variants are
significantly associated with the likelihood of smoking cessation throughout adulthood.
Identifying these long-term associations has important implications for precision approaches to
smoking cessation in the clinic. The internal validity of these results is enhanced by the fact that
the study population was comprised of two well-designed and implemented cohort studies, the
NHS and NHS-2, with high quality genotyping data. Further, these findings were replicated in
the two cohorts and were robust to correction for multiple testing in the NHS-2 validation cohort.
These findings were generated in cohorts comprised of all women and for statistical
consideration limited to women of European ancestry. Thus, these associations need to be
examined both in men and in populations of non-European ancestry to assess the
generalizability of the findings beyond this subpopulation of women of European ancestry.
However, this study provides novel and important insights in relation to genetic associations
among women of European ancestry with smoking cessation throughout adulthood.
With respect to the specific findings, the strongest association observed in this study
was in relation to CHRNA5 SNP rs503464, a variant that may influence CHRNA5 mRNA
expression.34 While SNP rs503464 has not been associated with nicotine dependence35,36, a
study of various pharmacotherapy cessation interventions found that the minor allele was
associated with smoking fewer CPD and increased likelihood of abstinence from smoking during
treatment, at end of treatment, and 12-months post-cessation.37 This present study is the first to
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confirm this association, and the first to do so with long-term follow-up data, showing that
women of European ancestry with the minor allele of SNP rs503464 are more likely to quit
smoking. Our findings not only confirmed the association in both discovery and validation
analyses, but also demonstrate that the associations persist throughout adulthood.
The minor alleles of two additional SNPs within CHRNA5, SNPs rs637137 and rs684513
were also associated with increased odds of smoking cessation throughout adulthood.
Although one prior study observed that both SNPs were associated with nicotine dependence35,
another study failed to confirm this association for SNP rs68451336 and another found that
neither SNP was associated with nicotine dependence.8 However, this later study observed that
among smokers with high levels of nicotine dependence, those with haplotypes containing both
of these variants had increased odds of end of treatment abstinence.8 The association
observed in this later study was no longer present at six-months follow-up. A separate analysis
of each SNP among women in the placebo arm (n = 106) found that those with the minor allele
of either SNP rs637137 or rs683514 had increased odds of abstinence at six-months follow-up,
but these associations were not statistically significant.38 This study was likely underpowered in
the analysis of women in the placebo arm, which could have precluded observing the significant
effect at the six-month follow-up that was observed at EOT (8-weeks), especially given that half
of all smokers who quit will relapse within the first 12-months.39 The large sample size of our
study of women over decades of follow-up, inclusive of lifetime light smokers who presumably
have lower nicotine addiction levels, has substantially greater power and confirms the
suggested associations in women from this prior study. In addition, we show that these
associations with smoking cessation persist throughout adulthood.
We found that the minor alleles of three SNPs of CHRNB4 were associated increased
likelihood of having quit smoking throughout adulthood. To our knowledge, none of the three
variants have been previously reported in the scientific literature in relation to smoking addiction
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or behavior. However, one of the SNPs, CHRNB4 SNP rs12441998, is in high linkage
disequilibrium (R2 = 0.96, D’ 1.00 in CEU) with CHRNB4 rs3813567 which has been reported,
though sparsely, in the available evidence. CHRNB4 SNP rs3813567 was associated with
nicotine addiction in a prior candidate gene study35, but this association was not confirmed in a
subsequent study.36 In addition, three prior clinical trials of smoking cessation did not observe
an association between rs381356740,41 with the exception of participants in the selegiline
treatment arm of one trial in which participants with minor allele had significantly higher odds of
abstinence at end of treatment4. This association among those receiving selegiline was no
longer present at 12-months follow-up.4 These prior studies were of small samples of 231 to
301 people and had limited follow-up; thus, it is plausible they were not sufficiently powered to
observe the association. This example of limitations of prior research highlights the
methodologic strengths of the present study, such as the large sample size, the repeated
measures over long-term follow-up of up to 38 years, and the ability to replicate associations in
two independent study populations.
We observed a possible interaction by smoking intensity for a fourth SNP of CHRNB4,
rs4887074. This SNP was associated with increased likelihood of having quit smoking among
moderate-to-heavy smokers after correcting for multiple testing. In contrast, among lifetime light
smokers the association was in the opposite direction, though the finding was not statistically
significant potentially due to the low prevalence and resulting small sample size for light
smokers. Based on a minor allele frequency of 0.38 and the dominant genetic model, a priori
power calculations assuming 10 repeated measures and autoregressive covariance indicated
this study had 80% power to detect an odds ratio of approximately 0.74 among light smokers for
SNP rs4887074. Thus, we may not have been sufficiently powered to detect the association
among light smokers. A prior study found the minor allele of CHRNB4 SNP rs4887074 was
associated with having lower nicotine dependence levels.42 In addition, in a further haplotype
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analysis of the inheritance of the minor allele of SNP rs4887074 with the minor allele of
CHRNA5 rs16969968, a key genetic indicator of risk for nicotine addiction, indicated SNP
rs4887074 mediated some of the associated risk of SNP rs16969968.42 This could explain the
stronger association of rs4887074 in our present study with increased likelihood of having quit
smoking only among moderate-to-heavy smokers as nicotine dependence may play a stronger
role in smoking behavior among heavier smokers compared to light smokers.
Of the two CYP2A6 SNPs that we found strongly associated with decreased smoking
cessation throughout adulthood, to our knowledge only SNP rs56113850 has been previously
reported in the scientific literature in relation to smoking. In a previous study, participants with
the minor allele (T allele) had reduced CYP2A6 enzyme activity (often correlated with smoking
fewer CPD) and reduced lung cancer risk.43 A more recent study partially confirmed these
findings showing that those with the T allele had decreased odds of smoking cessation despite
also having lower risk of heavier smoking, lung cancer and COPD.44 Our findings confirm the
later study findings showing that the minor allele is associated with lower odds of smoking
cessation.
In response to the findings showing that the statistically significant SNP associations
with smoking cessation were consistently stronger in the more recent NHS-2 cohort than in
NHS, we conducted a post-hoc analysis by year of birth cohorts. This analysis consistently
showed weaker genetic associations among women born in the earliest year of birth cohort
(1921 – 1935). The genetic associations appeared to consistently strengthen with each
subsequent birth cohort with the exception of the most recent year of birth cohort, women born
between 1956 and 1964. However, the later strata (1956 – 1964) was of a much smaller
sample of women than the other stratum. These associations could lend strength to the
hypothesis that some characteristics of smokers have changed over time and that a hardening
of smokers. This “hardening” hypothesis suggests that tobacco control policies have effectively
162

helped many of the “easy” quitters successfully quit smoking.45,46 It is theorized that as a
consequence, the proportion of smokers who are more highly addicted and have greater
difficulty quitting has increased over time. If true, this could contribute to an increase among the
smoking population in the contribution of genetic susceptibility to addiction.
This study examined associations between individual SNPs within genes that could
potentially influence smoking addiction. Individuals SNPs typically have small effects when
considering complex phenotypes, such as smoking behavior, nicotine dependence, and
smoking cessation. The small effect sizes often spread over numerous genetic variants which
can make it difficult to characterize the genetic risk associated with these phenotypes. Methods
to combine the risk associated with multiple variants could improve the understanding of genetic
susceptibility and smoking cessation. For example, although we did not detect strong
associations with smoking cessation for individual variants within DBH or DRD2, consideration
of the effect of multiple variants within these genes likely holds promise for understanding the
role these genes play in smoking behavior. Evidence to support this hypothesis comes from a
study that showed that in smokers a haplotype of six SNPs within DBH was predictive of odds of
abstinence at end of treatment.8 It could be that these individual SNPs on their own have a
small effect on abstinence that can be difficult to identify in studies of individual variants.
10.6 Conclusion
This candidate gene study identified associations with replication in an independent
study population for several SNPs that were not previously identified. In addition, the findings
for CHRNA5 SNPs rs503464, rs637137, and rs683514, and CYP2A6 SNP rs56113850 provide
important confirmation of previous novel associations that had yet to be replicated. In addition,
this is the first study to identify these SNP associations using repeated measurements over up
to 38 years of long-term follow-up. These findings are valid for women of European ancestry
and will need to be examined in men and in populations of non-European ancestry to ascertain
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the generalizability to other populations of smokers. Nevertheless, the strength of the
methodology using long-term data provides important insights regarding genetic risk of
persistent smoking (failure to quit smoking) throughout adulthood in women. These insights
hold promise for informing precision medicine approaches to long-term smoking cessation in
this subset of smokers.
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10.7 Figures

Figure 1. Study Population. NHS = Nurses’ Health Study,
NHS-2 = Nurses’ Health Study 2

Figure 2. Summary of results of three-step approach
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Figure 3. SNP genotype associations for the eight SNPs identified as associated with smoking
cessation throughout adulthood in the full study populations, replication in NHS-2 with FDR <
0.05.
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Figure
Figure4.
1.Associations
Summary ofinthe
theresults
full study
of the
population
three-step
and
approach.
stratified by smoking intensity (light vs
moderate/heavy smokers) for the two SNPs that failed to replication with FDR < 0.05 in the full
cohort but replicated in the NHS-2 with FDR < 0.05 among moderate/heavy smokers. Also,
examination of ORs indicate that associations differ by smoking intensity.

Figure 5. Post-hoc analysis of the eight SNPs associated with smoking cessation in the full study
population. Analysis is stratified by year of birth stratum. NHS 1921 to 1935, NHS 1936 to 1946,
NHS-2 1946 – 1955, NHS-2 1956 - 1964
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10.8 Tables
Table 1. Selected tag SNPs within CHRNA3, CHRNA5, CHRNB4, CHRNB2, CYP2A6, DRD2, and DBH
Gene

location

SNP rsID

Gene

location

SNP rsID

CHRNA3

15:78892784

rs62010327

CYP2A6

19:41352263

rs4514794

15:78900701

rs138544659

19:41354712

rs8192725

15:78912278

rs8025188

19:41343700

rs76112798

15:78907736

rs12443170

19:41354941

rs200110220

15:78912472
15:78906637

rs117832812
rs77438700

19:41354442
19:41353107

rs57607700
rs56113850

15:78873976

rs637137

19:41349550

rs8192733

15:78910463

rs503464

19:41349640

rs7248240

15:78858400

rs684513

19:41353849

rs2388868

15:78860818

rs634662

19:41349943

rs373949046

15:78858491

rs871058

19:41353338

rs56267346

15:78884553
15:78997922

rs76474922
rs12907178

19:41355195
19:41356379

rs7250713
rs28399433

15:78939964

rs79045860

19:41357344

rs4803381

15:79007950

rs11638490

11:113294976

rs11608185

15:78984507

rs28444683

11:113280724

rs6278

15:78952110

rs4887074

11:113345339

rs10789943

15:78952697
15:78929372

rs11072774
rs12441998

11:113320419
11:113301266

rs4245148
rs2471850

15:78948850

rs12900336

11:113344912

rs61902807

15:78929498

rs36045869

11:113318007

rs4245147

15:78923845

rs28534575

11:113283477

rs6275

15:78918762

rs62010332

11:113282275

rs1124492

15:78964498

rs8032156

11:113310340

rs79549222

15:79004643
15:78922638

rs12592823
rs2869548

11:113323831
11:113327294

rs72999670
rs77541954

15:78961449

rs58946838

11:113323199

rs61902784

15:78934318

rs67426328

11:113299273

rs75349786

15:78995488

rs12442575

11:113323201

rs61902785

15:78924604

rs11635249

11:113321211

rs55697087

15:78968268

rs11857532

11:113310681

rs7125415

15:78942035
15:78958788

rs3971872
rs8034028

11:113289862
11:113317067

rs78044862
rs17529477

15:78928264

rs12441088

11:113283459

rs6277

15:78928411

rs79609284

11:113329774

rs7131056

15:78993975
15:78931057

rs199611682
rs9920506

9:136505114
9:136504598

rs1108580
rs2519155

15:78953785

rs17487514

9:136502572

rs13284520

1:154550724
1:154544651

rs6680410
rs4845378

9:136509679
9:136519258

rs3739886
rs61149283

1:154548880

rs2072661

9:136519392

rs7871224

1:154548521

rs2072659

9:136504064

rs2797850

CHRNA5

CHRNB4

CHRNB2

DRD2

DBH

168

DBH

1:154551368

rs4845653

9:136509370

rs4531

1:154547292

rs12072348

9:136509634

rs2519152

1:154549470
9:136514668
9:136502328
9:136502321

rs12130403
rs6479643
rs2519143
rs3025382

9:136510086
9:136512275
9:136515284
9:136522928

rs1548366
rs2519154
rs7864658
rs2073837

9:136512071
9:136510059
9:136512515
9:136519021
9:136516570
9:136510894
9:136507473

rs2797854
rs1548367
rs2797853
rs3025416
rs739398
rs2797855
rs5320

9:136520282
9:136503819
9:136523669
9:136523959
9:136519216
9:136505241
9:136511516

rs2073833
rs2007153
rs129882
rs13306304
rs7851898
rs1108581
rs1541332

Table 2. Descriptive statistics of Nurses' Health Study (NHS) and Nurses' Health Study 2 (NHS-2)
cohorts. Baseline status data were collected in 1976 for NHS and 1989 for NHS-2.
NHS
NHS-2
1976 - 2014
1989 - 2015
(N = 10,017)
(N = 2,793)
Age (years),
baseline

mean, (SD)

(kg/m2),

mean, (SD)

BMI
baseline
Female

Race, White
Postmenopausal,
baseline
HRT use, baseline

43.0 (6.7)

36.3 (4.3)

29-55

24-43

23.7 (4.0)

24.0 (4.7)

n (%)

10,017 (100)

2,793 (100)

n (%)

10,017 (100)

2,793 (100)

Yes, n (%)

3,208 (32.0)

171 (6.1)

Yes, n (%)

923 (9.2)

148 (5.3)

1,305 (13.0)

393 (14.1)

574 (5.7)

471 (16.8)

111,493

36,534

Range

Early initiation of
Yes, n (%)
smoking (<16 years
old in NHS, <15
years old in NHS-2_
Lifetime light smoker
n (%)
(<5 cigarettes/day)
Total # of observations

# of repeated measures per
3 - 18
participant
BMI = body mass index, HRT = hormone replacement therapy

5 – 14
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11.1. Abstract
11.1.1. Background: Single nucleotide polymorphisms (SNPs) of nicotinic acetylcholine
receptor (nAChR) and dopaminergic genes have been linked to short-term cessation or crosssectional smoking status, but studies have been limited by short-term follow-up which cannot
account for multiple quit attempts and relapse events throughout adulthood.
11.1.2. Methods: Based on prior short-term studies, ten SNPs in nAChR or dopaminergic
genes were selected, six in CHRNA5-A3-B4, one in CHRNB2, two in DRD2, and one in COMT.
A zero-inflated beta regression was used to model SNP associations with odds of relapse
during follow-up and, conditional on relapse, SNP associations with proportion of follow-up in
relapse. Data are based on two longitudinal cohort studies of female nurses. Participants
included 12,060 ever smokers of European ancestry who reported having quit smoking at ≥1
timepoint and who also had existing quality-controlled genotype data. Follow-up time was
counted after the first report of smoking cessation with a median follow-up of 32 years.
11.1.3. Results: Higher odds of sustained abstinence throughout adulthood were seen among
women with AA genotypes compared to those with AG or GG genotypes for CHRNA5 SNP
rs16969968 G>A (15% higher) or CHRNA3 SNP rs1051730 G>A (16% higher; p-value = 0.04
for both). Among women who relapsed, four SNPs were associated with the proportion of
follow-up in relapse; these included a higher proportion for women with CC genotypes (versus
CT or TT genotypes) of CHRNA5 SNPs rs588765 T>C (p = 0.04) and rs680244 T>C (p = 0.048)
and AA genotype (versus AG or GG genotypes) for DRD2 SNP rs6277 G>A (p = 0.01), whereas
the proportion was less for those with AA or AG genotypes (versus GG genotype) for COMT
SNP rs4680 G>A (p = 0.03).
11.1.4. Conclusion: Some CHRNA5 and CHRNA3 SNPs were associated with relapse over
decades of follow-up. Several CHRNA5, COMT, and DRD2 SNPs were not associated with
likelihood of relapse but, if women relapsed, were associated with the proportion of follow-up in
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relapse during adulthood. The findings emphasize the value of long-term follow-up to
characterize smoking phenotypes, allowing identification of smokers with high-risk genotypes for
long-term relapse prevention interventions.
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11.2 Introduction
Smoking-attributable illness is responsible for more than 480,000 deaths annually.1 The
rates of smoking-caused morbidity and mortality increase with duration and intensity of
smoking2 and begin to decrease upon smoking cessation. Some health benefits of quitting
smoking can be observed relatively quickly after cessation, such as improved pulmonary
function. Even so, several years of smoking abstinence is required to experience many
significant health benefits of smoking cessation. For example, coronary heart disease risk
returns to that of a non-smoker after 15 years of abstinence and cancer risk decreases by 30 to
50% after 10 years of abstinence.1,3
Abstinence is typically unstable over multiple and episodic attempts to quit smoking,
especially during early periods of a quit attempt. Relapse rates exceed 50% throughout the first
year post cessation, dropping only to 36% and 25%, respectively, after 2 and 5 fully abstinent
years.4 Smokers typically undergo several unsuccessful quit attempts before, if ever,
permanently quitting smoking.5 Factors associated with cessation and relapse cannot be fully
understood from studies with follow-up of 1-year or less. Despite this, smoking cessation
research has typically evaluated prolonged smoking cessation by measuring smoking
abstinence 6 – 12 months post quit date. In addition, studies commonly utilize point-prevalent
abstinence outcomes measuring abstinence within the 7 days prior to the study endpoint. This
outcome does not capture relapse to smoking at timepoints earlier during follow-up. For
example, a longitudinal study of former smokers abstinent for up to 5 years at baseline6 found
that a significant proportion of the participants abstinent at 4-years follow-up had been abstinent
for <2 years, and thus had relapsed to smoking during follow-up before once again successfully
quitting.6
Understanding the risk factors associated with relapse, including late relapse one or
more years after quitting, is important for promoting sustained abstinence and reducing the
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smoking-caused burden on public health. Long-term smoking cessation management could
play an important role in preventing relapse. However, because the smoker population is so
large and resources to implement such interventions are limited, it is necessary to identify those
smokers most at risk for and impacted by smoking relapse throughout their lifetime.
Genetic susceptibility is a key risk factor in smoking behavior as twin studies suggest
nicotine dependence, withdrawal symptoms, and smoking cessation are between 31% and 60%
heritable.7-10 Research to identify specific variants associated with smoking behavior is in
relatively nascent stages. However, genes influencing nicotinic acetylcholine receptors
(nAChRs) and properties of the mesolimbic dopaminergic (DA) system are promising
candidates due to the respective contributions to both nicotine response and cognitivebehavioral phenotypes such as associative learning, cue-primed behavior11, and inhibitory
control.12-15 Despite the promise of variation in these genes for improving identification of
smokers at high-risk for relapse, studies have typically used <1-year follow-up. The aim of this
study was to expand upon prior research limited by shorter follow-up. We herein examine
associations between genetic variants and smoking relapse throughout adulthood, as well as
the proportion of follow-up in relapse. Additionally, this study focused solely on women, an
important design characteristic due to sex differences in risk factors for relapse such as weight
gain concerns and changes in menstrual phase.16-18
11.3 Methods
11.3.1 Study population. The Nurses’ Health Study (NHS) (N = 121,700) and NHS 2 (N =
116,429) are large prospective cohorts of female registered nurses with data collected every 2
years beginning in 1976 for NHS and 1989 for NHS 2.19 Quality controlled, consented whole
genome genotype data were previously collected20,21 for 10,049 and 2,804 former or current
smokers (at baseline) in the NHS and NHS 2 cohorts, respectively. Of those baseline eversmokers with genotype data, there were 32 women in the NHS cohort and 16 women in the
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NHS 2 cohort that were of non-European ancestry; these women were excluded from the
analysis to avoid confounding due to population stratification. We further excluded 505 and 171
participants from the NHS and NHS 2 cohorts, respectively, because they failed to quit smoking
during follow-up and were not at risk for relapse. Lastly, 63 women in NHS and 11 women in
NHS 2 did not have follow-up observations following their initial report of smoking cessation;
these participants were excluded from the analysis since it was not feasible to observe relapse.
The final analysis population included 9,449 women from the NHS cohort and 2,611 women
from the NHS 2 cohort for a total study population of 12,060.
11.3.2. Single nucleotide polymorphism selection. Seven single nucleotide polymorphisms
(SNPs) within nAChR genes and three SNPs within dopaminergic genes were selected based
on existing evidence of potential associations with either short-term smoking abstinence (8 to 24
weeks post cessation) or cross-sectional smoking status. Six of the nAChR SNPs were located
within the CHRNA5-A3-B4 gene complex, encoding for the α-5, α-3, and β-4 nAChR subunits,
and the seventh nAChR SNP selected was within CHRNB2, encoding for the β-2 nAChR
subunit. The specific nAChR SNPs identified were CHRNA5 SNPs rs16969968 G>A22-26,
rs680244 T>C26,27, rs588765 T>C28-30, CHRNA3 SNPs rs1051730 G>A29,31,32 and rs578776
G>A28, CHRNB4 SNP rs12914008 G>A27, and CHRNB2 SNP rs2072661 G>A33,34. The three
dopaminergic variants identified were SNPs rs1800497 G>A35-40 and rs6277 G>A41 within
DRD2, encoding for D2 dopamine receptors, and SNP rs4680 G>A42-44 within COMT, encoding
for the catechol-o-methyltransferase enzyme that metabolizes dopamine. Two pairs of SNPs
were in linkage disequilibrium (D’ = 1.00, R2 = 1.00): CHRNA5 rs16969968 with CHRNA3
rs1051730 and CHRNA5 rs588765 with CHRNA5 rs680244. All four were considered;
however, SNPs in linkage disequilibrium are expected to have similar results.
11.3.3. Variables. The independent variables were the selected SNPs. Genetic associations
were tested using the dominant, recessive, and additive genetic models for all SNPs except
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CHRNB4 rs12914008 which has a minor allele frequency (MAF) less than 0.05 making it
feasible to evaluate only the dominant model.
The dependent variable was the proportion of timepoints returned to smoking (relapsed)
throughout adulthood. For simplicity, we term this “proportion of follow-up in relapse.” We
calculated proportion of follow-up in relapse as the number of observed timepoints in which the
participant reported current smoking status divided by the total number of observed timepoints
after the first-reported former smoker status. For current smokers at baseline, observations
were considered after the first transition to former smoker during the follow-up period. For
example, consider three participants who were current smokers at baseline in the NHS cohort
and who reported former smoker status in 1980 beginning follow-up at that time. Figure 1
depicts these three example smokers and the corresponding calculation of proportion follow-up
in relapse. Participant 1 reported former smoker status and participant 2 reported current
smoker status on all subsequent questionnaires following 1980, thus, the proportion of follow-up
in relapse was 0% and 100%, respectively. Participant 3 reported current smoker status for four
of the seventeen follow-ups after 1980, thus, the proportion follow-up in relapse is 24%. For
former smokers at baseline, all observations available during the follow-up were considered and
observations were added to account for the time since quit smoking at baseline. Missing
observations (<1% of observations) were not counted in the numerator or denominator.
Additional variables considered included smoking intensity, age quit smoking, number of
follow-up observations, cohort (NHS or NHS 2), menopausal status, and body mass index
(kg/m2), the latter two assessed at the time of smoking cessation. Smoking intensity classified
participants as lifetime light smokers or moderate to heavy smokers. Smokers have been
typically classified as light smokers using a cut-off of 5 cigarettes per day (CPD)45; thus, women
who consistently self-reported smoking <5 CPD throughout the follow-up were categorized as
light smokers. All others were classified as ever moderate to heavy smokers. Age quit smoking
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did not satisfy linearity in the logit, thus age quit was grouped as: ≤20 years, 21 to 30 years, 31
to 40 years, 41 to 50 years, 51 to 60 years, 61 to 70 years, and 71+ years of age.
11.3.4. Statistical Analysis. Descriptive statistics were calculated for the NHS and NHS 2
cohort studies and the combined cohort study population. A zero-inflated beta regression model
using a logit transformation of the proportion of follow-up in relapse was implementing with the
SAS Beta Regression macro.46 This joint model evaluated 1) SNP genotype associations with
the log odds of having zero observations relapsed during follow-up, and 2) conditional on
relapse, SNP genotype associations with the proportion of follow-up in relapse. We also
stratified the analysis by menopausal status at cessation to determine differences in genetic
associations with relapse in women prior to and post menopause. Model assumptions and fit
were checked graphically.
11.4. Results
Descriptive statistics for the NHS and NHS-2 cohorts and the combined cohorts are
shown in Table 1. A higher proportion of women in NHS-2 (24.9%) relapsed to smoking during
follow-up compared to women in NHS (20.0%; p-value < 0.001). Women who relapsed on
average spent 33.7% of the follow-up returned to smoking; the proportion of follow-up returned
to smoking on average was greater among women in NHS-2 (39.8%) than among women in
NHS (31.7%; p-value < 0.001). The proportion of light smokers was higher in the more recent
NHS-2 cohort overall (18.0%) compared to the NHS (6.1%; p-value < 0.001), a trend consistent
with the increasing prevalence of light smokers among U.S. adult smokers in general.47 On
average, women in NHS-2 were 11 years younger than women in NHS and were less likely to
be post-menopause at the time of smoking cessation (p-value for both < 0.001). Women in
NHS-2 had a mean BMI of 24.0 kg/m2 at smoking cessation which was slightly higher than the
mean BMI of 23.7 kg/m2 seen among women in NHS at cessation (p-value = 0.005).
Prior to considering genetic associations, we determined the associations of smoking
intensity and menopausal status at cessation and with the likelihood of relapse and, among
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women who relapsed, the proportion of follow-up in relapse. Compared to light smokers,
moderate to heavy smokers had 1.45 (95% CI 1.20 – 1.75) times the odds of at least one
relapse episode during follow-up. Conditional on relapse, moderate to heavy smokers also
spent a significantly higher proportion of follow-up time returned to smoking than light smokers,
specifically 11.6% (95% CI 7.5 – 15.7%) more time returned to smoking among those who quit
before menopause, and 11.0% (95% CI 7.2 – 14.9%) more time returned to smoking among
those who quit post-menopause.
11.4.1. SNP associations with likelihood of relapse during follow-up (Table 2). The minor
alleles of two of the ten SNPs evaluated, CHRNA5 SNP rs16969968 G>A and CHRNA3 SNP
rs1051730 G>A, were associated with lower likelihood of relapse throughout the follow-up.
Women with two copies of the minor allele of rs16969968 were 15% [95% CI 0 – 33%, p-value
< 0.05] more likely and those with two copies of the minor allele of rs1051730 were 16% [95%
CI 1 – 34%] more likely to have sustained abstinence (zero relapse) throughout adulthood
compared to women with heterozygous or homozygous common allele genotypes. None of the
other eight SNPs were associated with likelihood of relapse during follow-up.
11.4.2. SNP associations with the proportion of follow-up in relapse (Figure 2, Table 2).
Conditional on relapse to smoking, four SNPs were significantly associated with the proportion
of follow-up in relapse. Women with two copies of the minor allele of CHRNA5 SNP rs588765
G>A had 2.6% [95% CI 0.1 – 5.0%] more follow-up and those with two copies of the minor allele
of CHRNA5 SNP rs680244 G>A had 2.4% [95% CI 0.2 – 4.9%] more follow-up in relapse than
women with heterozygous or homozygous common allele genotypes. Similarly, women with
one or two copies of the minor allele of DRD2 SNP rs6277 G>A had 3.3% [95% CI 0.8 – 5.7%]
more follow-up in relapse than women without the minor allele. In contrast, those with two
copies of the minor allele of COMT SNP rs4680 G>A had 2.7% [95% CI 0.2 – 5.2%] lower
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proportion of follow-up in relapse than women with heterozygous or homozygous common allele
genotypes.
11.4.3. SNP associations stratified by menopausal status at smoking cessation (Figure 3,
Table 3). The associations of SNPs rs16969968 and rs1051730 with the likelihood of sustained
abstinence (zero relapse) were slightly stronger among women who quit smoking premenopause [rs16969968 OR = 1.17 (95% CI 1.00 – 1.37), rs1051730 OR = 1.19 (95% CI 1.02 –
1.38)]. However, these SNPs were not associated with sustained abstinence among women
who quit post-menopause [rs16969968 OR = 1.01 (95% CI 0.71 – 1.43); rs1051730 OR = 1.00
(95% CI 0.70 – 1.41); genotype by menopause interaction p-value = 0.65 for both SNPs].
Conditional on relapse, the association of SNPs rs588765 and rs680244 with a higher
proportion of follow-up in relapse was significantly stronger among women who quit smoking
post-menopause [rs588765 risk difference = 9.5% (95% CI 3.8 -15.2%), rs680244 risk
difference = 10.1% (95% CI 4.4% - 15.9%)]. No difference in proportion follow-up in relapse by
genotype was observed among women who had quit smoking prior to menopause [rs588765
risk difference = 0.8% (95% CI -1.6 – 3.3%), p-value of genotype by menopause interaction =
0.003; rs680244 risk difference = 0.6% (95% CI -1.9% - 3.0%), p-value of genotype by
menopause interaction = 0.001]. Similarly, the genetic association of SNP rs6277 with more
follow-up in relapse was greater among women who reported quitting smoking post-menopause
[risk difference = 7.6% (95% CI 1.5 – 13.6%)] and was not statistically significant among women
quitting pre-menopause [risk difference = 2.1% (95% CI -0.3 – 4.5%), p-value of genotype by
menopause interaction = 0.04].
11.5. Discussion
This study is the first to examine genetic associations with the likelihood of smoking
relapse throughout adulthood and, among women who relapse, the proportion of follow-up in
relapse in a long-term prospective cohort. In addition, stratification of the analysis by
menopausal status at the first report of smoking cessation investigated potential differences in
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genetic associations by menopausal status. To our knowledge, this is the first study to examine
these differences by menopausal status. None of the 10 SNPs examined were associated with
both the likelihood of relapse throughout adulthood and, conditional on relapse, the proportion of
follow-up in relapse. However, we did observe associations for either likelihood of relapse or
proportion of follow-up in relapse for six SNPs: four within nAChR genes and two within genes
influence dopaminergic function. Furthermore, associations for several of these SNPs were
significantly stronger among women who first reported quitting smoking post-menopause.
Four SNPs within nAChR genes were associated with either likelihood of relapse
throughout adulthood or, conditional on relapse, the proportion follow-up in relapse. These four
SNPs comprised two pairs of SNPs in high linkage disequilibrium (correlation in inheritance):
SNP rs16969968 with rs1051730, and SNP rs588765 with rs680244. The first pair, rs16969968
and rs1051730, were associated with sustained abstinence (zero relapse) during follow-up but
were not associated with the proportion follow-up in relapse. This result is somewhat surprising
given consistent prior evidence that these SNPs are associated with increased nicotine
dependence, smoking more cigarettes per day, and lower likelihood of smoking cessation. 48 It
is plausible that smokers with the minor alleles of these SNPs may be more nicotine dependent
and less likely to successfully quit smoking, but after successful cessation may be more likely to
sustain abstinence over long-term follow-up. The indication that this could be the case
demonstrates the importance of investigating genetic associations with various smoking
phenotypes such as nicotine dependence, cessation, and relapse as well as examining these
phenotypes over different duration of follow-up. These lines of inquiry are needed to fully
understand the complexity of smoking behavior.
In contrast to SNPs rs16969968 and rs1051730, CHRNA5 SNPs rs588765 and
rs680244 were not associated with the likelihood of sustained abstinence during follow-up but,
conditional on relapse, were associated with the proportion of follow-up in relapse. Animal
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models suggest the α-5 nAChR subunit, encoded by CHRNA5, may partially mediate the effect
of nicotine on mood and anxiety levels.49 It is possible that variation in rs588765 and rs680244
contributes to the mediating effects of nicotine on mood leading to increased response among
those with these minor alleles. Women are more likely to report smoking to improve negative
mood.50 Thus, these alleles may not influence whether women relapse, but after relapse the
mediating effect on mood may lead to more prolonged duration of smoking.
Two additional SNPs were not associated with likelihood of sustained abstinence
throughout adulthood but, if relapse occurred, were associated with the proportion follow-up in
relapse. Both SNPs influence dopaminergic function. The first is SNP rs4680 within COMT, the
gene that encodes for catechol-o-methyltransferase (COMT), an enzyme that metabolizes
dopamine. Each copy of the minor allele of rs4680 functionally leads to a greater decrease in
COMT enzyme activity resulting in higher levels of dopamine in the prefrontal cortex.51
Prefrontal cortex dopamine levels are important for cognitive function, and people with the minor
allele of rs4680 have been found to have improved executive control function, the ability to
accomplish goal-directed behavioral control.52 This could explain why women with the
homozygous minor allele genotype of SNP rs4680 had a significantly lower proportion follow-up
in relapse than women with heterozygous or homozygous common allele genotypes. Higher
dopamine levels, presumably from lower COMT activity in women with the homozygous minor
allele genotype, could also minimize the nicotine reward experienced through nicotinestimulated dopamine release during relapse episodes. Lower nicotine reward upon relapse may
lead to less incentive to continue smoking.
Several prior studies have found no association between COMT rs4680 genotype and
smoking cessation, though the majority of these studies have not considered men and women
separately.43,53,54 Sex differences in COMT enzyme activity, possibly due to the role of estrogen
in downregulating activity, have been identified, as have differences in associations between
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COMT genotypes and psychiatric disorders.51 Prior studies of COMT rs4680 and smoking
cessation may have been confounded by the combined male and female study populations.
However, a few prior studies have considered women specifically and may lend insight into
potential associations. Colilla et al. found that women with the minor allele of SNP rs4680 were
more likely to be abstinent from smoking, with the strongest effect observed among those with
two copies of the allele, but observed no association among men.55 A study of women during
pregnancy found no association between the minor allele and the likelihood of quitting smoking
during pregnancy.56 In contrast, a study of older smokers (at least 55 years of age at
recruitment) found that both men and women with the minor allele were less likely to report
having quit smoking.42 Though the results from these studies are disparate, higher estrogen
levels downregulate COMT activity and the differences among women in these studies could be
due to stage of life and hormone levels. This could be the case since estrogen increases during
pregnancy and decreases post-menopause. Thus, changes in estrogen levels could have
impacted the results of the later studies. This demonstrates the complexity of understanding
smoking behavior among women and the need to consider changes throughout adulthood that
might interact with genetic susceptibility to influence smoking-related outcomes.
The second SNP influencing dopaminergic function is SNP rs6277 within DRD2 which
encodes for the D2 dopamine receptor; the minor allele of rs6277 variant is associated with
increased striatal D2 receptor density.57 Typically, decreased D2 receptor availability has been
associated with risk of addiction. Thus, it is somewhat surprising that the present study found
that women with the minor allele of rs6277 had a higher proportion follow-up in relapse than
women without the minor allele. However, SNP rs6277 was not associated with the likelihood of
relapse throughout adulthood in the present study and prior studies have found no association
with the likelihood of smoking cessation.41,58,59 People with the minor allele have been shown to
have a bias toward negative learning, a bias toward avoiding behaviors with high probability of
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negative feedback rather than learning to choose behavior with probabilistic positive feedback.60
Thus, it is plausible this bias influences continued smoking after relapse, but does not contribute
to either likelihood of cessation or relapse.
11.5.1. Genetic associations and menopause
Significant differences in the associations of SNPs rs588765, rs680244, and rs6277 with
the proportion follow-up in relapse by menopausal status at cessation were observed. The
differences in proportion follow-up in relapse between genotypes of SNPs rs588765 and
rs680244 were considerably larger among women who first reported quitting smoking postmenopause. In contrast, there was no difference (~0% difference) in proportion follow-up in
relapse by genotype among the women who reported quitting pre-menopause. In a similar
fashion, the difference in proportion follow-up in relapse between women with and without the
minor of allele of rs6277 was significantly greater among women who first reported quitting
smoking post-menopause compared to those who quit pre-menopause.
This phenomenon of greater genetic effect post-menopause could be partially due to the
fact that estrogen levels decrease after menopause. These decreases can lead to decreased
dopaminergic functioning, a possible explanation for higher risk of negative affect among
women during peri- and post-menopause.61,62 The effect of nicotine on mood and anxiety may
be mediated by the α-5 nAChR subunit.49 Thus, some variants within CHRNA5, including
rs588765 and rs680244, may play a stronger role in smoking relapse among post-menopausal
women by influencing the effect of nicotine intake on mood. For some post-menopausal
women, regulation of mood could be a more important motivator for smoking. In addition, the
bias toward avoiding negative feedback observed among people with the minor allele of rs6277
could more strongly influence women who first quit smoking later in life. Negative effect
combined with other factors related to smoking cessation, such as concerns about weight
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management, may have a stronger influence post-menopause.62 A genetic susceptibility to
avoid these negative consequences may be experienced more strongly in older women during
relapse episodes. In addition, chronic exposure to nicotine through cigarette smoking leads to
neuroadaptations in nicotinic and dopaminergic receptors.63,64 The interplay of neuroadaptation
and genetically conferred properties could play an important role in those older smokers who
have had greater long-term, chronic nicotine exposure.
11.6. Conclusion
This study is the first to quantify genetic associations with relapse throughout adulthood
and the proportion of time in relapse among smokers who successfully quit smoking and
subsequently relapsed. The findings showed that some SNPs, though not associated with the
likelihood of relapse, are associated with the amount of follow-up in relapse suggesting that
genetic risk markers differ depending on the smoking phenotype. Though the increased
proportion of follow-up in relapse for some individual variant may be relatively small for some
SNPs (e.g. 2.7% for rs4680), the combined risk of multiple variants could have a much larger
effect on the risk for long-term smoking.
Prolonged, chronic exposure to cigarette smoking results in increased risk of smokingattributable disease; thus, it is an important line of inquiry to identify markers that may predict
the potential long-term impact of relapse to smoking. The genetic associations for some SNPs
with the proportion follow-up in relapse were considerably stronger in women who first quit
smoking post-menopause. Menopause is associated with increased risk for cardiovascular and
other smoking-attributable disease,62 thus, more research focused on genetic risk in women by
menstrual and menopausal phase (to include peri- and post-menopause) is warranted.
The identification of smokers at the greatest risk for long-term cigarette smoking due risk
of cessation failure, relapse to smoking, and increased time in relapse after a relapse episode
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could inform precision medicine approaches. Long-term cessation management and relapse
prevention may be necessary to reduce smoking rates in the most high-risk smokers.
Identification of high-risk smokers is needed to guide development and implementation of these
long-term interventions.
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11.7 Figures and Tables
Figure 1. Participant examples of proportion follow-up in relapse calculations. The count of total
observations begins after the first report of former smoker status.
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Total
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58 (2.2)
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30 (1.5)

397 (20.2)

1,546 (78.8)

24.0 (4.8)

-

14 (0.7)

75 (3.8)

193 (9.8)

543 (27.7)

1,005 (51.2)

131 (6.7)

30.0 (9.4)

18
19

16.9

0
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Nurses’ Health Study 2

Table 1. Descriptive Statistics for the Nurses’ Health Study, Nurses’ Healthy Study 2, and the combined cohorts.
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Recessive
AA vs (AG+GG)

Recessive
CC vs (CT+TT)
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CC vs (CT+TT)

Dominant
(AA+AG) vs GG

Dominant
(AA+AG) vs GG

Dominant
(AA+AG) vs GG

Dominant
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GG
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Dominant
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CHRNA3 SNP
rs1051730 G>A
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rs588765 T>C

CHRNA5 SNP
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CHRNB4 SNP
rs12914008 G>A
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0.98 (0.88,
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0.98 (0.87,
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1.03 (0.93,
1.13)

1.06 (0.89,
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1.00 (0.91,
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OR (95% CI)
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1.15 (1.00,
1.33)*

Part 1: Zero model

CHRNA5 SNP
rs16969968 G>A

Single Nucleotide
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(SNP)

0.312 (0.272, 0.352)
0.339 (0.289, 0.389)
0.312 (0.272, 0.352)
0.331 (0.288, 0.375)
0.309 (0.269, 0.349)
0.331 (0.287, 0.374)
0.309 (0.269, 0.349)

0.458 (0.425, 0.491)
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0.425 (0.410, 0.439)
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AA or AG
GG

AA

GG
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0.01

0.03

0.16

0.332 (0.277, 0.386)
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0.390 (0.360, 0.419)
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0.384 (0.356, 0.412)

0.408 (0.376, 0.439)

0.383 (0.355, 0.411)

0.408 (0.376, 0.440)

0.430 (0.413, 0.448)

0.79

0.048

0.04

0.388 (0.360, 0.415)

0.417 (0.376, 0.457)

0.388 (0.360, 0.415)

0.417 (0.377, 0.458)

Mod/Heavy Smoker

0.257 (0.214, 0.301)

0.284 (0.241, 0.327)

0.285 (0.242, 0.328)

0.264 (0.221, 0.306)

0.274 (0.232, 0.317)

0.288 (0.244, 0.332)

0.275 (0.233, 0.317)

0.291 (0.237, 0.346)

0.282 (0.239, 0.325)

0.277 (0.234, 0.320)

0.281 (0.238, 0.325)

0.279 (0.235, 0.322)

0.274 (0.232, 0.316)

0.294 (0.249, 0.339)

0.273 (0.231, 0.315)

0.294 (0.249, 0.340)

0.277 (0.235, 0.319)

0.302 (0.251, 0.353)

0.277 (0.235, 0.319)

0.303 (0.252, 0.354)

Light Smoker

Menopause at cessation

GG

CC

CT or TT

CC

AG or GG

AA

0.09

0.340 (0.290, 0.389)

0.428 (0.414, 0.442)

AG or GG

AA

0.459 (0.426, 0.492)

Pre-menopause at cessation
Light Smoker

Genotype
RD
p-value
0.08
Mod/Heavy Smoker

Genotype

Part 2: Proportion of follow-up returning to smoking conditional on relapse (95% CI)

Table 2. SNP associations with likelihood of sustained abstinence (zero relapse) during follow-up (Part 1 of the zero-inflated beta regression model), and, conditional on relapse,
the proportion of follow-up in relapse (Part 2 of the zero-inflated beta regression model). Zero-inflated beta regression models were used controlling for age at cessation, total
observations during follow-up, BMI at cessation, menopausal status at cessation, smoking intensity (light vs. moderate to heavy smoker), and study cohort. *Odds ratio (OR) pvalue < 0.05. RD = Risk Difference (difference in proportion follow-up in relapse) between genotypes. Recessive genetic model referent group is heterozygous and homozygous
common allele genotypes. Dominant genet model reference group is homozygous common allele genotype.
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Recessive
AA vs (AG+GG)

Recessive
CC vs (CT+TT)

Recessive
CC vs (CT+TT)

Dominant
(AA+AG) vs GG

Dominant
(AA+AG) vs GG

Dominant
(AA+AG) vs GG

Dominant
(AA+AG) vs. GG

Recessive
AA vs (AG+GG)

Dominant
(AA+AG) vs GG

CHRNA3 SNP
rs1051730 G>A

CHRNA5 SNP
rs588765 T>C

CHRNA5 SNP
rs680244 T>C

CHRNA3 SNP
rs578776 G>A

CHRNB2 SNP
rs2072661 G>A

CHRNB4 SNP
rs12914008 G>A

DRD2 SNP
rs1800497 G>A

COMT SNP
rs4680 G>A

DRD2 SNP
rs6277 G>A

0.99 (0.89 –
1.11)

0.98 (0.88 –
1.10)

1.04 (0.94 –
1.15)

1.05 (0.87 –
1.26)

0.97 (0.88 –
1.07)

0.99 (0.90 –
1.09)

1.01 (0.91 –
1.13)

1.01 (0.91 –
1.13)

1.19 (1.02 –
1.38)*
AA
AG or GG
CC
CT or TT
CC
CT or TT
AA or AG
GG
AA or AG
GG
AA or AG
GG
AA or AG
GG
AA
AG or GG
AA or AG
GG
0.415 (0.392 - 0.439)

0.438 (0.423 - 0.452)

0.439 (0.424 - 0.453)

0.413 (0.389 - 0.437)

0.426 (0.412 - 0.441)

0.444 (0.423 - 0.465)

0.431 (0.419 - 0.443)

0.451 (0.408 - 0.493)

0.435 (0.419 - 0.451)

0.428 (0.411 - 0.447)

0.434 (0.416 - 0.452)

0.429 (0.411 - 0.448)

0.431 (0.417 - 0.444)

0.437 (0.414 - 0.460)

0.429 (0.416 - 0.443)

0.438 (0.416 - 0.461)

0.428 (0.414 - 0.441)

0.463 (0.428 - 0.499)

0.10

0.06

0.17

0.38

0.62

0.72

0.64

0.51

0.06

0.89 (0.68 –
1.18)

1.04 (0.80 –
1.36)

0.97 (0.77 –
1.23)

1.09 (0.71 –
1.68)

0.86 (0.69 –
1.08)

0.79 (0.52 –
1.20)

1.06 (0.82 –
1.36)

1.02 (0.79 –
1.31)

1.00 (0.70 –
1.41)

AA
AG or GG
CC
CT or TT
CC
CT or TT
AA or AG
GG
AA or AG
GG
AA or AG
GG
AA or AG
GG
AA
AG or GG
AA or AG
GG

0.299 (0.243 - 0.355)

0.374 (0.339 - 0.410)

0.366 (0.331 - 0.402)

0.335 (0.281 - 0.388)

0.355 (0.317 - 0.394)

0.364 (0.318 - 0.411)

0.358 (0.323 - 0.392)

0.368 (0.270 - 0.468)

0.362 (0.321 - 0.403)

0.355 (0.312 - 0.397)

0.354 (0.312 - 0.396)

0.362 (0.321 - 0.403)

0.330 (0.295 - 0.365)

0.431 (0.377 - 0.485)

0.331 (0.295 - 0.367)

0.425 (0.371 - 0.479)

0.359 (0.325 - 0.393)

0.355 (0.278 - 0.431)

0.02

0.29

0.74

0.83

0.78

0.76

0.0005

0.001

0.91

Table 3. Stratified analysis by smokers who first reported cessation prior to menopause and smokers who first reported cessation post-menopause. SNP associations with
likelihood of sustained abstinence (zero relapse) during follow-up (Part 1: Zero-inflated beta regression model), and, conditional on relapse, the proportion of follow-up in
relapse. RD = Risk difference (difference proportion follow-up in relapse) between genotypes. Recessive genetic model referent group is heterozygous and homozygous
common allele genotype. Dominant genetic model referent group is homozygous common allele genotype. Zero-inflated beta regression models were used controlling
total observations during follow-up, BMI at cessation, smoking intensity (light vs. moderate to heavy smoker), and study cohort.
*Odds ratio (OR) p-value < 0.05, **Proportions shown are among moderate/heavy smokers, 16 observations (median number of observations among participants in the
strata), ***Proportions shown are among moderate/heavy smokers, 7 observations (median number of observations among participants in the strata)
Smoking cessation pre-menopause**
Smoking cessation post-menopause***
Part 1:
Part1:
Part 2:
Genotype
Part 2:
Genotype
OR (95% CI)
OR (95% CI)
Gene/SNP
Genetic Model
Genotype
Proportion follow-up
RD
Genotype
Proportion follow-up
RD
sustained
of sustained
in relapse (95% CI)
p-value
in relapse (95% CI)
p-value
abstinence
abstinence
0.464 (0.428-0.499)
0.355 (0.278 - 0.431)
CHRNA5 SNP
Recessive
1.17 (1.00 –
AA
0.06
1.01 (0.71 –
AA
0.92
rs16969968 G>A AA vs (AG+GG)
1.37)*
1.43)
(0.415
(0.325
0.428
0.441)
0.359
0.393)
AG or GG
AG or GG
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12.0 Conclusion
Cigarette smoking remains a leading cause of preventable illness and premature death
in the United States even though the prevalence of smoking among adults in the country has
decreased from 43% in 1965 to 14% in 2019. The rate of the smoking prevalence decrease has
stagnated somewhat falling by only 1% from 2015 to 2019.1-3 The Surgeon General’s Health
Consequences of Smoking Report from 2014 warned that progress toward lowering the burden
of cigarette smoking could be stalling since the quit ratio (percentage of smokers who have quit)
has plateaued for smokers under the age of 65 years and the number of adolescents and young
adults (<26 years of age) initiating smoking has remained relatively stable since the early
2000’s.1
The prevalence of combustible cigarette use among adolescents has declined to
historical lows.4 However, the average age of smoking initiation increased between 2002 and
2018 shifting from adolescence toward young adulthood.5 Specifically, there was a significant
increase in the proportion of smokers initiating use as young adults between the age of 18 and
23 years of age.5 Furthermore, the tobacco product marketplace has changed substantially with
the addition of electronic nicotine delivery systems. Overall tobacco product (smokeless
tobacco, cigars, pipes, combustible and electronic cigarettes) use among youth in the U.S. has
remained generally stable,6 and even increased between 2017 and 2019 largely due to rising
prevalence of electronic cigarette use.6,7 Though electronic cigarettes may present reduced
health risks compared to combustible cigarettes, the long-term health risks associated with
these products are unknown. Additionally, compared to adolescents who do not use electronic
cigarettes, those that use these products are more likely to initiate use of combustible
cigarettes.8,9 Thus, it is not clear how the availability of these alternative products will impact the
health burden of cigarette smoking and tobacco use in the population.
A hypothesis has emerged suggesting that tobacco control efforts have succeeded in
helping less addicted, “easy quitters” to quit smoking, leaving behind a higher proportion of
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highly addicted, “hardcore” smokers in the remaining smoking population.10 Proponents of this
“hardening” hypothesis reason that the prevalence of smoking has stagnated as the remaining
population finds it harder to quit smoking. Some evidence suggests this may be true among
treatment seeking smokers, though perhaps not among the general population of smokers.11,12
The severity of nicotine dependence has been shown to be approximately 70%
heritable13, thus the role of genetic variation in smoking behavior is an important factor in
understanding how to improve smoking cessation. Furthermore, if, as the hardening hypothesis
suggests, the proportion of smokers susceptible to severe addiction is increasing, gaining a full
understanding of genetic factors associated with smoking cessation will be even more crucial for
informing precision medicine approaches to smoking cessation interventions in the future.
This project aimed to examine genetic associations with smoking cessation and relapse.
To inform this research we first investigated prior evidence of associations between genetic
variation and smoking cessation focusing on genes influencing three primary pathways
contributing to nicotine addiction: nicotine metabolism, nicotinic acetylcholine receptor (nAChR),
and mesolimbic dopaminergic pathways. Several broad findings resulted from the evidence
review. First, though a few large genome-wide association studies of smoking status have been
conducted14-16, the majority of the research has focused on a small number single nucleotide
polymorphism (SNPs) within genes influencing these pathways. Table 1 depicts the ten SNPs,
within genes of the aforementioned three primary pathways, which were identified in a review of
the scientific literature as potentially associated with smoking cessation. Across this limited
number of SNPs, the strength of the evidence varied significantly, and research of nonEuropean ancestry populations was sparse. Thus, a comprehensive understanding of this line
of inquiry is far from having been achieved.
In addition, the evidence review demonstrated that genetic studies of smoking cessation
have typically used short-term follow-up (≤6 months for trials and ≤12 months for cohort studies)
or cross-sectional smoking status measurements. In only one prospective study were
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participants followed for as long as five years assessing abstinence annually, and even in this
study repeated measurements were used to examine associations for only one specific SNP
(DRD2 rs1800497); otherwise, repeated measurements of smoking abstinence were not
examined over multiple years. In three other studies with follow-up over multiple years and
repeated smoking status measures available, the smoking trajectories over time were not
considered.17-19 Instead, the outcome considered was whether participants had ever
successfully quit for 6 to 12 months at any follow-up point. Because high rates of relapse to
smoking occur both during and after the first 12 months of abstinence, most smokers go through
multiple quit attempts and relapse episodes throughout their lifetime.20 Thus, smokers
commonly exhibit transitions between smoking and abstinence throughout their lifetime13, but
these transitions and the complexity of smoking trajectories over time have been left
unaccounted for in almost all prior genetic studies of smoking cessation.
Furthermore, the prior evidence suggested that there are likely differences by biological
sex in genetic associations with smoking cessation. However, only limited data concerning sex
differences are available. Most studies include both men and women, but either do not account
for sex differences or lack the statistical power to do so. The few studies of women specifically
have often focused on smoking during pregnancy only and none have accounted for
menopausal status. In addition, almost all of the prior studies have excluded smokers who
smoke less than 10 cigarettes per day (CPD), defining these smokers as light smokers. The
exclusion of light smokers from genetic studies has precluded identifying genetic risk factors
that may be unique within this population of smokers. The health risks associated with light
smoking, though less than those attributed to heavy smoking, are substantial.21 The proportion
of smokers in the United States who are light smokers has increased over time; for example,
16.4% of smokers were light smokers in 2005 whereas 26.9% of smokers were light smokers by
2014.3 Given the considerable health consequences and increase in prevalence of light
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smoking, it is becoming progressively more important to understand factors associated with
smoking cessation among this special population of smokers.
This project aimed to overcome these limitations by examining genetic associations with
phenotypes quantifying the trajectory of smoking behavior from a novel longitudinal and longterm perspective specifically in women. We used two independent, all-female study populations
with follow-up time of up to 38 years and repeated measures every 2 years. In addition, we
included more than 1,000 lifetime light smokers, defined as women who had only reported
smoking five or fewer CPD throughout the follow-up. The use of long-term, repeated measure
data comprising only women and inclusive of light smokers made it possible to evaluate genetic
associations with smoking longitudinally while also examining potential differences between light
and heavy smokers and accounting for factors unique to women, such as menopausal status
and hormone replacement therapy use.
This research quantified genetic associations with complex phenotypes of longitudinal
smoking behavior encompassing transitions between current smoking, abstinence, and
relapse.13 Specifically, we examined genetic associations with persistent smoking (failure to
quit smoking) throughout adulthood as well as the likelihood and degree of relapse among
participants who were able to successfully quit smoking. Focusing on different aspects of longterm smoking trajectory offered new insight into genetic research relating to smoking cessation
and relapse.
This research allowed us to identify SNPs that were associated with both short-term and
long-term smoking cessation and relapse outcomes, while also identifying SNPs in which the
risk associated with short-term cessation failure did not persist long-term (Table 2). Several of
the ten SNPs identified in the literature review as associated with short-term cessation or crosssectional smoking status were also associated with persistent smoking (failure to quit smoking)
throughout adulthood in women. In contrast, for several other SNPs, the risk associated with
short-term cessation failure did not persist over long-term follow-up. We also identified SNPs
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that were associated with both persistent smoking (failure to quit smoking) throughout adulthood
and sustained abstinence after successfully quitting, as well as SNPs that were not associated
with persistent smoking or the likelihood of sustained abstinence after quitting but that were
associated with the amount of follow-up in relapse (Table 2). By examining the genetic
associations with these different phenotypes, we demonstrated the complexity of quantifying
genetic risk of long-term smoking behavior, and we observed genetic associations with varying
aspects of smoking cessation and relapse over time.
In addition to investigating genetic associations with long-term smoking phenotypes
among the ten SNPs identified in the literature review, we also sought to identify new variants
within genes of the nicotine metabolism, nAChR, and dopaminergic pathways that were
associated with persistent smoking throughout adulthood. This candidate gene approach
allowed us to use a hypothesis-driven SNP selection methodology focusing on biologically
plausible genes rather than the agnostic approach taken by genome-wide association studies.
Using this methodology, we were able to both reproduce several previously novel genetic
findings, while maintaining statistical power to identify new genetic associations with persistent
smoking within these genes. Specifically, this research identified 10 additional SNPs within
nicotine metabolism or nAChR genes that were associated with persistent smoking throughout
adulthood in both the NHS and NHS-2, two independent all-female study populations (Table 3).
An important characteristic of our study was the focus on women. By focusing on two
all-female cohorts, we avoided confounding of potential genetic associations by biological sex
which may have contributed to the strength of some our findings compared to previous studies.
For example, we found that the minor allele of CHRNA3 SNP rs578776 was strongly associated
with lower risk of persistent smoking throughout adulthood whereas this association had not
been previously observed in several studies of European ancestry men and women; however,
the minor allele had been associated with lower intrinsic reward response to smoking-specific
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cues.22 Since cue-reactivity plays a stronger role in smoking relapse among women, the
strength of our findings could be a result of our focus on women.23
In addition, the focus on women allowed us to account for factors unique to women such
as menopausal status. Our observation that some genetic associations with smoking relapse
phenotypes may be stronger among women who quit smoking post-menopause suggests that
more research is needed to fully understand risk factors in pre- and post-menopausal women.
This is especially important given the increased risk for smoking-related disease and other
comorbidities among post-menopausal women. Furthermore, these findings suggest that
controlling for age in genetic studies of smoking cessation may not sufficiently account for
differences across stage of life. We show that differences across stage of life should be
considered and that it may be necessary to account for confounding and moderating factors
specific to stage of life instead of merely adjusting for age. Even in studies where it is only
feasible to assess cross-sectional smoking status, investigators should think about adjusting for
specific stage of life factors, such as menopausal status.
Lastly, because light smokers were included in this study, a novel examination of
potential differences in genetic associations with smoking cessation between light and heavy
smokers demonstrated the importance of this line of inquiry for future research. We
demonstrated that several genetic associations may differ between light and moderate to heavy
smokers. Though the associations among light smokers were not statistically significant, the
prevalence of light smokers is low reducing the available sample size and statistical power.
However, the consistency of the apparent interactions in both cohort studies (in both NHS and
NHS-2) lends strength to the findings. This is an important insight as almost all previous studies
have excluded light smokers. Given the health risks associated with light smoking and the
rising prevalence of light smokers in the population, our findings, though preliminary for this line
of inquiry, show the importance of working to understand unique risk factors leading to
persistent light smoking.
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In conclusion, we have demonstrated the complexity of quantifying smoking behavior
over time and that genetic contributions to smoking can differ depending on phenotype
definitions, time periods, and potential confounding variables such smoking intensity and stage
of life. We also demonstrate the importance of considering how genetic risk among women may
be different than that among men, and that future research should be conducted with a priori
planning for such considerations.
12.1 Limitations
Despite the numerous strengths of the current project and the unique insights provided
in relation to genetic associations with smoking cessation, some important limitations remain to
be overcome. Identifying differences in genetic susceptibility to persistent smoking by ancestry
has been difficult due to the limited number of genetic studies of non-European populations. In
fact, it was not feasible for this project to evaluate differences by ancestry because genotype
data for participants in our two studies was available only for those of European ancestry. Thus,
it is necessary to either identify existing longitudinal studies of non-European populations or to
conduct new studies of these populations, to fully understand genetic susceptibility to long-term
smoking outcomes and behavior across diverse groups of people. Likewise, though our allfemale study was a characteristic important for identifying genetic factors among women, similar
studies of men are necessary to understand where associations are generalizable across sexes
as well as where associations differ by biological sex.
In addition, this research project focused on genetic variation within genes influencing
nicotine metabolism, nAChRs, and the mesolimbic dopamine system. Nicotine metabolism,
nAChR properties, and the dopaminergic pathway are three of the primary biological
mechanisms that influence smoking behavior and identifying genetic variants within these
pathways that are associated with long-term smoking cessation and relapse phenotypes
provides considerable insight into the role of genetic susceptibility in smoking. However, there
are other important neurobiological drivers of smoking behavior. For example, in addition to
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dopamine, several other neurotransmitters such as glutamate, serotonin, and gammaaminobutyric acid (GABA) contribute to the effect of nicotine on various aspects of learning,
memory, mood, anxiety levels, and appetite suppression.24,25 Thus, the scope of this line of
inquiry into the role of genetic variation in long-term smoking cessation and relapse throughout
adulthood should be expanded to include genes influencing additional neurobiological
pathways. Broadening the range of genes in this manner holds promise for identifying
additional variants to inform precision medicine approaches to long-term cessation and relapse
prevention interventions.
The present research was well-suited for studying genetic associations but did not
include important non-genetic factors that contribute to the likelihood of smoking cessation (and
persistent smoking). It was not feasible to control for such factors as motivation to quit,
diagnosis of a comorbid mental illness, and comprehensive measures of exposure to other
smokers at home, work, and within social networks.20 Furthermore, the inclusion of only
registered nurses resulted in homogeneity in socioeconomic status and education level. The
homogeneity in socioeconomic status and education level avoided confounding of associations
due to these factors, both of which are associated with prevalence of smoking and likelihood of
cessation20; however, the homogeneity also precluded the examination of these factors in this
research. In addition, comprehensive measures of nicotine dependence (e.g. Fagerström Test
for Nicotine Dependence scores) were not available, but the present research was able to
adjust for factors such as early age of initiation of cigarette smoking and light versus moderateto-heavy smoking intensity, both factors associated with degree of nicotine dependence.
Other factors that may contribute to persistent smoking were also adjusted for including
BMI (m2/kg). Smoking is associated with lower BMI on average, but the relationship between
smoking behavior and BMI is complex and likely bidirectional.26 For example, women are more
likely to report smoking for weight management, and concerns about weight gain following
smoking cessation also inhibit quit attempts. Thus, weight management may be a motivator for
208

smoking initiation as well as a barrier to smoking cessation, particularly among women.
However, the actual net effect of smoking and smoking cessation on changes in BMI may be
small27, and it could be that it is the perceived “benefit” of smoking for weight control that is a
stronger motivating factor. Smoking is also associated with other unhealthy behaviors such as
physical inactivity and poor dietary intake, both factors impacting BMI and obesity26, and
smoking may be associated with changes in the distribution of body mass such as increased
waist-to-hip ratios (e.g. increased abdominal obesity).28 Due to these complex relationships,
more detailed analyses of the association between changes in BMI, body mass distribution,
perceived risk/benefit of smoking for weight management and smoking cessation would be
needed to fully understand the role of BMI in persistent smoking.
Diagnosis of a new illness or health condition may also play a role in smoking
cessation.29 However, the likelihood of smoking cessation following diagnosis of a new
condition differs by level of education and age, with less educated and younger smokers less
likely to quit smoking after diagnosis.29 In addition, it is common for smokers to spontaneously
quit prior to an official diagnosis or presentation of clinical symptoms of disease30; this
phenomenon could confound the observance of a temporal relationship between onset of
disease and smoking cessation. Though data on diagnoses were available in these cohorts,
more complex analyses considering these factors would be needed to parse this out.
A more complete understanding of the genetic, social, environmental, and health factors
associated with smoking behavior is needed. Integration of these factors would allow for
identification of those factors, both genetic and non-genetic, that are strongly associated with
smoking cessation outcomes. A complete understanding of both genetic and non-genetic
factors influencing smoking cessation are needed to fully inform, develop, and implement
precision medicine approaches to improving rates of successful cessation.
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12.2 Future Directions
Examination of genetic associations with smoking cessation and relapse throughout
adulthood can be broadened to examine genetic variation within genes influencing additional
neurobiological mechanisms that mediate the effects of nicotine. Thus, the next step in this line
of inquiry is to expand the breadth of genes examined in relation to longitudinal smoking
trajectory within the NHS and NHS-2 beyond nicotine metabolism, nAChR, and dopaminergic
genes. Potential areas for future research include examining associations between variation
within glutamatergic, GABAergic, and serotonergic genes and longitudinal smoking trajectory.
This future research holds considerable promise for identifying additional genetic factors
associated with long-term smoking cessation and relapse among women of European ancestry.
Furthermore, studies of people of non-European ancestry have been sparse and no
long-term studies have been conducted to examine genetic associations with smoking cessation
longitudinally in a population of African ancestry. We have identified the Southern Community
Cohort Study (SCCS), a cohort study with a large proportion of Americans with African ancestry
that has collected longitudinal smoking behavior data covering seven-years follow-up. Among
participants in this cohort, some existing genotype data is currently available. In addition,
participant biospecimens have been preserved and are available for future genetic assays
which will provide additional genotype data. The large sample of people of African ancestry will
make it feasible to study genetic associations with smoking over the course of seven years in an
understudied and underserved group of people. In addition, both men and women comprise the
study population which will enable examination of potential differences by sex in people of
African ancestry. This future research will provide much needed insight into genetic risk factors
of persistent smoking and differences by biological sex among people of African ancestry.
In addition to future research to identify genetic associations with smoking behavior
longitudinally in people of African ancestry, we also have the ability to examine associations in
an all-male cohort study. The Health Professionals Follow-up Study (HPFS) is an all-male
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cohort study designed to complement the NHS. Similar to NHS and NHS-2, the HPFS has
collected data every two years beginning in 1986 and more than 12,000 participants (of which
an estimated 6,000 are ever-smokers) have existing quality-controlled genotype data. Though
the HPFS genotype data is of men of European ancestry, this immediately available data will
allow us to examine genetic associations with persistent smoking throughout adulthood
specifically in men. Thus, in the near future, we can compare the genetic associations observed
within the two all-female cohort studies with the findings observed within the complementary allmale cohort study. Such comparison holds promise for identifying differences in genetic
associations by biological sex among people of European ancestry.
The aforementioned future research projects can be accomplished in the near future and
hold promise for advancing the current scientific knowledge of genetic risk factors of smoking
behavior. However, long-term research along this line of inquiry should also focus on methods
to combine the risk of multiple variants in order to more effectively identify smokers who may be
at high risk for difficulty quitting. The association between a single genetic variants and smoking
phenotypes often has a small effect size; however, the combined risk of multiple genetic
variants could have a much larger effect. One promising method of combining the risk of
multiple genetic variants is the development of polygenic risk scores. Effectively developed
polygenic risk scores hold promise for informing precision medicine approaches. Furthermore,
these risk scores may be informative across nicotine delivery systems. For example, polygenic
risk scores for smoking initiation have been shown to be associated with both initiation of
combustible cigarette smoking and electronic cigarette use in young adults.31 And genetic risk
scores for regular combustible cigarette use are predictive of use of electronic cigarettes.32
The application of genetic risk scores to behaviors related to both combustible and
electronic cigarette use indicates shared genetic influences across these nicotine delivery
systems. Shared genetic influences related to neurobiological mechanisms of nicotine
response are likely to exist across all tobacco products. However, it has been shown that
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nicotine response alone is not sufficient to explain the high addictiveness of cigarette smoking.33
Sensory characteristics of cigarette smoking are a critical component of smoking addiction;
factors such as taste, smell, and tracheobronchial sensations have been shown to play an
important role in smoking behavior.33,34 These sensory characteristics in denicotinized
cigarettes have been shown to lessen withdrawal symptoms (e.g. negative effect) and craving in
smokers and the associated withdrawal symptom relief is greatest among those smokers who
score higher on the Fagerström Test for Nicotine Dependence.33 This phenomenon is at least
partially explained by associative learning linking sensory cues with cigarette smoking reward
and explains why nicotine replacement therapy is not effective for most smokers in cessation
attempts. Due to the importance of non-nicotine factors in cigarette smoking addiction, it cannot
be assumed that the genetic factors associated with combustible cigarette use and electronic
cigarette use are identical. Future research is needed examine where shared and unique
genetic influences exist between these two behaviors. This line of research will become
increasingly important as the prevalence of electronic cigarette use is increasing among both
ever- and never-smokers of combustible cigarettes.35
In addition, genetic predictors of susceptibility will need to be incorporated with
environmental and social factors into comprehensive risk prediction models to effectively
develop and implement tailored personalized approaches to smoking cessation. For example,
genetic susceptibility to cue-reactivity may increase susceptibility to smoking cessation failure;
however, the level of exposure to smoking-related cues in a person’s environment and social
networks would logically interact with such genetic susceptibility to increase or decrease the
magnitude of the effect. Through the identification of both genetic and environmental factors,
and the relevant genetic by environment interactions, precision medicine approaches can be
applied that target one or both of these factors for the most feasible and effective interventions.
A research framework focusing on a complete understanding of genetic, environmental,
and social factors, and how these factors interact to influence smoking behavior holds promise
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for developing precision approaches to smoking cessation that can be translated into clinical
practice in the future. Through this research paradigm, composite risk prediction models can be
developed that integrate genetic and non-genetic factors. These models could identify groups
of smokers who are at notably higher risk of not being able to successfully quit smoking in the
long term and inform innovative intervention strategies based on the specific risk characteristics
of each group. Such innovative and targeted interventions could assist smokers in overcoming
the relevant biological, environmental, and social barriers to cessation to achieve long-term
abstinence. If successful, this would result in more successful long-term cessation in the
population yielding enormous public health benefits.
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European (n = 6)

DRD2 rs6277

N = 1.026

N = 301
N = 835

Prospective: 12 weeks
*Cross-sectional: 2 years
Prospective: 11 weeks
Prospective: 12 weeks
*Cross-sectional: 2 years
†
Prospective: annual abstinence
over 5-years follow-up
*Cross-sectional: 1 year

Prospective: 12 months
*Cross-sectional: 1 year
Prospective: 6 months
*Cross-sectional: 1 year

N = 2,630

Prospective: 12 weeks
*Cross-sectional: 2 years

N = 2,167

N = 2,167

N = 2,633

Largest sample size
for prospective
follow-up**

Prospective: 12 months
*Cross-sectional: 2 years

Longest Cessation outcome

1.) Study of Asian ancestry (100% men)
2.) No studies of women
1.) 2 studies of Asian ancestry (100% men or 93% men)
2) 2 studies of Asian ancestry = could stratify results by
sex
3.) 1 study of European ancestry (100% women)
4). 4 studies of European ancestry = could stratify results
by sex

1.) Study of Asian ancestry (100% men)
2.) No studies of women

1.) Study of Asian ancestry (100% men)
2.) 1 study of European ancestry: 100% women, only
during pregnancy
1.) Study of Asian ancestry (100% men)
2.) No studies of women

Notes on biological sex (studies of men or women, or
in which stratification by sex was feasible)

COMT rs4680

European (n = 9)
Asian (n = 3)
African (n = 3)

N = 2,928

1.) 3 studies of Asian ancestry (100% or 94% male)
2.) 2 studies of African ancestry (100% women)
3). 3 studies of European ancestry (100% women)
4.) 1 study of European = could stratify results by sex
* Cross-sectional former versus current smoker status – most studies require smokers to self-report having quit for at least 1 year to be considered a former smoker.
** Does not count age of cessation studies (retrospective in design)
†
There was a single study that examined annual abstinence from smoking for 5-years follow-up, longest cessation outcome for other studies was 1 year
‡
SNPs are shown together due to high linkage disequilibrium (correlation in inheritance)

DRD2/ANKK1
rs1800497

CHRNB4 rs12914008
CHRNB2 rs2072661

CHRNA3 rs578776

European (n = 18)
Asian (n = 1)
African (n = 2)
European (n = 7)
Asian (n = 1)
African (n =2)
European (n = 6)
Asian (n = 1)
African (n = 2)
European (n = 3)
European (n = 3)
Asian (n = 1)
European (n = 14)
Asian (n = 4)
African (n = 1)
Mexican (n = 1)

No. of Studies by
ancestry

CHRNA5 rs16969968
or CHRNA3
rs1051730‡
CHRNA5 rs588765 or
CHRNA5 rs680244‡

Gene & SNP

Table 1. Summary of single nucleotide polymorphisms (SNPs) identified in a review of the scientific evidence conducted for Aim 1 of the research project. Each
SNP listed has at least one study finding indicating an association with smoking abstinence (typically for 12-months or less) or cross-sectional former smoker
status.
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Based on 3 trials (nicotine
replacement therapy arm)
[European ancestry]

Based on 11 trials, 1 cohort
study, and 2 case-control studies
[European ancestry]

Based on 1 trial [European
ancestry]
Based on 1 trial [European
ancestry]

Based on 1 cross-sectional study
[Asian ancestry]

COMT rs4680

No association

No association

No association

Minor allele associated with risk of
persistent smoking in moderate to
heavy smokers. Indication minor
allele may be associated with
lower risk in light smokers

No association

No association

No association

No association

No association

Minor allele associated with
decreased risk of persistent
smoking throughout adulthood
No association

No association

Minor allele associated with
higher proportion follow-up in
relapse. Significant interaction
with menopausal status at
cessation
Minor allele associated with lower
proportion follow-up in relapse.

No association

No association

No association

No association

Minor allele associated with
higher proportion follow-up in
relapse. Significant interaction
with menopausal status at
cessation.

No association

Part 2: Conditional on relapse,
association with the proportion
of follow-up in relapse

Aim 3a, Joint model
Part 1: Association with
persistent abstinence (no
relapse events)
Among women who had quit
smoking, minor allele associated
with increased odds of persistent
abstinence over follow-up

No association

Minor allele associated with risk of
persistent smoking throughout
adulthood

Based on evidence from 2 age of
cessation studies, 5 cohort
studies, 4 trials (placebo arm)
[European ancestry]
Based on 3 trials (placebo arm)
[European ancestry] and 1 crosssectional study [Asian ancestry]

Aim 2a: Association with
Smoking Status over time

Aim 1: Basis of evidence of
prior association with shortterm or cross-sectional
smoking cessation outcome

Based on 2 cohort studies and 1
No association
trial [European ancestry]
‡
SNPs are shown together due to high linkage disequilibrium (correlation in inheritance)

DRD2 rs6277

DRD2/ANKK1 rs1800497

CHRNB2 rs2072661

CHRNB4 rs12914008

CHRNA3 rs578776

CHRNA5 rs588765 or
CHRNA5 rs680244‡

CHRNA5 rs16969968 or
CHRNA3 rs1051730‡

Gene & SNP

Table 2. Summary of findings from the Aims 1, 2, and 3 for the 10 single nucleotide polymorphisms (SNPs) identified for the candidate SNP approach. Aim 1
indicates associations with short-term or cross-sectional smoking abstinence identified in prior studies. Aim 2 summarizes results of the examination of SNP
genotype associations with persistent smoking throughout adulthood utilizing repeated measures in the Nurses’ Health Study (NHS) and NHS-2. Aim 3
summarizes results of the examination of SNP genotype associations with Part 1: the likelihood of persistent abstinence (zero relapse events after successfully
quitting) and Part 2: conditional on relapse, the association with the proportion of follow-up in relapse.
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CYP2A6

CHRNB4

CHRNA5

CHRNA3

Gene

rs56113850
rs56267346

rs4887074

rs637137
rs503464
rs684513
rs11072774
rs12441998
rs12441088

rs77438700

SNP

Minor allele associated with increased risk of persistent smoking

Minor allele associated with lower risk of persistent smoking throughout adulthood in
moderate to heavy smokers. Indication associated with increased risk in light smokers.

Minor allele associated with lower risk of persistent smoking

Minor allele associated with lower risk of persistent smoking

Minor allele associated with lower risk of persistent smoking throughout adulthood in
moderate to heavy smokers. Indication associated with increased risk in light smokers.

Association with Smoking Status over time

Confirms finding from 2020 study
Novel finding

Novel finding

Novel finding
Confirms finding from 2017 study
Novel finding
Novel finding
Novel finding
Novel finding

Novel finding

Notes

Table 3. Summary of results from Aim 2b in which single nucleotide polymorphisms (SNPs) providing full coverage of seven genes (CHRNA3, CHRNA5,
CHRNB2, CHRNB4, DRD2, DBH, and CYP2A6) were examined for associations with persistent smoking throughout adulthood in women. The listed SNPs
were validated with robust replication (FDR < 0.05) in two independent study populations [Nurses’ Health Study (NHS) and NHS-2]
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